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Luminal B Brustkrebs tritt bei 20 % aller diagnostizierten Mammakarzinome auf. 
Jedoch haben Patientinnen bei dieser Diagnose nur eine 50 prozentige 
Überlebenswahrscheinlichkeit für die nächsten 5 Jahre. Hierbei zählt vor allem ein 
Rückfall oder die spätere Metastasierung nach wie vor zu den häufigsten 
Todesursachen, auch wenn es zwischenzeitlich einige Fortschritte in deren 
Behandlung gibt. Dennoch stellt vor allem die Risikoeinschätzung, die ein potentielles 
Rezidiv und/oder die Manifestierung von Fernmetastasen vorhersagt, ein Problem dar. 
Die gängigen Marker die hierzu verwendet werden, wie der Hormonrezeptor Status, 
die Proliferationsindizes, die Zelldifferenzierung und genetischen „Assays“ reichen 
nicht aus, um Luminal B Patientinnen in „Hoch und „Niedrig-Risikogruppen“ 
einzuteilen. Deshalb war die Zielsetzung dieses Projekts Marker zu identifizieren, die 
eine Einteilung der hoch aggressiven Luminal B Tumoren ermöglichen und 
Tumorzelldisseminierung und Metastasierung vorhersagen. Diese sollen es 
erleichtern eine Therapieentscheidung zu treffen und zusätzlich die Frage 
beantworten, ob eine Luminal B Brustkrebspatientin Chemotherapie benötigt oder 
nicht.  
Um diese Fragen zu beantworten, wurden die Primärtumore der Luminal B 
Patientinnen phänotypisch untersucht. Gleichzeitig wurden aus den Primärtumoren 
sogenannte Luminal B Xenotransplantations-Modelle generiert (Tumormäuse TM) und 
analysiert. Zudem sollte auch der Einfluss des humanen Immunsystems auf Luminal 
B Tumoren analysiert werden, was durch das Generieren der humanisierten 
Tumormäuse (HTM) ermöglicht wurde. Phänotypisch zeigte sich, dass man Luminal B 
Tumoren anhand der erhöhten CD24 Expression im Vergleich zu Luminal A ermitteln 
kann. Zudem zeigte sich bei den primären Luminal B Hoch-Risikotumoren (definiert 
durch Todesfall der Patientin, Rückfall oder Metastasierung, und durch das 
Anwachsen eines Luminal B Tumors als Xenotransplantations-Model) ein erhöhtes 
Vorkommen der Co-expression von CD44/cMET/CD47 der sogenannten 
Metastasierungs-initiierenden Zellpopulation im Vergleich zu Luminal B Niedrig-
Risikotumoren (alle Patientinnen, die überlebt haben; keinen Rückfall erlitten und bei 
welchen der Tumor nicht im Xenograftmodel angewachsen ist). Zusätzlich konnte beim 
phänotypischen Vergleich von Luminal B Primärtumoren und der zugehörigen 




zeigte sich sowohl beim Vergleich von TM oder HTM Tumoren mit der dazugehörigen 
Lungenmetastase, als auch bei den Primärtumoren der Patientinnen die mit Luminal 
B Aszites Präparaten oder Pleuraergüssen verglichen wurden. Es konnte auch ein 
erhöhtes CD4/CD8 Verhältnis auf Immunzellen, die den Tumor infiltrieren, in Luminal 
B Hoch-Risikotumoren nachgewiesen werden. Eine der wichtigsten Entdeckungen 
dieser Arbeit stellte dabei das vermehrte Auftreten einer MDM2 Amplifikation in 
Luminalen Tumoren dar. Diese zeigte sich mit erhöhter Tumoraggressivität und einer 
hohen Metastasierungswahrscheinlichkeit in Luminal B TM und HTM. In TM und HTM 
wiesen MDM2 amplifizierte Tumore zudem häufig Lungenmetastasen und 
disseminierte Zellen im Knochenmark auf. Diese Ergebnisse wurden in 
Zellkulturversuchen durch eine Herunterregulierung von MDM2 validiert und zeigten 
dabei einen p53 abhängigen Mechanismus, der die Proliferation und Apoptose der 
Tumorzellen steuert. Im Einklang mit diesen Ergebnissen stand auch die Behandlung 
der Zellen mit einem MDM2 Inhibitor (AMG232) und liefert dadurch einen klinisch 
relevanten Ansatz zur Therapie von MDM2 amplifizierten Tumoren. Zudem wurden 
genetische TP53 Mutationen in Luminal B Tumoren mit erhöhter Disseminierung von 
Tumorzellen ins Knochenmark in Verbindung gebracht. Die Amplifikation von MDM4 
in Luminal B Tumoren zeigte in der TM hingegen sogar eine Metastasierung des 
Tumors in multiple Organe wie der Lunge, der Leber, des Gehirns, und des 
Knochenmarks. Interessanterweise regulieren sich alle entdeckten genomischen 
Aberrationen (MDM2/P53/MDM4) gegenseitig und gehören zum gleichen Signalweg. 
Das wiederum deutet auf eine wichtige Rolle von MDM2, p53 und MDM4 beim 
aggressiven Luminal B Mammakarzinom hin. Auffallend hierbei sind nicht nur die 
Aggressivität der Tumore, sondern auch die aberrationsabhängige Metastasierung in 
bestimmte Organe. Ein weiterer Teil dieser Arbeit beschäftigte sich mit den 
genetischen Unterschieden zwischen Einzelzellen aus dem Primärtumor und 
disseminierten Tumorzellen im Knochenmark in der TM und HTM. Hierbei konnte 
gezeigt werden, dass die Tumorzellen aus dem Primärtumor (TM und HTM) und die 
disseminierten Tumorzellen aus dem Knochenmark unterschiedliche Cluster bilden 
und damit unterschiedliche genetische Modifikationen aufweisen. Interessanterweise 
differenzierten sich zudem disseminierte Tumorzellen aus dem Knochenmark von 
HTM von allen anderen Tumorzellen und auch den disseminierten Zellen aus der TM. 
Dies deutet auf einen möglichen Selektionsdruck auf Zellen mit bestimmter 




verursacht wird. Zudem kann dies aber auch auf Knochenmarksnischen-bedingte 
Selektion, die durch humane Immunzellen verändert wird, zurückgeführt werden. 
Insgesamt zeigte sich in diesen Experimenten die generell geringe Immunogenität von 
Luminal B Tumoren sowohl auf Patientenebene als auch in der HTM. Somit spiegelt 
das HTM Xenotransplantations-Modell die Situation im Luminal B Patienten erfolgreich 
wider und ist damit auch ein Modell für zukünftige Therapiestudien für dieses 
Patientenkollektiv. 
Zusammenfassend zeigte sich, dass Luminal B Xenotransplantations-Modelle und 
humanisierte Luminal B Xenotransplantations-Modelle ein geeignetes System zur 
Identifizierung von phäno- und genotypischen Veränderungen sind, die mit einem 
erhöhten Metastasierungspotential und einer erhöhten Aggressivität einhergehen. 
Zurzeit werden MDM2 Amplifikationen und Expressionen im Zusammenhang mit dem 
(tumorfreien) Überleben an einem größeren Patientenkollektiv in unserem Labor 
untersucht. Weitere klinische Studien könnten dann zeigen, ob Luminal B 
Brustkrebspatientinnen mit Tumoren, die eine MDM2/MDM4/TP53 Veränderungen 
aufweisen, zusätzlich von einer Chemotherapie oder eventuell von einer 
















The breast cancer subtype Luminal B is diagnosed in 20% of all breast cancer cases 
whereas only 50 % of the patients are still alive 5 years after the first diagnosis. Despite 
the advances in treatment, patients suffering from Luminal B breast cancer frequently 
experience a relapse or develop distant metastases. Besides the current strategy of 
hormone-receptor-positivity, proliferation indices, grading, and gene signature assays 
to categorize the Luminal breast cancer patients into high and low-risk groups, there is 
still a lack of appropriate markers that reliably predict events of recurrence. Overall, 
this thesis aims to identify biomarkers that are associated with aggressivity, cell 
dissemination and/or metastases formation. Importantly these markers might 
contribute to the therapy decision if Luminal B breast cancer patients need a 
chemotherapeutic intervention or not.  
Therefore, the primary Luminal B patient samples were analyzed and PDX models 
were generated by the transplantation of primary Luminal B patient samples into NSG 
mice, the so-called tumor mouse (TM). Additionally, humanized Luminal B tumor mice 
(HTM) were generated and assessed under the influence of the human immune 
system. The phenotypic analysis of the primary patient samples revealed that a high 
expression of CD24 in Luminal B breast cancer patients differs from Luminal A breast 
cancer patients. The occurrence of MICs (CD44+/cMET+/CD47+) in the high-risk 
Luminal B tumors (patients that died, suffered from a relapse, or when the PDX model 
was successful) compared with low-risk Luminal B tumors (patients that are alive, 
without a relapse, and where the PDX model failed) could serve as a marker for the 
identification of high-risk Luminal B breast cancer patients. Remarkably, tumor cells of 
lung metastases differed phenotypically to those of the primary tumor, showing an 
increased CD44 and cMET expression in the TM, as well as in the patient metastases 
(e.g. pleural effusion and ascites). Enhanced expression of cMET and CD44 in Luminal 
B metastases were determined to be independent of the absence or the presence of a 
human immune system. Moreover, an increased CD4/CD8 ratio was determined as an 
indicator of a high-risk Luminal B tumor. However, the most important finding was the 
dependence of MDM2 amplification to form highly aggressive tumors accompanied by 
the high probability for metastatic spread in Luminal B TM and HTM. When MDM2 was 
amplified in tumors, the metastases preferentially were found in the lung of the PDX 




Luminal breast cancer characterizes the patients as high-risk patients. These findings 
were confirmed in vitro by a MDM2 knockdown experiment, showing a p53 mediated 
mechanism of apoptosis and cell proliferation. Targeting MDM2 by AMG232 inhibition 
revealed increased apoptosis and reduced proliferation, which demonstrated the 
potential clinical relevance. TP53 mutation was also detected as a high-risk marker in 
Luminal B TM as this alteration in the primary tumor promoted BM DTCs. MDM4 
amplification was verified to promote metastatic spread into various organs, such as 
the lung, the liver, the brain, and the BM, and subclassifies the tumor as a high-risk 
tumor. All the determined genomic alterations of MDM2, p53, and MDM4 regulate each 
other, which shows the importance of the pathway for high-risk Luminal B breast 
cancer.  
Single cell sequencing revealed one cluster formation of primary tumor with specific 
genomic losses and gains and another cluster mainly formed by DTCs. The differences 
in copy number profiles were preferentially shown by DTCs that derived from HTM 
PDX but not from TM, implicating a selection pressure in the periphery potentially 
evoked by human immune cells. Moreover, a selection determined by the bone marrow 
niche, which is altered by human immune cells in the HTM, could enable DTCs with a 
special genetic profile to colonize. The low immunogenicity of Luminal B tumors was 
demonstrated in primary patient samples and in the HTM, rendering the Luminal B 
HTM PDX as an adequate model to analyze Luminal B breast cancer. These models 
could be useful for preclinical immune-modulatory studies in Luminal B breast cancer 
in the future. 
In summary, we showed the suitability of Luminal B PDX and humanized PDX models 
that are able to identify geno- and phenotypic markers that predict a high potential for 
metastatic spread and aggressiveness of the tumor. However, prospectively further 
studies on MDM2 amplification and MDM2 expression in Luminal B breast cancer have 
to be validated in large patient cohorts. Further clinical studies should determine if 
breast cancer patients with genetic MDM2/MDM4/TP53 predisposition might 
additionally benefit from cytotoxic intervention or from specific MDM2 targeting (e.g., 





Suffering from breast cancer metastases is the final and fatal step in the progression 
of Luminal B breast cancer. Despite the stratification of hormone receptor-positive 
Luminal B tumors by means of molecular intrinsic marker like the proliferation index (> 
14%), the grading, and molecular assays for risk assessment, there is still a lack of 
appropriate markers to identify the high-risk Luminal B tumors, that might metastasize. 
While Luminal A (low-risk) tumors can be treated efficiently, Luminal B high-risk tumors 
have an unfavorable outcome of disease. The worse prognosis is mainly determined 
by therapy resistance and the development of distant metastases after a long latency. 
Therefore, it is important to understand the biology of Luminal B breast cancer as well 
as the metastatic driver molecules. Moreover, the influence of human immune cells 
should be taken into account to detect appropriate markers for the better identification 
of Luminal B high-risk breast cancer. 
1.1 From breast physiology to the pathophysiology of Luminal B breast cancer 
1.1.1 Different cell types involved in breast (cancer) physiology 
Before birth, until puberty, in the reproductive phase, during pregnancy and after 
menopause, the mammary gland is subjected to continuous remodeling processes that 
are due to the hormonal changes (Macias and Hinck, 2012). The adult female 
mammary gland consists of branching trees of ducts that radially extend from the nipple 
and terminate in the lobules that comprise clusters of alveoli. The mammary alveolus 
is built up of the basement membrane, containing the basal cells referred to as 
myoepithelial cells, and the inner layer composed of luminal cells (Figure 1). The 
multipotent stem cells give rise to luminal epithelial stem cells and basal stem cells that 
further divide into luminal and basal progenitor cells. However, the luminal progenitor 
cells differentiate into two types of hormone receptor-negative cells and one hormone 
receptor-positive cell type (Cristea and Polyak, 2018). The basal layer is embedded in 
breast stroma containing adipocytes, fibroblasts, and immune cells (macrophages and 





Figure 1: Anatomy of the human mammary gland 
Each lactiferous duct in the mammary gland originates from the nipple and branches into ducts that end in the 
alveoli. Those mammary alveoli comprise the basal cells on the outside and an inner layer of luminal cells. The 
alveoli are embedded in the mammary stroma containing fibroblasts and adipocytes. The picture is adapted and 
modified from Pellacani 2019. 
During the reproductive phase of a female, the mammary gland is susceptible to 
restructure the tissue due to the monthly menstrual cycle that is orchestrated by the 
uterus and pituitary hormones like estrogen and progesterone resulting in the 
continuous reorganization of the mammary gland (Ramakrishnan et al., 2002).  In the 
case of pregnancy, the luminal epithelial layer is able to produce and secrete milk upon 
hormonal stimulus. Furthermore, the luminal layer is characterized by its high epithelial 
cell adhesion molecule (EpCAM), cytokeratin (CK) 18, and CK 8 expression. In 
contrast, the basal cells express EpCAM very low and could be identified by CK 14 
staining. In normal mammary tissue, approximately 7 % of the epithelial cells in the 
mammary gland are hormone receptor-positive, whereas 87 % of the cells are luminal 
epithelial cells or occupied an intermediate position in the duct wall (Petersen et al., 
1987). These distinct expression patterns are not only helpful to identify the different 
cell types in healthy mammary tissue but are also responsible for the different entities 
in breast malignancies. 
1.1.2 Breast cancer etiology  
In the mammary gland, the cells grow and divide and are strictly controlled through 
homeostatic regulation between proliferation and death. However, an imbalance 




whereas the reasons for carcinogenesis are not fully understood. There are several 
risk factors that promote the formation of breast malignancies like the genetic 
predisposition, race or ethnicity, childlessness, non-breastfeeding, hormone receptor 
replacement therapy after menopause, excessive alcohol consumption, smoking, or 
obesity (Feng et al., 2018). Besides the so-called acquired risk factors for breast 
cancer, only 5-10 % of breast cancer malignancies are due to inherited reasons like 
BRCA1/2 mutations or TP53 mutations (Duda and Schulz-Wendtland, 2017; Feng et 
al., 2018).  
1.1.3 Classification of breast cancer and breast cancer subentities 
One of the most common types of breast cancer is the non-invasive or pre-invasive 
intraductal carcinoma in situ (DCIS) which develops inside the normal ducts. DCIS 
itself is not invasive but in situ carcinomas have a high potential to become invasive. 
In contrast, invasive breast cancer invades and spread outside the normal breast 
lobules and ducts and grows into the surrounding tissues. The invasive breast cancer 
cells derive either from the epithelial cells of the mammary ducts (ductal) or from the 
mammary lobules (lobular). The invasive ductal carcinoma (70-80 %), as well as the 
invasive lobular carcinoma (10 %), represents the highest proportion of mammary 
malignancies and derives from early lesions (carcinoma in situ).   About 90 % of breast 
cancer cases are invasive (Feng et al., 2018). Besides this histological classification, 
the classification of breast cancer is performed according to the pTNM staging. This 
staging considers the size of the primary tumor (T), the lymph node involvement (N), 
and the presence of distant metastases (M), as it represents important information for 
therapy and prognosis of the carcinoma (Duda and Schulz-Wendtland, 2017). The 
grading system which is scaled into three stages (G1-G3), provides additional 
information on the degree of malignancy, thereby including the formation of tubular 
gland structures, the nuclear atypia, and the frequency of mitosis (Elston and Ellis, 
1991). The higher the grading the worse is the prognosis. Accordingly, Grade 1 
proliferates slowly and is well-differentiated,  Grade 2 is moderately differentiated, and 
Grade 3 propagates fast and is poorly differentiated (Klöppel et al., 2013). However, 
an additional important low prognostic but highly predictive factor is the hormone 
receptor status.  The nuclear estrogen receptor alpha (ER) expression and the nuclear 
progesterone receptor expression (PR) expression is determined by 
immunohistochemical staining and calculated according to the Remmele Score 




percentage of the stained nuclei which are summarized in an immune reactive score 
(0-12). The chief markers to subcategorize breast cancer are not only ER and PR but 
also the oncogene human epidermal growth factor receptor 2 (Her2). The combination 
of these markers allows the assignment of individual cases to specific categories, 
namely Luminal breast cancer ER+ (ER+/HER2–), HER2+ breast cancer (ER–/HER2+), 
triple-negative breast cancer (TNBC; ER–/PR–/HER2–), and Luminal B /Her2+ breast 
cancer (ER+/PR(+/-)/HER2+) (Bertos and Park, 2011). 
1.1.4 Luminal breast cancer  
Luminal breast cancer is the predominant type of breast cancer with an incidence of 
70-80%. This tumor entity can further be subdivided into Luminal A (low-risk) and 
Luminal B (high-risk) tumors (Sørlie et al., 2001; Perou et al., 2000). According to St. 
Gallen conference 2011, the proliferation capacity of these tumors is characterized by 
Ki67 < 14 % and Ki67 > 14 %, respectively (Goldhirsch et al., 2011; Cheang et al., 
2009). This classification is a guidance value for therapy decisions. In matters of a high 
proliferation capacity, the decision for Luminal B breast cancer patients is in favor of 
chemotherapy treatment, whereas this therapy approach is disputable when the 
proliferation threshold is close to 14 %. Luminal A tumors with a low proliferation 
capacity do not necessarily benefit from cytostatic drugs and receive only endocrine 
therapy in most cases. It is known that the response of an anti-hormonal therapy is 
more efficient in Luminal A breast cancer patients compared to Luminal B breast 
cancer patients (Rouzier et al., 2005; Hayes et al., 2007; Goldhirsch et al., 2011). 
However, the differentiation between high and low-risk Liminal B tumors remains 
crucial. Another step towards risk stratification in Luminal breast cancer are the gene 
expression tests that are able to predict a risk assessment for recurrence or the 
development of distant metastases and therefore help to estimate the need for 
chemotherapeutic intervention. Oncotype DX (21 gene assay) and EndoPredict (11 
gene assay) were both prognostic for the risk of distant recurrence (Narain and Adcock, 
2017). Mammaprint (Agendia) assesses the risk of recurrence through the 
determination of 70 genes. The Prosigna (PAM50; 55 gene assay) assay has been 
validated as a prognosticator in clinically low-risk, postmenopausal patients with ER+ 
early-stage breast cancer treated with endocrine therapy (Narain and Adcock, 2017). 
The test separates the high and low-risk Luminal B patients by a risk of recurrence 
score. However, the prediction of variable gene expression tests is still unsatisfying as 




(Alvarado et al., 2015). Luminal B tumors also tend to metastasize into various organs 
including the bone marrow and are therefore associated with a poorer prognosis. 
However, if Luminal B breast cancer patients profit from chemotherapy is still disputed 
(Goldhirsch et al., 2011; Lønning, 2012). 
1.2 Breast cancer metastases  
One of the major problems of suffering from breast cancer is still not the primary tumor 
but the development of distant metastases. Although approximately 6 % of the newly 
diagnoses patients harbor metastases, about 30 % of the women with breast cancer 
will develop distant metastases (O'Shaughnessy, 2005). The frequency did not change 
in the last decades, which is referable to the fact that the biology of metastatic 
processes and adequate prevention is less understood. 
1.2.1 Metastatic sites in breast cancer 
Breast cancer metastases are frequently found in the distant lymph nodes, the liver, 
the lung, the bone marrow, and the brain (Wu et al., 2017). However, there are 
differences between breast cancer subentities and metastatic sites. Luminal B tumors 
show preferentially metastases in the liver, the lung, and the distant lymph nodes. If 
the Luminal B tumors additionally overexpress Her2, the brain, and the bone marrow 
are frequent sites of metastatic colonization (Chen et al., 2018). Still, 70 % of the 
metastases are determined in the bone and is, therefore, the most prominent target 
site in breast cancer (Weilbaecher et al., 2011). This so-called organotropism was 
shown to be driven by the different breast cancer subentities, different gene signatures, 
and different signaling pathways of metastatic tumor cells, and the crosstalk with the 
host (immune) microenvironment, (Chen et al., 2018). This phenomenon is supported 
by the hypothesis of “seed and soil” that was claimed by Paget decades ago. The 
tumor cells (seed) can only grow in a distant organ (soil) if it is “planted” in the 
appropriate microenvironment (Paget, 1889). The chemical attraction is one of the key 
modulators to successfully colonize at distant organs. Multiple factors like cytokines, 
bone sialoprotein, or osteopontin expression in the microenvironment are implicated to 
play a major role in metastases formation (Ibrahim et al., 2000). Nevertheless, the 





1.2.2 EMT and MET in breast cancer metastases  
Metastases development is a multifactorial process that requires several factors to 
enable the cancer cell to spread. In each step, the cancer cell could be eliminated by 
the failure of adaption or due to immune cell eradication. Therefore, only a few cells 
that are adjusted will succeed in the colonization of distant organs (Fidler, 2003; 
Valastyan and Weinberg, 2011).  The stepwise cascade from the primary tumor to the 
adaptation to foreign tissue microenvironments comprises (1) the local invasion of 
primary tumor cells through surrounding extracellular matrix (ECM) and stromal cell 
layers accompanied by the intravasation of the tumor cell into the blood vessels, (2) 
the survival as a circulating tumor cell (CTC) in the vasculature periphery, (3) the 
arresting at distant organ sites, (4) the adherence to the vessel wall and the 
extravasation into the distant tissues, (5) the persistence in the foreign 
microenvironment, and (6) the proliferation to form micrometastases in the distant 
organ (Valastyan and Weinberg, 2011; Fidler, 2003; Bill and Christofori, 2015). 
 
 
Figure 2: Schematic description of the development of distant metastases  
A) The initial step requires progressive tumor growth. B) The tumor needs extensive vascularisation to allow the 
tumor cells to C) detach and invade the blood vessels. D) The tumor cells are then circulating in the peripheral 
blood where they have to survive. Next, the cells arrest in an organ by the adherence to the vessel wall. E) The 
extravasation is followed by the adaptation to the new microenvironment. F) The proliferation and the 
angiogenesis completes the metastatic process to form solid metastases. This figure is adapted and modified 




These multiple processes require an adaptation of the tumor cell to the physiology of 
a certain location. Epithelial to mesenchymal transition (EMT) is a reversible process 
that attains the tumor cells a mesenchymal phenotype in order to exit the primary tumor 
site and allows them to metastasize to distant organs (Kotiyal and Bhattacharya, 2014). 
In contrast, mesenchymal to epithelial transition (MET) is required after colonization of 
an organ to build a new malignant tumor growth the so-called metastasis.  In terms of 
EMT, the TGFbeta and RTK/ Ras signaling, EMT transcription factors, and pathways 
such as Wnt, Notch, and Hedgehog are known to contribute to that process (Bill and 
Christofori, 2015; Felipe Lima et al., 2016). The reduced expression of E-cadherin, as 
a cell-cell adhesion molecule, regulated by the transcription factors Snail and Twist 
seems to be one of the crucial steps that drive EMT (Huber et al., 2005). Cancer 
stemness has been associated with an enhanced capacity for EMT. Breast cancer 
stem cells exhibit cellular plasticity as they are able to reversibly transit between the 
mesenchymal and the epithelial state. This tumor cell plasticity and the evolvement of 
breast cancer stem cells (CSC) are associated with EMT that typically goes along with 
altered expression or activity of cytokeratin, vimentin, CD24, Claudin, ALDH, SLUG, 
and SNAIL and consequently with an increased capacity of self-renewal, tumor 
initiation, and recurrence (Al-Hajj et al., 2003; Liu and Wicha, 2010). 
1.2.3 Stem cells traits and their relevance in EMT-MET and breast cancer 
metastases  
To date, it remains still challenging to detect all tumor cells in the periphery e.g. as 
DTCs in the BM or circulating tumor cells (CTCs) in the peripheral blood. The DTC and 
CTCs are a prognostic factor for patient survival and metastatic spread (Braun et al., 
2005). The established method for CTC detection in the blood is the CellSearch® 
system that is able to quantify the tumor cells in seven ml blood due to the expression 
of EpCAM on the surface of the tumor cells. EpCAM as epithelial cell adhesion 
molecule is only expressed on epithelial cells and thereby this method excludes the 
mesenchymal and hematopoietic cells (Gires and Stoecklein, 2014). EpCAM plays a 
major role in embryonic development and is located at the basolateral membrane in 
normal epithelial tissue (Gires, 2011). Besides the expression in normal tissue EpCAM 
is expressed in a variety of malignancies including breast cancer. Preferentially  
EpCAM is found on luminal cells (Visvader and Stingl, 2014). However, its regulation 
is rather dynamic. While EpCAM is highly expressed in the primary tumor, the 




This fact shows that CTC capturing through EpCAM expression might not detect all 
tumor cells. EpCAM is highly expressed especially in Her2+ Luminal B breast cancer 
and associated with a rather unfavorable prognosis (Soysal et al., 2013). Additionally, 
EpCAM expression in the primary breast cancer tumor is associated with increased 
bone marrow metastases and increased stem cell capacity of the tumor cells (Hiraga 
et al., 2016; Huber et al., 2015). Not only EpCAM as a cell adhesion molecule but also 
CD44 and CD24 play a pivotal role in breast cancer stemness and metastases. CD44 
is necessary for the communication and adhesion between adjacent cells and between 
cells and the extracellular matrix and was shown to contribute to metastasis formation 
(Naor et al., 2002). It can interact with a variety of effectors such as the hyaluronic acid 
– an abundant compound of the extracellular matrix (Toole, 2009; Louderbough and 
Schroeder, 2011) and is expressed by a multitude of carcinoma cells especially on 
cancer-initiating ones (Zöller, 2011; Wang et al., 2018b). Moreover, it plays a major 
role in cell adhesion, cell proliferation, migration, invasiveness, chemoresistance and 
metastasis initiation (Baccelli et al., 2013; Zöller, 2011; Naor et al., 2008; Williams et 
al., 2013). CD24 is a heavily glycosylated mucin-like glycosylphosphatidyl-inositol-
linked cell surface protein and is expressed in a wide variety of human malignancies 
(Jaggupilli and Elkord, 2012). The high CD24 expression levels are associated with 
enhanced proliferation (Baumann et al., 2005), clonogenicity in vitro (Smith et al., 
2006), and metastases (Friederichs et al., 2000). However, the expression of CD44 high 
/CD24 low was determined previously to be the tumor-initiating phenotype for breast 
cancer stem cells whereas the multitude of cells within the same tumor exhibit CD44 
low / CD24 high (Al-Hajj et al., 2003; Mani et al., 2008). It was also shown that the CD44 
high /CD24 low phenotype is frequently expressed in highly aggressive TNBC and Her2+ 
breast cancer (Honeth et al., 2008). CD47 is an integrin associated transmembrane 
protein and known for its interaction with the SIRP alpha receptor to prevent 
phagocytosis by macrophages or dendritic cells. The expression of CD47 as “Don’t eat 
me signal”, therefore, enables the cancer cell to be eradicated by immune cells 
(Nagahara et al., 2010). High expression of CD47 in CTCs and DTCs was associated 
with decreased DFS in breast cancer patients (Nagahara et al., 2010). Additionally, 
high CD47 and CD44 co-expression were shown previously to be a prognosticator for 
limited survival in Luminal breast cancer (Baccelli et al., 2014). Another important 
biomarker is cMET also called HGFR (hepatocyte growth factor receptor). This 




diverse cellular functions that play an important role in organ development and cancer 
progression (Trusolino et al., 2010). HGF is one of the factors that promote invasive 
tumor growth, metastases formation and induction of EMT (Christofori, 2006). By 
means of its role in metastasis initiation (Baccelli et al., 2013) a high cMET expression 
has been shown to be associated with reduced survival and an aggressive phenotype 
in breast cancer patients (Ho-Yen et al., 2015). In addition, cMET has also been 
determined to inversely correlate with tumor size in breast cancer (Ho-Yen et al., 2014). 
Interestingly, the HGF induced activation of cMET stimulated the CD44 signal 
transduction and stabilized the androgen receptor functions in prostate cancer (Ghatak 
et al., 2010). However, the co-expression of EpCAM+/ CD44+/ CD47+/cMET+ was 
demonstrated by Baccelli to be the prominent phenotype in CTCs to initiate metastases 
(metastases initiating cells (MIC)) in breast cancer (Baccelli et al., 2013) further 
showing the potential of CD47 and cMET as CSC biomarkers. Another important 
oncogene in breast cancer is Her2. Her2 as receptor tyrosine kinase is overexpressed 
in 20 - 25 % of invasive breast cancer and predicts a poor clinical outcome (Slamon et 
al., 1987). The overexpression of Her2 is in most cases due to the amplification of the 
Her2 gene. The constitutive kinase activity in Her2+ breast cancer, therefore, promotes 
increased proliferation and invasion of the tumor cells (Olayioye, 2001). Despite the 
prognostic and predictive value of Her2 in breast cancer, it is also implicated as a driver 
for breast cancer stemness as Her2+ breast cancer cells showed an increased 
mammosphere formation due to increased clonogenicity (Korkaya et al., 2008; 
Korkaya and Wicha, 2009; Magnifico et al., 2009). Other researchers reported the 
detection of Her2+ DTCs that arose from Her2- breast cancer tumor, suggesting a small 
subpopulation of Her2 overexpressing tumor cells in the primary tumor that might be 
missed by routine diagnostic of the primary tumor (Pantel and Alix-Panabières, 2014). 
The prognosis of Her2 breast cancer is poor as those tumors often tend to generate 
distant metastases. However, it is possible to treat Her2+ breast cancer adequately 
with the monoclonal antibody Trastuzumab (Herceptin) in combination with 
chemotherapy. This therapeutic intervention targets Her2 and therefore efficiently 
diminish the proliferation and increases disease-free survival (Piccart-Gebhart et al., 
2005). Even though several biomarkers are known to be regulated in breast cancer 
and breast cancer metastases, it still remains to be elucidated which additional factor 




1.2.4 Disseminated tumor cells (DTCs) 
During the way of the tumor cells through the periphery (e.g. the blood or the lymph 
vessels) the cells referred to CTC, whereas after extravasation and colonization the 
tumor cells are termed as disseminated tumor cells (DTC). The DTCs can be detected 
in the mesenchymal tissue due to their epithelial origin thereby expressing cytokeratins 
such as CK8, CK18, and CK19 (Braun et al., 2005). The occurrence of DTCs in the 
bone marrow of breast cancer patients is a risk factor for the development of distant 
metastases (Wiedswang et al., 2003). Moreover, the DTC persistence correlates with 
diminished disease-free survival (DFS) and reduced overall survival (OS) (Janni et al., 
2011). However, the time at which dissemination takes place is still disputed. There 
are two well-known theories when dissemination occurs. The first one is that the cancer 
cells were shown to disseminate at late stages (Koscielny et al., 1984), and the second 
one is the well-accepted theory of parallel progression of tumor cell dissemination and 
tumor growth (Klein, 2009). Moreover, tumor cell dissemination can occur even in the 
absence of a detectable tumor as so-called cancer of unknown primary(van de Wouw 
et al., 2002). Surprisingly, epidemiologic studies revealed that metastases could be 
initiated already five to seven years before the primary tumor is diagnosed (Engel et 
al., 2003). Supporting the early dissemination hypothesis it was shown that DTCs from 
breast cancer patients harbor fewer aberrations than the primary tumor cells at an 
advanced state, indicating a slow progression of DTCs (Schmidt-Kittler et al., 2003). 
However, there are some studies that demonstrated a genomic congruency of DTCs 
and primary tumor cells in breast cancer (Mathiesen et al., 2012; Stoecklein et al., 
2008). Interestingly, the recurrence and metastases in breast cancer take a long period 
of time after primary tumor detection indicating that DTCs could somehow 
transform/switch in a state of dormancy. To date, there are two types of dormancy 
known. One state of dormancy is defined by the potential of the cancer cell to stay in 
an arrested cell cycle phase (G0/G1) that is reversible (Hayat, 2013) and the other 
state is called tumor mass dormancy where the equilibrium of cell death and self-
renewal of the cancer cell (Kareva, 2016). However, the fate of the disseminated cell 
is supposed to be triggered by several intrinsic and extrinsic factors that contribute to 
dormancy or active proliferation (Osisami and Keller, 2013).  
1.3 The role of genetic aberrations in breast cancer   
Despite Her2, there are several other aberrations that are frequently altered in breast 




detected frequently. The latter is preferentially found in very aggressive tumor types 
such as TNBC and Her2+ breast cancer (Abubakar et al., 2019) and is associated with 
poor clinical outcome. P53 as a product of the TP53 tumor suppressor gene is not 
expressed in healthy cells or rather to a low degree. If stressors like DNA damages, 
hypoxia, or activation of oncogenes occur in healthy cells, p53 turns on transcriptional 
target genes to send the cell in cell cycle arrest in order to prevent DNA lesions. 
However, if the DNA damages are irreparable the p53 upregulation promotes 
apoptosis (Shi and Gu, 2012). P53 also induces the transcription of mouse double 
minute protein 2 (MDM2), an E3-ligase, which serves as a negative feedback regulator. 
It ubiquitinylates p53 for its degradation on the proteasome. MDM2 deregulations 
frequently occur in Luminal B breast cancer (31%) and in Her2+ breast cancer (30%) 
(Network, 2012) and were shown to promote invasiveness, EMT, and metastases in 
breast cancer (Haupt et al., 2017). In contrast, TP53 mutations are predominantly 
detected in TNBC and Her2+ breast cancer. 
1.4 TILs and immune checkpoints in breast cancer  
The evaluation of tumor-infiltrating lymphocytes (TIL) is gaining more and more clinical 
relevance in breast cancer as they were shown to have a potential prognostic and 
predictive value (Salgado et al., 2015). The most TILs can be found in in TNBC with 
an average of 20 % infiltration (range: 4 % - 37 %) and in Her2+ breast cancer with an 
average of 16 % (range: 11 % - 24 %). In both subtypes/entities, increased  infiltration 
is associated with a survival benefit (Stanton et al., 2016). Furthermore, all breast 
cancer subtypes with TILs predicted response to neoadjuvant chemotherapeutic 
intervention. The same study described increased immune cell infiltration as an 
adverse prognostic factor for the outcome in Luminal-HER2- breast cancer patients, 
(Denkert et al., 2018). Even though the TNBC and Her2+ subtypes are immunogenic, 
Luminal breast cancer is rather escaping immunosurveillance and is only low infiltrated 
with an average of 6 % (range: 3 % - 12 %) (Stanton et al., 2016). Nevertheless, 
Luminal B Her2+ breast cancer is infiltrated with TILs to a greater extent (9 %) 
compared to Luminal A/B Her2- breast cancer (1%) (Pruneri et al., 2017). The CD8 
infiltration inversely correlated with the ER-alpha and PR expression whereas the 
presence of CD8+ immune cells predicted a favorable outcome for the patient 
(Mahmoud et al., 2011). The infiltration of CD4+ cells was shown to be increased 
preferentially in aggressive tumor types such as TNBC and Her2+ breast cancer (Meng 




like T regs or B cells play a prognostic role in different stages of the mamma carcinoma 
(early breast cancer, neoadjuvant or adjuvant situation, metastasized) (DeNardo and 
Coussens, 2007; Emens, 2012). Not only the immune cell infiltration but also the tumor-
immune cell interactions play a pivotal role. This interaction involves tumor cell 
elimination, tumor-immune cell equilibrium, but also the escape of tumor cells from the 
immunological defense. This could be achieved, besides other mechanisms, by the 
expression of inhibitory immune checkpoint molecules (Mittal et al., 2014). Therapeutic 
strategies designed to stimulate the patient’s inherent immunological tumor defense 
e.g., by targeting immune checkpoints are considered to enhance conventional 
treatment regimens. A prominent target that contributes to tumor cell evasion is the 
immune checkpoint programmed death-ligand 1 (PD-L1). If expressed by tumor cells 
(Blank et al., 2005), the interaction of PD-L1 with its counterpart, the programmed 
death receptor 1 (PD-1) leads to T-cell anergy or apoptosis (Keir et al., 2008). Triple-
negative breast cancer (TNBC) specimens showed the highest level of PD-L1 
expression, followed by Her2 overexpressing subtypes, and lastly the Luminal 
(Luminal A and Luminal B) entities (Ali et al., 2015; Ghebeh et al., 2006). However, 
PD-L1 expression on tumor cells has repeatedly been associated with a worse 
outcome (Wang et al., 2016). Still, the relevance of PD-L1 and PD-1 expression in 
breast cancer is discussed controversially (Stovgaard et al., 2019). 
1.5 PDX models and humanized PDX models in breast cancer research 
Mice are still the most common animals for usage as a model organism because of 
high genetic homology, easy genetic manipulation, a fully sequenced genome, low cost 
in breeding and quick reproduction cycles (Perlman, 2016). The understanding of the 
genomic landscape, the metastatic spread and the biology of breast cancer still 
remains challenging. The development of patient-derived xenografts (PDX) opened up 
new possibilities, thus, the breast cancer tumor engrafted in mice properly, reflected 
the heterogeneity of the primary tumor, the tumor behavior, and also the metastatic 
properties. Moreover, it was possible to detect new breast cancer targets and the PDX 
model was susceptible to predict treatment response which was a big step towards 
personalized medicine (Whittle et al., 2015; Landis et al., 2013). Different ways of 
primary tumor transplantations were used for the generation of breast cancer PDX 
models. In most cases, the tumors were transplanted orthotopic, hence, into the 
mammary fat pad of the mice (Al-Hajj et al., 2003; DeRose et al., 2011; Zhang and 




subrenal capsule, intraductal or interscapular transplantations were also successful 
(Marangoni et al., 2009; Cottu et al., 2012; Reyal et al., 2012; Fiche et al., 2019; Eirew 
et al., 2015; Bergamaschi et al., 2009). It was shown that successful engraftment is 
also determined by breast cancer subentity and their molecular traits. TNBC and Her2+ 
breast cancer and metastatic breast cancer showed higher engraftment rates 
compared with the Luminal hormone receptor-positive entities (Landis et al., 2013; 
Baccelli et al., 2013). However, several improvements contributed to increased PDX 
take rates like the supplementation of estradiol as a subcutaneous transplanted pellet 
in hormone receptor-positive tumors (Al-Hajj et al., 2003; Marangoni et al., 2007), the 
use of Matrigel (Fleming et al., 2010; Kabos et al., 2012), the supplementations of 
human mesenchymal stem cell, (DeRose et al., 2011) or the use of highly 
immunosuppressed mice (Oakes et al., 2012; Zhang et al., 2013; Kabos et al., 2012). 
Highly immunosuppressed mice like NOD-SCID IL2Rγnull (NSG) mice have no T, B, 
or natural killer cells and a reduced myeloid cell function (Shultz et al., 2005). The 
enhanced life span of these mice of over 1.5 years is an advantage due to the 
prolonged engraftment duration of a primary breast cancer tumor of approximately six 
months up to one year. Additionally, the NSG mouse strain exhibited the highest 
engraftment rates (Carreno et al., 2009). A list of the most important breast cancer 
PDX studies, different breast cancer entities, mouse strains, transplantation sites and 
the overall success rate of engraftment is provided in Table 1. Various studies with 
breast cancer PDX models were shown to display the patients tumor heterogeneity,  
the metastatic behavior of the tumor, the patients disease outcome (DeRose et al., 
2011; Valdez et al., 2011), and the concordance of drug response in patients 
(Marangoni et al., 2007; Cottu et al., 2012; Cottu et al., 2014). The EurOPDX 
consortium was founded to enable translational knowledge in oncology by providing 
access to a multitude of PDX models. Hence, the EurOPDX harnesses the clinically 
relevant models in cancer, avoids the duplication of research efforts and improves drug 
development processes through interchanging data with other researchers. 
Nevertheless, the influence of the human immune system cannot be elucidated in 
these PDX models. The severe combined immune deficiency (SCID) mutation of the 
NSG mice additionally provides the opportunity to engraft human immune cells. This 
can be performed by the isolation of hematopoietic stem cells (CD34+) from the human 
peripheral blood, the cord blood, the fetal liver cells from an abort, or the bone marrow, 




or intrahepatically using neonatal or adult immunodeficient mice (Wege, 2018). The 
humanized PDX model is another option of the humanized mouse model whereby the 
transplantation of primary breast cancer cells follows 12 weeks after humanization. 
These mouse models have been used in preclinical checkpoint inhibitor studies of 
TNBC humanized PDX mice that were treated with anti-PD-1 therapy. This resulted in 
a reduction of the tumor size whereby this reduction could be traced back to the 
inhibition of PD-1/CD8+ cells (Wang et al., 2018a). However, to date humanized PDX 
models in breast cancer research are used only rarely, which might be due to the fact 
that several factors like the availability of newborn mice, the immune system 
engraftment, primary tissue availability and toleration, and long latencies until tumor 
outgrowth that has to be combined in one experiment. Nevertheless, humanized breast 
cancer PDX models are a step towards a detailed understanding of breast cancer 
biology, metastasizing, and dissemination, under the influence of a human immune 
system. In addition, these mice can be used for preclinical studies in the area of 
immunomodulation. 
Table 1: Overview of generated breast cancer PDX models 
Study Breast cancer 
subtype 
Mouse Strain Transplantation site 





(Visonneau et al., 
1998) 
N.A. SCID s.c. 
tumor fragments 
50 %  
(Beckhove et al., 
2003) 




(Ma et al., 2012) TNBC NOD/SCID mfp 
single cells  
fibroblasts  
N.A. 
(Liu et al., 2010; Al-
Hajj et al., 2003) 
4 TNBC 2 Her2+ 2 
ER+ 




(Marangoni et al., 
2007; Cottu et al., 
2012; Reyal et al., 
2012) 
15 TNBC,2 Her2+, 1 
ER+, (Marangoni et 
al., 2007), 22 
TNBC, 8 ER+ (Cottu 
et al., 2012) 




(Bergamaschi et al., 
2009) 
1 TNBC, 1 ER+ SCID s.c. in the back pocket 






(DeRose et al., 2011) 5 TNBC, 2 Her2+, 2 
ER+, 
NOD/SCID cleared mfp 
tissue fragments, 
metastastic single cells 
estradiol  
27 % 






 +/- fibroblasts, estradiol  
30 % 





42 %  
(Petrillo et al., 2012) 4 TNBC, 1 Her2+, 0 
ER+ 




(Fleming et al., 2010) 2 Her2+, 2 ER+ NOD/SCID abdominal mfp 
pleural effusion cells  
estradiol, matrigel 
N.A. 
(Vaillant et al., 2013; 
Oakes et al., 2012) 
17 TNBC, 13 ER+, 2 
ER-PR+, 5 Her2+, 
NSG inguinal mfp 
tumor fragments  
estradiol 
23 % 
(Eirew et al., 2015) 6 TNBC, 5 ER+, 4 
Her2+ 
NSG, NRG mfp, s.c., sr N.A. 
(Fiche et al., 2019) 21 ER+ NSG intraductal mfp 
single cells 
N.A. 
TNBC Triple-negative breast cancer, ER estrogen receptor, Her2 human epidermal growth factor receptor, 
NOD/SCID non-obese diabetic / severe combined immune deficiency, NSG NOD-SCID IL2Rγnull, NRG NOD.Cg- 
Rag1tm1Mom IL2rgtm1Wjl, mfp mammary fat pad, s.c. subcutaneous, id intraductal, sr subrenal capsule, im 






1.6 Aim of the thesis 
The aim of this thesis, as part of the Deutsche Krebshilfe founded Luminal B 
consortium, was to determine markers for the heterogeneous Luminal B group to 
differentiate them into high and low-risk patients. Hence, the therapy decision could be 
facilitated if a Luminal B breast cancer patient might benefit from chemotherapeutic 
intervention or not. This goal should be realized by the generation and the analysis of 
patient-derived Luminal B xenografts in the so-called tumor mice (TM) or humanized 
tumor mice (HTM). These mice were generated by orthotopic transplantation and the 
subsequent expansion of primary tumor material from Luminal B patients in 
immunodeficient NSG mice. Finally, the expanded tumor material from these mice was 
further transplanted into mice which were neonatally reconstituted with human 
hematopoietic stem cells (HSC) derived from human cord blood. These mice 
developed a human immune system together with human tumor growth and allowed 
studies under human-like conditions. The main questions which should be addressed 
are:  
(1.) the phenotypic differences of human high- and low-risk Luminal B  
(2.) the evaluation of the capacity of Luminal B breast cancer to disseminate and 
to form metastases in TM and HTM (i.e., in the presence of a human immune 
system), 
(3.) the identification of geno- and phenotypic patterns in primary Luminal B tumors 
that are associated with tumor outgrowth and cell dissemination (metastasis 
formation) and EMT / basal cell-like traits,  
(4.) the analysis of phenotypical changes between the primary tumor and the 
corresponding metastases in the TM and HTM model, and 
(5.) the assessment of human immune cell activity and invasion in correlation to 
tumor outgrowth, dissemination, and metastases.  
Overall, the main goal of this thesis was to identify biomarkers that are associated with 






2. Material  
2.1 Consumables  
12 % Mini Criterion TGX Stain-free gels BioRad Laboratories, Munich, Germany 
15 ml tube Greiner Bio-One Bioscience, Frickenhausen, 
Germany 
17ß-Estradiol pellets 0,18mg/90days  Innovative Research of America, Florida, USA 
40 µm cell strainer  Corning, NY, USA 
50 ml tube Greiner Bio-One Bioscience, Frickenhausen, 
Germany 
Adhesion slides Carl Roth, Karlsruhe, Germany 
BD Discardit II 2 ml, 5 ml, 10 ml, 20 ml 
(syringes) 
BD Biosciences, Heidelberg, Germany 
BD Microlance 3 20G, 22G, 27G 
(cannulas) 
BD Biosciences, Heidelberg, Germany 
BD SafetyGlide Insulin syringe BD Biosciences, Heidelberg, Germany 
Cell Scraper  Greiner, Solingen, Germany 
Cord blood collection bag  Macopharma, Langen, Germany 
Culture-Insert 2 Well in µ-Dish 35 mm Ibidi, Gräfelfing, Germany 
Cyro tubes  Greiner, Solingen, Germany 
MACS separation LD columns Miltenyi Biotech, Bergisch Gladbach,Germany 
MACS separation MS columns   Miltenyi Biotech, Bergisch Gladbach,Germany 
Medicon Einsatze unsteril  BD Biosciences, Heidelberg, Germany 
Medimachine Medicon sterile  BD Biosciences, Heidelberg, Germany 
Petri dish sterile Sarstedt AG & Co., Nümbrecht, Germany 
Round Bottom Polystyrene Test Tube 
(5ml) 
Falcon, Heidelberg, Germany 
SuperFrost Plus Slides  Menzel GmbH, Braunschweig, Germany 
T25 tissue flask Greiner Bio-One, Frickenhausen, Germany 
Trimming blades pfm medical AG, Cologne, Germany 
Vicryl surgical sutures Johnson & Johnson, New Brunswick, New 
Jersey, USA 
2.2 Buffers and Solutions  
AB serum, human BioRad Laboratories, Munich, Germany 
Accutase 100 ml  
Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Amphotericin B solution  Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
B27 supplement 50x minus Vitamin A Life Technologies, Carlsbad, CA, USA 
BSA 10x 10ml  BioRad Laboratories, Munich, Germany 
Cell Lysis Buffer Cell Signaling Technology, Inc., Beverly, 
MA, USA 
Cholera Toxin 5ml 






Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
CryoStor® CS10  Stemcell Technologies, Vancouver, Canada 
DAB plus substrate-chromogen solution Dako, Santa Clara, CA United States 
Dako REAL™ Peroxidase-Blocking Solution DAKO, Hamburg, Germany 
DAKO wash buffer 10x DAKO, Hamburg, Germany 
DMSO  Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
DNAse I 
Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
EDTA Thermo Scientific, Rockford, USA 
EDTA-Lösung pH 8,0 (0,5M)  Applichem, Darmstadt, Germany 
FCS   Gibco, Rockford, USA 
HALT Protease Inhibitor  Thermo Fisher Scientific, Rockford, USA 
HEPES solution 
Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Hyaluronidase 
Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Hydrocortison 
Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Insulin solution 5ml 
Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Matrigel (Cultrex PathClear Basement 
Membrane Extract) 
 R&D Systems, Inc., Minneapolis, USA 
Methanol Merck Millipore, Darmstadt, Germany 
Pancoll human, density 1077g/ml PAN Biotech GmbH, Aidenbach, Germany 
PBS Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Penicillin/Streptomycin (10 U/μL)  PAN Biotech GmbH, Aidenbach, Germany 
PMSF AppliChem, Darmstadt, Germany 
rh EGF 100µg  Immunotools, Friesoythe, Germany 
rh FGF basic/FGF-2 50 µg Immunotools, Friesoythe, Germany 
RIPA buffer  Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Trypsin with EDTA PAN Biotech GmbH, Aidenbach, Germany 
Türk′s solution Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
2.3 Buffers 
Tris/Borate/EDTA (TBE) buffer 10x 539 g Tris 
275 g Boric acid 
37 g EDTA 
5 l Demineralized water 
FACS buffer  PBS  
0.01 % NaN3 
1 % FCS  




1.4 M NaCl 
25mM CaCl2 
PBS /EDTA 2mM PBS  
EDTA 2mM 
TAC buffer 
TRIS: 170 mM, pH: 7.4 
NH4Cl:  150mM pH: 7.4 
Millipore H2O 
Separation buffer  
PBS   
BSA  0.5 % 
EDTA  2mM 
2.4 Culture Media  
Basal Medium  DMEM/F12  
1 % HEPES (1M) 
1 % Pen/Strep 
1 % Amphotericin B  
DMEM Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
DMEM/F12  PAN Biotech, Aidenbach, Germany 
RPMI-1640 PAN Biotech, Aidenbach, Germany 
2.5 Cell lines  
N1 = normal human skin fibroblasts (cloned 
but not immortalized) 
Department of Clinical Chemistry, University 
of Regensburg 
NIH/3T3 (primary mouse embryonic 
fibroblast cells) 
ATCC number CRL-1658 
JIMT 1 DSMZ ACC-number -589 
BT474 ATCC number HTB-20 
MDA-MB 231 ATCC number HTB-26 
SK-BR-3  ATCC number HTB-30 
ZR-75-1 ATCC number CRL-1500 
2.6 Anesthesia 
amount  product name 
(concentration) 
active component dose 
10 ml (2 ml + 8 ml 
aqua dest.) 
Dormicum (1 mg/ml) Midazolam 5 mg/kg 
2 ml Fentanyl (0.05 
mg/ml) 
Fentanylcitrat 0.05 mg/kg 
1 ml Domitor (1 mg/ml) Medetomidin 0.5 mg/kg 
 
amount  product name 
(concentration) 
active component dose 
5 ml Anexate (0.1 mg/ml) Flumazenil 0.5 mg/kg 
0.5 ml Antisedan (5 mg/ml) Atipamezol 2.5 mg/kg 
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2.8 Antibody Immunohistochemical Staining 
Antibody Supplier  Clone  Dilution 
CK 18  DAKO DC10 1:50 
ER  DAKO 6F11 1:35 
PR Novocastra Clone 16 1:50 
Her2 DAKO Rab poly 1:250 
Ki67 DAKO MIB-1 1:200 
EpCAM DAKO Ber-EP4 1:200 
PD-L1  Abcam [28-8] 2 μg/ml 
MDM2 Calbiochem IF2 1.5 µg/ml 
CD44 cell signaling 156-3C11 1: 50 
CD47 R&D catalog number 
AF4670 
1: 25 
Cytokeratin A 45 
B/B3 (CK 8, CK 18, 
CK 19) 
Micromet, Munich A 45 B/B3 1:100 
Isotype IgG1 Kappa  Sigma  MOPC 21 M9269-
1MG) 
1:500 
2.9 Kits  
Ampli1TM LowPass Kit (SET 
A+Set B) 2 x 48 reactions 
Menarini Silicon Biosystems, Castel 
Maggiore BO, Italy 
Ampli1™ WGA (Menarini Silicon 
Biosystems, USA) 
Menarini Silicon Biosystems, Castel 
Maggiore BO, Italy 
Annexin V FITC  Immunotools, Friesoythe, Germany 
AP conjugate Substrate Kit BioRad Laboratories, Munich, Germany 
BCA-Protein-Assay-Kit  Thermo Fisher Scientific, Rockford, USA 




CD34 microbead kit, human Miltenyi Biotech, Bergisch Gladbach, 
Germany 
CD45 MicroBeads, human Miltenyi Biotech, Bergisch 
Gladbach,Germany 
iQ Sybr green supermix  Bio-Rad Laboratories GmbH, Munich, 
Germany 
iView DAB detection kit Ventana, Tucson, USA 
SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate 
Thermo Fisher Scientific, Rockford, USA 
2.10 siRNA 
Dharmafect 1 (T-2001-02) Horizon (Dharmacon), Lafayette, CO, USA 
ON TargetPlus NON-Targeting Pool Horizon (Dharmacon), Lafayette, CO, USA 
Smart pool: ON TargetPlus MDM2 siRNA Horizon (Dharmacon), Lafayette, CO, USA 
2.11 Reagents and chemicals  
1 kb Plus DNA Ladder + Dye New England Biolabs, Massachusetts, USA 
ß-Estardiol water soluble Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Agarose LE Anprotec, Bruckberg, Germany 
AMG232 Axon Medchem BV, Groningen, 
Netherlands 
BSA 20 mg/ml Roche Diagnostics, Basel, Switzerland 
DAPI 50 µg/ml Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Entellan  Merck, Darmstadt, Germany 
Eosin Carl Roth, Karlsruhe, Germany 
Ethidium Bromide Solution (10 mg/ml) Sigma-Aldrich Chemie GmbH, Deisenhofen 
Expand Long Templ.PCR Syst. 3600 U Roche Diagnostics, Basel, Switzerland 
FastStart Taq DNA Polymerase, dNTPack 5 
U/µl 
Roche Diagnostics, Basel, Switzerland 
GeneRuler 100bp Plus DNA ladder Thermo Fisher Scientific, Rockford, USA 
Hematoxylin Merck, Darmstadt, Germany 
Heparin  Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
PCR-H2O, Water for Chromatographie VWR, Darmstadt, Germany 
PI 1 mg/mL Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
Precision plus protein Western C marker Bio-Rad, Munich, Germany 
Ribonuclease A (1 mg/mL) Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
RNAse Sigma-Aldrich Chemie GmbH, Deisenhofen, 
Germany 
SuperSignal™ West Pico PLUS 
Chemiluminescent Substrate 
Thermo Fisher Scientific, Rockford, USA 





2.12 Devices  
AxioImager Z1 microscope Zeiss, Oberkochen, Germany 
ELISA-Reader: EMax precision 
microtiter reader 
Molecular Devices GmbH, Ismaning, Germany 
FACSCanto-II flow cytometer BD Biosciences, Heidelberg, Germany 
ImageQuant LAS 4000 mini imager GE Healthcare, Buckinghamshire, UK 
MACS MultiStand Miltenyi Biotech, Bergisch Gladbach, Germany 
Medimachine System  BD Biosciences, Heidelberg, Germany 
MidiMACS™ Miltenyi Biotech, Bergisch Gladbach, Germany 
MiniMACS™ Miltenyi Biotech, Bergisch Gladbach, Germany 
Thermolux heating plate Witte + Sutor GmbH, Murrhardt, Germany 
NanoDrop 2000c spectrophotometer Peqlab Biotechnologie GmbH, Erlangen, Germany 
2.13 Software 
https://info.progenetix.org/uploader.html University of Zurich, Switzerland 
ImageQuant TL GE Healthcare, Buckinghamshire, UK 
AxioVision 4.8 Carl Zeiss Werk, Göttingen, Germany 
Diva software Ver. 7.0 BD Biosciences, Heidelberg, Germany 
ModFit LT 3.2 software  Verity Software House, Topsham, ME, USA 






3.1 Human sample preparation 
All patient samples included in the study were pre- or postmenopausal women 
diagnosed with primary or metastatic breast cancer and underwent surgery or 
therapeutic interventions at Caritas Hospital St. Josef Regensburg. Written informed 
consent was provided by every patient. Fresh, solid tumor material was removed under 
sterile conditions by a pathologist after the arrival at the institute of pathology at the 
University clinic Regensburg. The specimen were taken based on the permission of 
the Ethics Committee of the University of Regensburg (permission number: 14-101-
0063 and 17-527-101). Table 20 shows all samples included in the study. The 
specimen number of the experiments conducted varies due to the fact of limited 
material of some samples. 
3.1.1 Isolation of tumor cells from serous effusions 
Pleural effusion or ascites samples were immediately shipped at room temperature 
after thoracentesis or laparocentesis. The tumor cells were isolated according to the 
protocol of DeRose 2013 (DeRose et al., 2013). In brief, the fluid was transferred to a 
sterile falcon and centrifuged at 530 g for 5 min at 4 °C. The supernatant was discarded 
and red blood cells were lysed with the incubation of the cells in 10 ml TAC buffer 
gently agitating the suspension in a water bath at 37 °C for 10 min. After centrifugation 
at 530 g for 5 min at 4 °C, the lysis was repeated if red blood cells remained on the top 
layer of the tumor cell pellet. The tumor cell suspension was then counted under a light 
microscope with trypan blue staining using a hemocytometer. Occasionally, the 
suspension was cultured in basal medium (DMEM/F12 supplemented with 1 % 1M 
HEPES, 1 % Penicillin/Streptomycin (10 U/μL), and 1 % Amphotericin B) overnight 
until the next day. In order to get rid of remaining immune cells, the was suspension 
was depleted with CD45 MicroBeads (human) according to the manufacturers' protocol 
using manual separators for column-based cell isolation (Miltenyi Biotech). Therefore, 
the cell suspension was centrifuged at 300 g for 10 min at RT, the supernatant was 
aspirated and the pellet was resuspended in the appropriate amount of pre-cooled 
separation buffer (80 µl buffer per 107 total cells). Accordingly, 20 µl of CD45 
Microbeads were added per 107 total cells, mixed and incubated for 15 min in the 




and centrifuged at 300g for 10 min. The supernatant was discarded and the pellet was 
resuspended in separation buffer (108 cells in 500 µl buffer). Before separation, the cell 
suspension was filtered through a 40 µm strainer. The magnetic separation columns 
were pre-rinsed with the appropriate amount of buffer depending on the column size 
(MS (500 µl) or LS (3 ml)). The cell suspension was applied to the column and the 
unlabeled cells that passed through were collected - that is the tumor cell fraction. The 
column was washed three times (3 x 3 ml) and the process was repeated with a fresh 
column to increase the purity of the tumor cell suspension. The column containing the 
CD45+ cells was discarded and the flow containing the tumor cells was counted with 
trypan blue (1:2) using a hemocytometer. Occasionally, the cells were cultured in non-
adherent Nunclon Sphera 6-well plates in basal medium until further use. 
3.1.2 Primary tumor tissue  
The solid tumor material was removed under sterile conditions under a laminar flow 
hood by a pathologist. The tumor was collected in prewarmed basal medium 
(DMEM/F12, 1 % HEPES (1M), 1 % Pen/Strep, 1 % Amphotericin B) in a petri dish 
and minced into fragments of 2 x 2 mm.  The tumor fragments were either transplanted 
subsequently into NSG mice, cryopreserved or stored in basal medium until 
transplantation. Another method was the mechanical dissociation of the primary tumor 
under the laminar flow hood in prewarmed PBS using the Medimachine System with a 
sterile Medicon application. The cell suspension was filtered through a 40 µm strainer 
and centrifuged at RT for 2min at 210 g. The pellet was resuspended in DMEM and 
counted with trypan blue (1:100) using a hemocytometer. 1.5 x 106 tumor cells were 
used for flow cytometric analysis (SCF, RECON, and TCF see Table 4 and Table 5) 
and 2* 106 single cells were used for subcutaneous transplantation into NSG mice. 
3.1.3 Isolation of hematopoietic stem cells from cord blood 
Cord blood samples were obtained based on the approval given by the Ethics 
Committee of the University of Regensburg (permission number 17-527-10). All 
patients provided informed written consent. In order to humanize mice, CD34+ 
hematopoietic stem cells (HSC) were isolated from the umbilical cord blood as 
described in the following:  
Most of the samples were taken during a cesarean section to provide a high amount 
of umbilical cord blood. Immediately after cord blood puncture, the cord blood 




isolation of CD34+ cells was performed under sterile conditions. The content of the 
cord blood collection bag was mixed carefully to avoid blood agglutination, disinfected, 
and placed under the laminar flow hood. The blood was mixed with PBS (1:1) in 50 ml 
falcons (25 ml PBS and 25 ml cord blood). 50 ml falcons pre-filled with 15 ml Pancoll 
were overlayed with 30 ml of the PBS-blood mixture while holding the tube angular to 
avoid agitation. After gradient centrifugation without brake for 30 min at 600 rcf at RT, 
the yellow plasma layer was aspirated and the interphase (buffy coat) containing the 
mononuclear cells (MNCs) was pipetted with a 1000 µl pipette into a 50 ml tube pre-
filled with 25 ml PBS / 2 mM EDTA solution (Figure 3). The bottom layer containing the 
Pancol layer, and a pellet of granulocytes and erythrocytes was discarded. 
 
Figure 3: Graphic presentation of the different layers before and after the density gradient centrifugation 
 Adapted and modified from PAN Biotech GmbH, Aidenbach, Germany 
 
The MNC cell suspension was then centrifuged at 300 rcf for 10 min at 4 °C. The 
supernatant was discarded, the pellet resuspended in 4 ml PBS/ EDTA and the cells 
were counted using a hemocytometer diluted 1:100 in trypan blue. All further steps 
were performed on ice under the laminar flow hood. The cells were centrifuged again 
for 10 min at 300 g at 4 °C, diluted in 300 µl separation buffer, 50 µl CD34 human 
MicroBeads, and 50 µl FcR Blocking reagent (Miltenyi) per 108 total cells. The 
suspension was incubated for 30 min at the refrigerator gently mixing the solution every 
10 min. After centrifugation at 300 rcf for 10 min at 4 °C, the supernatant was aspirated, 
the pellet resuspended in 500 µl separation buffer per 108 total cells and the LS column 




was pre-rinsed with 3 ml separation buffer and the bead labeled cells were pipetted 
through the cell strainer into the column. The flow-through containing the unlabeled 
cells was collected in a 15 ml tube. In order to increase the amount of CD34+ cells, the 
flow-through was pipetted again into the column. Afterwards, the column was washed 
with the appropriate amount of separation buffer (3 x 3 ml), the column was removed 
from the separator out of the magnetic field and placed on a fresh 15 ml tube. 5 ml 
buffer were added and the CD34+ labeled cells were collected by firmly pushing the 
plunger into the column. The cell suspension was stained with trypan blue (1:100), 
counted with a hemocytometer and 5 µl of the eluate were used to determine the purity 
of CD34+ cells by flow cytometry. If the cells were not used immediately after 
separation the flow was cryopreserved in 50 % RPMI, 30 % FCS, and 20 % DMSO 
and the CD34+ cells in 90 % FCS with 10 % DMSO until further use.  
3.2 Animal Experiments 
All animal experiments were performed according to the approval of the local 
veterinary of the district government of lower and upper Palatinate based on the 
national regulations of the German animal protection act and the European guidelines 
(permission number: 55.2 DMS-2532-2-422 and 54.2532.1-16/14). NOD-SCID 
IL2Rγnull (NSG) mice were obtained from Jackson Laboratories and bred and kept in 
a specialized pathogen-free facility at the University Clinic of Regensburg. The animals 
were housed in groups of 2 - 4 mice of the same sex (12 h light-dark-cycle, 22–24 °C) 
with access to water and food ad libitum. Breeding was performed by mating 1 - 2 
females with one male and the offspring was weaned three or four weeks postpartum. 
The maintenance of the phenotype was verified regularly by NSG PCR of the breeding 
animals posthumously (Quadros et al., 2016). 
3.2.1 Experimental Design  
In order to adapt the primary tumor specimen to the new NSG mouse 
microenvironment, the specimen were transplanted into NSG mice. After successful 
engraftment in the tumor mouse (TM), the tumors of the TM were used to generate 
humanized tumor mice (HTM) (Figure 4). All specimen were analyzed as described in 
the following: 
Primary tumors were phenotypically analyzed for EpCAM, CD44, CD24, CD47, 
cMET, Her2 (stem cell marker) expression, TILs (CD45, CD3, CD19, CD33), and T-




Additionally, the tumor was embedded in paraffin for immunohistochemical staining, 
cryopreserved and cultured. Panel Sequencing of the tumor was performed by our 
cooperation partner in Munich. Tumor fragments were used for transplantation into 
NSG mice. 
TM tumors were phenotypically analyzed on stem cell marker expression (EpCAM, 
CD44, CD24, CD47, cMET, Her2), cryopreserved, cultured and used for single-cell 
analysis. Additionally, the tumor was embedded in paraffin for immunohistochemical 
staining and fragments were flash-frozen for HuMo PCR and Western Blot analysis. 
Panel Sequencing of the tumor was performed by our cooperation partner in Munich. 
The lung, the liver, the brain, and the kidney were embedded in paraffin for 
immunohistochemical staining and analyzed phenotypically with the SCF on 
metastases. BM DTCs were characterized by SCF analysis, cultured and spotted on 
slides for single-cell analysis which was performed in cooperation with Christoph 
Irlbeck. TM tumors fragments were used for further transplantation into HTM.  
HTM tumors were phenotypically analyzed on stem cell marker expression, TILs 
(RECON), and T-cell subsets (TCF). Furthermore, the tumor was embedded in paraffin 
for immunohistochemical staining, cryopreserved, cultured and used for single-cell 
analysis. The humanization was analyzed by RECON in the spleen, the blood, the BM 
and the LN. Additionally, the TCF was performed by flow cytometry in the spleen and 
the BM. For immunohistochemical analysis, the spleen was paraffin-embedded. The 
lung, the liver, the brain, and the kidney were embedded in paraffin for 
immunohistochemical staining and analyzed phenotypically with the SCF on 
metastases. BM DTCs were characterized by SCF analysis, cultured and spotted on 






Figure 4: Schematic description of the workflow with Luminal B tumors in TM and HTM.  
The graphic shows the transplantation flow from the primary tumor to the TM and from the TM to the HTM. All 
analyses of the different tissues and the used methods are described below each step. 
3.2.2 Generation of tumor mice (TM)  
33 primary or metastatic patient tumor samples were sent from Caritas Hospital St. 
Josef Regensburg to our laboratory in the institute of pathology at the University clinic 
Regensburg. The solid tumor material was removed under sterile conditions under a 
laminar flow hood by a pathologist. The tumors were collected in prewarmed basal 
medium (DMEM/F12, 1 % HEPES (1M), 1 % Pen/Strep, 1 % Amphotericin B) in a petri 
dish and minced into fragments of 2 x 2 mm. The transplantation was carried out in 
seven to eight weeks old, virgin, non-ovariectomized, female NSG mice according to 
the protocol of Al-Hajj (Al-Hajj et al., 2003). More specifically, the mice received an 
antagonizable anesthesia intraperitoneally according to their weight and were placed 
under a laminar flow hood on a heating plate to ensure constant body temperature 
during the surgery (Table 2).  
Table 2: List of the amount of anesthesia and antagonist required for the mouse according to the 
bodyweight 
animal weight anesthesia antagonist 
17 g 110 µl 180 µl 
18 g 120 µl 190 µl 
19 g 120 µl 200 µl 
20 g 130 µl 210 µl 




22 g 140 µl 240 µl 
23 g 150 µl 250 µl 
24 g 160 µl 260 µl 
25 g 160 µl 260 µl 
26 g 170 µl 275 µl 
The mice received artificial tears in the form of cream on their eyes to protect them 
from drying. The mice were disinfected at the mammary fat pad (mfp) and through a 
small incision by the 4th or the 5th right mammary fat pad the tumor fragments were 
transplanted without clearing the fat pad beforehand. Additionally, the fragment 
transplanted was supplemented with 50 µl of Matrigel to allow nutritional content and 
enhance engraftment success. After closing the suture with Vicryl absorbable sewing 
material the animals received the antagonist and buprenorphine for analgesia (2 µl/g, 
s.c.) subcutaneously. The mice were placed on a heating plate to maintain the body 
temperature at 38 °C until the animals fully recovered. Long-term estrogen 
supplementation was achieved by a subcutaneous transplantation of a 17ß-estradiol 
pellet at a concentration of 0.18 mg that was administered simultaneously with tumor 
transplantation. To overcome long engraftment durations of the primary tumors, three 
already existing Luminal B PDX tumors from Dr. Marangoni (Institute Curie, Paris, 
France) were sent to our laboratory (HBCx3, HBCx22, HBCx34) and preprocessed as 
described above (Cottu et al., 2012; Marangoni et al., 2007; Reyal et al., 2012; Cottu 
et al., 2014)(Table 3). In addition two already existing Luminal B PDX models (; one 
derived from circulating tumor cells in the blood (CTC) (Baccelli et al., 2013; Baccelli 
et al., 2014) and the other from a pleural effusion (Bpe) of a Luminal B patient were 
provided by our cooperation partner (Prof. Trumpp, HI-Stem, Heidelberg, Germany) to 
generate TM and HTM in our laboratory. After the arrival of the CTC and Bpe tumors 
from our cooperation partner in Heidelberg, tumors were mechanically dissociated 
under the laminar flow hood in prewarmed PBS using the Medimachine System with a 
sterile Medicon application. The cell suspension was filtered through a 40 µm strainer 
and centrifuged at RT for 2 min at 210 g. The pellet was resuspended in DMEM and 
counted with trypan blue (1:100) using a hemocytometer. 2* 106 single cells were 
resuspended in a mixture of Matrigel and DMEM medium (10 µl + 20 µl) and 
transplanted subcutaneously into NSG mice (Table 3). In contrast, single-cell 
suspensions deriving from metastatic breast cancer patients effusions (AB model)  0.3* 
106 tumor cells diluted in 50 µl DMEM were administered intraperitoneally into neonatal 




were palpated twice a week. The patient-derived xenograft (PDX) models were 
monitored for 12 months and euthanized beforehand if maximum tumor volume was 
reached or any signs of sickness occurred. If enough tissue was available the mice 
were transplanted in the left and the right mammary fat pad.  
Table 3: Transplantation methods for the successfully established PDX models 
PDX name tumor Derived from Transplantation 
site 
TM P solid Caritas Hospital St. Josef orthotopic mfp 
fragments 
TM AB  Pleural effusion Caritas Hospital St. Josef i.p. single cell 
suspension 
TM X  solid Caritas Hospital St. Josef orthotopic mfp 
fragments 
TM V solid Caritas Hospital St. Josef orthotopic mfp 
fragments 
TM U pleural effusion Caritas Hospital St. Josef orthotopic single-
cell suspension 
TM CTC solid Prof. Trumpp, HI-Stem, 
Heidelberg, Germany 












TM 3 solid Dr. Elisabetta Marangoni, 
Institute Curie, Paris, France 
(Cottu et al., 2012) 
orthotopic mfp 
fragments 
TM 22 solid Dr. Elisabetta Marangoni, 
Institute Curie, Paris, France 
(Cottu et al., 2012) 
orthotopic mfp 
fragments 
TM 34 solid Dr. Elisabetta Marangoni, 
Institute Curie, Paris, France 
(Cottu et al., 2012) 
orthotopic mfp 
fragments 
mfp mammary fat pad, TM tumor mouse, s.c. subcutaneous, 
                                                                                                                                                                                                                                                                      
3.2.3 Generation of humanized tumor mice (HTM)  
Humanized Tumor Mice (HTM) were generated as described previously (Wege et al., 
2011). In brief, newborn NSG mice were irradiated (1 Gy) within the first 48 h after 
delivery to clear the BM stem cell niche and allow successful settling of HSC to the 
BM. Three hours later the mice received an intrahepatic injection of 50 µl human CD34+ 




cells diluted in 20 µl DMEM and 10 µl Matrigel using a BD Safety Glide Insulin syringe 
(HTM CTC and HTM Bpe model). In the case of a tumor fragment transplantation, the 
mice were humanized beforehand and transplanted with tumor fragments into the mfp 
at the age of six to seven weeks (HTM P, HTM 3, HTM 22, HTM 34). The tumor 
fragments were taken either freshly isolated from a TM or from cryopreserved TM 
tissue. Avoiding any immune cell procrastinations of the HTM tumors into other mice 
the HTM tumors were never retransplanted as described in Figure 5. To determine the 
reconstitution of the HTM 12 weeks after humanization 50 µl peripheral blood was 
taken from the vena saphena, mixed with 20 µl 0.5 M EDTA to avoid clotting and 
analyzed by flow cytometry.  
 
Figure 5: Schematic description of tumor passaging from TM to HTM. 
3.2.4 Preparation of blood, organs and tumor tissue  
TM or HTM were anesthetized and peripheral blood was taken retrobulbar with a 
capillary from HTM. The peripheral blood was collected in a 1.5 ml tube, allowed to 
coagulate at 4 °C and the supernatant containing the serum was transferred to a fresh 
cup after a 10 min centrifugation step (4 °C, 1300 rpm). Afterwards, the mice were 
sacrificed by cervical dislocation.  
In the next step, 10 ml precooled PBS was injected using a 10 ml syringe with a 22G 
cannula into the peritoneum to isolate ascites cells. The isolated cell suspension was 
centrifuged at 300 rcf for 10 min at 4 °C, the supernatant discarded, the cells counted 
with a hemocytometer (trypan blue staining 1:100), and stored on ice until flow 




The liver, the lung, the lymph nodes (LN), and the spleen was removed and placed in 
PBS on ice. Approximately one half of each organ (liver, lung, spleen) was embedded 
in paraffin for histological staining while the other part was minced with PBS through a 
40 µm cell strainer using the plunger of a 2 ml syringe. The cell suspensions were 
centrifuged (4 °C, 300 g, 10 min), the supernatant was discarded and the cells were 
resuspended in FACS buffer for flow cytometric analysis. Due to the size of the organ, 
the LN of HTM was just analyzed by flow cytometry.  
The brain and the kidney were isolated and only embedded in paraffin for histological 
analysis. 
The solid tumors (subcutaneous or from the mammary fat pad) were removed, pruned 
of fat tissue, weighed and measured. The volume of the tumor was calculated 
according to the formula (ellipsoid shaped tumors): volume = π / 6 x length x width x 
height (Tomayko and Reynolds, 1989). One part of the tumor was embedded in 
paraffin for histological analysis. Two small fragments were flash-frozen for protein 
isolation and DNA extraction at - 20 °C and – 80 °C. 4 fragments of 2 x 2 mm size were 
cryopreserved in 1.5 ml CryoStor Medium for future transplantations and the remaining 
tumor was used for single-cell analysis, flow cytometry, and cell culture. For single-cell 
preparation, the tumor was minced with PBS in the Medimachine System and filtered 
through a 40 µm cell strainer. The cell suspension was centrifuged at 230 rcf for 3 min 
at RT and the supernatant containing fat, fibroblasts, and immune cells were analyzed 
flow cytometrically on TILs (RECON) and T-cell subsets. The tumor cells were 
resuspended in PBS, counted with a hemocytometer (trypan blue 1:100), and 500.000 
cells were pipetted on adhesion slides for single-cell analysis. The cells adhered on 
the slide within 90 min and the supernatant was discarded. The slides were dried 
overnight and stored at - 20 °C until further use. 500.000 tumor cells were used for flow 
cytometric analysis and the residual tumor cells were cultured in basal medium under 
two different conditions using adhesive or non-adhesive 6-well plates. 
Additionally, the right and the left hind leg were taken for bone marrow (BM) collection. 
Therefore, the bones were pruned of muscles and the ends of the femur were clipped 
and flushed with PBS using a 10 ml syringe with a 27G needle until the bone appeared 
white. The cell suspension was centrifuged (10 min, 300 g, 4 °C) and the supernatant 
was aspirated. The pellet was resuspended in fresh PBS, filtered through a 40 µm cell 




°C). The supernatant was discarded, the cell pellet was diluted in PBS, and counted 
with Türk′s solution to haemolyse remaining erythrocytes. 500.000 cells were spotted 
on adhesion slides and tilted of PBS after 90 min of incubation time. The slides were 
dried overnight and stored at - 20 °C until single-cell analysis. 500.000 cells were 
analyzed by flow cytometry and the remaining BM cells were cultured in adherent 
conditions in 6-well plates in basal medium in order to enable the disseminated cells 
to grow for 4 -5 months. 
3.3 Flow cytometry 
3.3.1 Phenotypic Analysis 
In order to determine phenotypic alterations, TILs, or reconstitution the organs were 
analyzed by flow cytometry using a FACS Canto-II flow cytometer run by the Diva 
software Ver. 7.0 (BD Biosciences, San Jose, USA). The Stem cell marker expression 
panel (stem cell marker FACS: SCF) was used for primary patient tumor, TM and HTM 
tumor, TM and HTM BM DTCs, TM and HTM lung and liver metastases and included 
CD44, CD47, MET, CD24, Her2, and CD45 (Table 4). In contrast, the T-cell subset 
panel (T cell marker FACS: TCF) comprised of CD3, CD4, CD8a, CD45RA, CD27, 
CD127, and PD-L1 and was determined on primary patient tumor samples or organs 
from HTM (tumor, spleen, BM)(Table 4). To verify the humanization in HTM ( spleen, 
BM, LN) or TILs in the primary patient tumor or HTM tumor CD45, CD3, CD19 and 
CD33 (RECON) were analyzed (Table 4). The appropriate mouse immunoglobulin was 
used for each staining as control and is described in Table 5. A detailed description of 
the used staining for each organ and tumor is summarized in Figure 4. 
Table 4: Antibody Staining 
Laser  Blue laser Red laser Violet laser 
Fluorochrome 




SCF Her2 CD47 CD44 c-MET CD24 CD45 EpCAM 
TCF CD3 CD127 CD27 PD-1 CD4 CD8a CD45RA 
RECON CD3 CD19 CD33 CD45 X X X 
 
Table 5: Isotype Control 
Laser  Blue Laser  Red Laser  Violet Laser  
 


































RECON No isotype necessary 
Prior to transplantation of tumor material in mice, each primary tumor specimen was 
analyzed phenotypically on stem cell marker expression, TILs, and reconstitution.  The 
tumors derived from TM were only analyzed on stem cell marker expression whereas 
the HTM tumors were additionally investigated on immune cell infiltration and the 
different T-cell subsets. The reconstitution of HTM with human immune cells was 
determined in the spleen, the BM, and the spleen of HTM.To identify metastases in 
liver or lung or disseminated cancer cells (DTCs) in the BM, the organs were analyzed 
using SCF staining whereas EpCAM (epithelial cell adhesion molecule) served as a 
surrogate marker for tumor cells. The existence and occurrence of EpCAM- tumor cells 
is possible but not included in the analysis. FACS staining procedure for all organs is 
described in the following. In order to reduce non-specific binding, 500.000 cells were 
incubated with 20 µl mouse serum on ice 10 min before specific antibody staining. The 
cells were stained then for 30 min with 50 µl FACS buffer including the appropriate 
amount of antibodies of the certain staining SCF, TCF, and RECON (Table 4). After a 
washing step with 1 ml FACS buffer, the cells were centrifuged (3 min, 300g, RT) and 
diluted in 300 µl FACS buffer.  
3.3.2 Apoptosis  
The apoptosis assay was used to analyze the treatment effects of tumor cells on cell 
death. Living cells are lacking a phosphatidylserine membrane flip to bind annexin V 
and their cell membrane is intact thereby prohibiting PI to enter the cell. Hence, living 
cells are negative for both, annexin V and PI. Cells in early apoptosis are annexin V 
positive but negative for PI at low concentrations, whereas annexin V and PI-positive 
cells reside in late apoptosis (Figure 6). In order to include the apoptotic cells in the 
measurement, the supernatant was pipetted into a 50 ml tube with 20 ml PBS. The 
adherent cells were washed, trypsinized, stopped with medium containing FCS and 
added to the tube with the supernatant in PBS. After centrifugation (3 min, 12000 rpm, 
4 °C) the supernatant was discarded and the cells were resuspended in 75 µl 
AnnexinV-FITC solution containing 5 µl Annexin V FITC and 70 µl binding buffer. After 
20 min of incubation on ice in the dark, the cells were resuspended in 200 µl binding 
buffer and transferred to a FACS tube. Prior to the measurement 10 µl of DAPI (stock 





Figure 6: Example of apoptosis assay analyzed by flow cytometry  
The staining is depicted as Annexin-V FITC versus DAPI. The percentage of vital cells, cells in early and late 
apoptosis are listed in each quadrant. 
3.3.3 S-phase fraction  
The S-phase fraction was analyzed to determine proliferative capacity after breast 
cancer cell line treatment. During cell proliferation, the cell enters different parts of the 
cell cycle which are subdivided in mitotic division (M-Phase) and the Interphase 
comprising gap 1 (G1), synthesis (S), and gap 2 (G2) phase. Due to the different 
chromosome sets of each phase, the cells can be analyzed on their proliferative 
capacity. Therefore, 500.000 cells were harvested, washed with PBS, and lysed with 
500 µl 70 % methanol in a closed tube overnight in the fridge. The next day the cells 
were washed two times with 2 ml FACS buffer, centrifuged and resuspended in 440 µl 
FACS buffer with 50 µl RNAse. After 20 min incubation in a 37 °C water bath, 10 µl 
DAPI (50 µg/ml) were added and incubated on ice in the dark for 30 min. The 
distribution of the cells in different cell cycle phases was analyzed by flow cytometry 
and calculated by ModFit Software. For each treatment condition, the appropriate 
untreated control and solvent control was applied. 
3.4 Human -Mouse PCR       
3.4.1 DNA extraction and quantitative real-time PCR 
To verify the human origin of the engrafted PDX tumors a quantitative RT PCR was 
performed according to the paper of Malek published in 2010 (Malek et al., 2010). The 
DNA of the TM derived tumor fragment was extracted using blood and cell culture DNA 
mini kit according to the manufacturer’s protocol. The DNA concentration was 




RT-PCR comprised 8 μl of the template DNA (250 ng of total genomic DNA), 10 μl 
iQTM SYBR® Green Supermix (Bio-Rad), and 1 μl of each forward and reverse primer 
(human ß-actin or mouse ß-2-microglobin,10 µM stock concentration) (Table 6 and 
Table 7).  
Table 6: HuMo PCR Master mix  
iQ™ SYBR® Green Supermix 10 µl 
Forward-Primer 1 µl 
Reverse-Primer 1 µl 
Template 8 µl 
Total  20 µl 
 
Table 7: HuMo PCR Primer 
 Sequence Amplicon length 
human ß-actin 5’ 5’-ctgttttgtggcttgttcag-3’  
122 bp human ß-actin 3’ 5’-aggaaaccttccctcctcta-3’ 
mouse ß-2-microglobin 5’ 5’-ttggttgagaagcagaaaca-3’  
181 bp mouse ß-2-microglobin 3’ 5’-cacacagtcaagttcccaaa-3’ 
RT-PCR was run with the program described in Table 8 
Table 8: RT-PCR program 
Description Temperature Duration cycle 
Initial melting 95 °C 05:00  
Melting 95 °C 00:45 
35 Annealing 59 °C 00:45 
Elongation 72 °C 00:45 
Elongation 72 °C 05:00   
Melting Curve       
Cooling 40 °C     
The melting blots were analyzed to validate PCR specificity. To determine the 
coefficients for data analysis a standard curve was performed. Therefore, different 
amounts of human (N1 = adult skin of a healthy donor, cloned but not immortalized 
(Department of Clinical Chemistry, University of Regensburg)) and mouse (NIH/3T3 
primary mouse embryonic fibroblast cells (ATCC® CRL-1658™)) genomic DNA were 




in each mixture (line 3) the corresponding percentage of human cells was calculated 
(line 4) by adjusting the differences in mouse and human genome size with the formula:   
% Human cells = (% HumanDNA/3.2)/(% HumanDNA/3.2 + % MouseDNA/2.7) x 100  
RT-PCR was run for each DNA mixture with human- or mouse-specific primers in 
triplicates. From the results given as cycle threshold (Ct) (line 5 and line 6), the 
amplification ratio was calculated for each pair of RT-PCR using Amplification Ratio = 
2(Ct [Human] – Ct [Mouse] (line 7) and was Log2 transformed (line 8). Input values (% 
human cells; line 4) and experimental results (Log2 amplification ratio; line 8) were 
fitted using the non-linear regression 3- parameter sigmoidal function f = a/(1+exp(-(x-
x0)/b)) and the constants were determined to be a = 99,8213, b = 1,4232, and x0 = -
1,4401. Based on these constants, the percentage of human cells was re-calculated 
from log (2) amplification for each standard (line 9). The detection limit of human cells 
in mouse tissue was therefore determined as 1.4 % human cells in mouse tissue. The 
DNA content of the TM and HTM tumor probes was calculated with the constants 
derived from the sigmoidal standard curve. As a control different mixtures of human 
and mouse DNA (Hu:Mo -50 %:50 %; 0 %:100 %; 100 %:0%) and H2O were applied 



















Table 9: Calculation of the standard curve for HuMo PCR 
1 Human DNA 
in ng 250,00 249,88 249,51 249,02 248,05 246,09 242,19 234,37 218,75 187,5 125 62,5 31,25 15,62 7,81 3,91 1,95 0,98 0,49 0,12 0 
2 Mouse DNA 
in ng 0 0,12 0,49 0,98 1,95 3,91 7,81 15,63 31,25 62,5 125 187,5 218,75 234,38 242,19 246,09 248,05 249,02 249,51 249,88 250 
3 Human DNA 
(%) 
100,000 99,951 99,805 99,609 99,219 98,438 96,875 93,750 87,500 75,000 50,000 25,000 12,500 6,250 3,125 1,563 0,781 0,391 0,195 0,049 0,000 
4 Human cells 
(%) 100,000 99,942 99,769 99,537 99,075 98,153 96,318 92,677 85,520 71,681 45,763 21,951 10,757 5,325 2,650 1,322 0,660 0,330 0,165 0,041 0,000 
 
qPCR results and calculations 
 
5 Ct with 
human 
primers 20,688 20,677 20,677 20,682 20,676 20,649 20,700 20,728 20,831 21,027 21,674 22,638 23,601 24,425 25,394 25,977 26,394 26,816 27,166 26,706 26,493 
6 Ct with 
mouse 
primers 30,000 30,000 28,078 26,988 26,117 25,046 24,018 22,959 21,982 20,980 19,934 19,355 19,181 19,052 19,028 18,929 18,908 18,897 18,895 18,856 18,894 
7 Amplification 
Ratio 635,659 640,277 168,995 79,119 43,416 21,069 9,974 4,695 2,220 0,967 0,299 0,103 0,047 0,024 0,012 0,008 0,006 0,004 0,003 0,004 0,005 
8 Log(2) Amp 
Ratio 9,312 9,323 7,401 6,306 5,440 4,397 3,318 2,231 1,150 -0,048 -1,740 -3,283 -4,420 -5,372 -6,365 -7,048 -7,487 -7,919 -8,272 -7,849 -7,599 
 
Reverse calculation  
 
9 Human cells 
(%) 99,769 99,769 99,622 99,391 99,034 98,196 96,416 92,787 85,904 72,548 44,667 21,462 10,948 5,926 3,040 1,904 1,406 1,041 0,815 1,093 1,300 
                       





                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
3.5 Immunohistochemical Staining 
Tissue samples of spleen, liver, lung, brain, pleural effusion, primary patient tumors or 
TM or HTM tumors were fixed in 4 % formalin, embedded in paraffin (FFPE) and cut 
into 1.5 µm slices as described previously (Rom-Jurek et al., 2018). The specimens 
were stained automatically for CK18 (DC10, DAKO), ER (6F11, Novocastra), PR 
(Clone 16, Novocastra), Her2 (order number A0485, DAKO), Ki67 (MIB-1, DAKO), 
EpCAM (Ber-EP4, DAKO), PD-L1 (28-8, Abcam) by Ventana Nexes autostainer 
(Ventana, Tucson, USA). The autostainer was programmed based on the instructions 
given in the manual of the iView DAB detection kit (Ventana, Tucson, USA, #760–091). 
Additionally, each tumor slide was stained with hematoxylin and eosin (H&E) to verify 
tumor cell morphology. H&E staining was manually performed by incubation of the 
slide for 5 min in acetone at -20 °C and a 5 min step to airdry the slides at RT. This 
was followed by the rehydration of the slide in a descending alcohol gradient (99 %, 
96 %, and 70 % ethanol, 1 min for each dilution) and a 20sec nuclei staining with 
hematoxylin. The slides were washed for 20 min in H2O and counterstained with eosin 
for 20 sec with a subsequent washing step in H2O for 20 min. Finally, the slides were 
dehydrated in descending alcohol gradient (70 %, 96 %, and 99 % ethanol, 1 min for 
each dilution), submerged in xylol and mounted with entellan. MDM2 ((IF2, 
Calbiochem), CD44 (156-3C11, cell signaling), and CD47 (catalog number AF4670, 
R&D) were also stained manually. In brief, the samples were deparaffinized followed 
by rehydration in a descending ethanol gradient (100%, 80%, 70%). Antigen retrieval 
was done with Tris/EDTA buffer (pH 9) at 121 °C for 5 min using the decloaking 
chamber. The slides were cooled down for 1 h in a water bath. After blocking 
endogenous peroxidase with Dako REAL™ Peroxidase-Blocking Solution the slides 
were washed with Dako wash buffer (dilution 1:10) for 5 min and the primary antibody 
MDM2 (IF2, Calbiochem), CD44 (156-3C11, cell signaling) and CD47 (catalog number 
AF4670, R&D) were applied in appropriate dilution (1.5 µg/ml / 1:50 / 1:25) for 45 min. 
Afterwards, the sections were washed with wash buffer and for CD47 antibody the 
slide was additionally incubated with Polink-2 Plus HRP Sheep for 10 min with three 
drops of reagent 1 and additional 10 min with three drops of reagent 2. CD47 slides 
were washed again and the secondary antibody was applied for 30 min at room 
temperature. CD47, MDM2, and CD44 sections were washed again and incubated for 




specimens were rinsed with distilled water and counterstained with hematoxylin for 2 
min. The sections were rinsed in tap water (5 min), distilled water (1 min), and 
dehydrated in ascending ethanol gradient (70 %, 80 %, 100 %). After 2 x 5 min cleaning 
steps the specimens were cover-slipped with xylene containing mounting medium. All 
histological specimens were imaged with an AxioImager Z1 microscope (Zeiss, 
Oberkochen, Germany). H&E, ER, PR, Her2, Ki67 stainings of the primary patient 
tumor and H&E and PD-L1 of TM and HTM tumor were analyzed in routine diagnostic 
at the institute of pathology at the University clinic Regensburg by a pathologist. To 
assess the PD-L1 staining an additional score was used as published previously 
(Brockhoff et al., 2018) (Table 10). 
Table 10: PD-L1 Score adapted from (Brockhoff et al., 2018) 
 
Score % PD-L1 
0 0 
1 1 to 9 
2 10 to 39 
3 > 40 
3.6 Analysis of Lung metastases  
To quantify the metastatic properties of the different PDX models as well as the 
influence of the human immune system, the 1.5 µm lung slices were stained for CK 18 
as described at 3.5 immunohistochemical staining. Three representative pictures of 
one lung slide for each animal were taken under the light microscope in 20-fold 
magnification. If minimum two of the three pictures contained lung micrometastases 
the general occurrence of lung metastases was considered as positive, otherwise the 
lung was recorded as negative for micrometastases.  
3.7 Fluorescence in-situ-hybridisation (FISH) 
Tumor tissue sections of the different TM PDX models (TM P, TM CTC, TM Bpe, TM 
34, TM 22, TM 3) and a paraffin-embedded cell pellet section of TM AB were applied 
on charged SuperFrost Plus slides and Fluorescence in-situ hybridization (FISH) was 
performed using the directly labeled dual-color probe MDM2/CEN12 or CD274, 
PDCD1LG1/CEN9 (both ZytoVision Ltd., Bremerhaven, Germany). The MDM2 and 
PD-L1 specific probes were labeled with ZyGreen™ (absorption 530 nm, emission 528 
nm) and the centromeric probes (CEN 12 and CEN 9) with ZyOrange™ (absorption 
547 nm, emission 528 nm). The centromeric regions (CEN 12, CEN 9) were taken as 




dual marker probes enable it to interpret a potential gain of MDM2 or PD-L1 either as 
gene amplification or to chromosome 12 or 9 polysomy. The staining was performed 
as published previously (Rom-Jurek et al., 2018).  
3.8 Cell culture and cryopreservation 
All cell culture work was performed under sterile conditions in a laminar flow hood, and 
the cells were cultured at 37 °C, 95 % O2 and 5 % CO2. The different cell lines required 
specific media as listed in Table 11. Before use, all media and solutions were pre-
warmed to 37 °C and supplementations were added freshly. To avoid contaminations, 
the primary cell culture and cell line cell culture was handled in a separate laminar flow 
hood and in a separate incubator.  
Table 11: Used cell lines and their corresponding media  
NIH/3T3  DMEM + 5 % FCS 
N1  DMEM + 10 % FCS 
ZR-75-1 RPMI (phenol red) + 5 % FCS 
BT474 DMEM + 5 % FCS 
MDA-MB 231 DMEM + 5 % FCS 
SK-BR-3  DMEM + 5 % FCS 
JIMT 1 RPMI (phenol red) + 5 % FCS 
Ascites of TM AB (primary culture)  DMEM  
rhEGF                                    20 ng/ml 
Insulin                                     5 µg/ml 
Amphotericin B                       1 % 
Pen/Strep                                1 % 
FCS                                         5 % 
MNCs (primary culture) RPMI + 10 % FCS 
BM and primary culture isolated of different 
TM and HTM 
Primary patient tumors  
DMEM/F12   
Pen/Strep                                   1 % 
Amphotericin B                           1 % 
FCS                                         5 %  
rhEGF                                       20 ng/ml 
Hydrocortisone                        0.5 µg/ml 
Insulin                                       10 µg/ml 
ß-Estradiol                                  5 nM 
3 D culturing DMEM/F12  
B27 diluted                               1:50 
rhEGF                                         10 ng/ml 
Pen/Strep                                1 % 
Heparin                                4 µg/ml 
rhFGF                               10 ng/ml 





Before reaching full confluence, cells were passaged by washing them with PBS and 
treating them with accutase (primary cells) for 10 - 15 min or trypsin-EDTA (cell lines) 
for 5 min at 37 °C. Trypsin-EDTA reaction was stopped by adding cell-specific medium 
with FCS in surplus whereas no neutralization was required after accutase treatment. 
The flasks were agitated thoroughly to detach all the cells from the bottom of the flask. 
Then the cell suspension was collected in a 50 ml tube and centrifuged at room 
temperature for 3 min at 1200 rpm and resuspended in the corresponding medium. To 
determine the cell number, 10 μl of the cell suspension was mixed with the same 
volume of trypan blue solution, transferred to a Neubauer hemocytometer. The cells 
were counted (mean of 4 x 16 panel) and calculated by multiplying the mean with the 
dilution factor and the hemocytometer factor. For long-term storage of primary cells, 
approximately 1- 2 million cells were cryopreserved in 1.5 ml CryoStor Medium 
whereas cell lines were preserved in 10 % DMSO, 20 % FCS, and 70 % medium. Cryo-
cups were frozen at – 80°C overnight and stored in liquid nitrogen until further use. 
3.9 Protein biochemical analysis 
3.9.1 Protein isolation  
Cell line total protein lysates were performed according to the protocol published 
previously (Rom-Jurek et al., 2018). For protein isolation out of flash-frozen tumor 
fragments 300 µl RIPA buffer supplemented with HALT protease inhibitor (1:100) and 
EDTA (1:100) were pipetted into a 1.5 ml cup and the tissue was homogenized with a 
pestle until the liquid was turbid. The tissue was stored on ice for 30 min, vortexed 
thoroughly in between, and centrifuged at 13000 rpm for 5 min at 4 °C. The supernatant 
was collected in a new tube and stored at – 20 °C until further use. 
3.9.2.BCA Assay  
The protein concentration was determined by bicinchoninic acid (BCA) assay 
according to manufacturers' instructions. This analytic method is based on the biuret 
reaction whereby divalent cuprous ions (Cu2+) are reduced to monovalent cuprous 
ions (Cu1+) in the presence of protein in an alkaline environment. BCA is capable of 
forming a purple complex with Cu1+. The produced complex is stable for approximately 
24h. The measured absorption at 562 nm is linear-proportional to protein 
concentrations over a range of 20 – 1200 µg/ml. The determination of protein 
concentrations was assigned in duplicates. Protein standard and probes (1:10) were 




bicinchoninic acid. After 30 min incubation time at 37 °C, absorption was assigned at 
562 nm with an ELISA reader. The final concentration of the samples was calculated 
via the standard curve method. 
3.9.3. Western Blotting  
20 µg protein per lane and an equivalent amount of 4 x loading dye were separated in 
10 % SDS-Page under non-reduced conditions and plotted onto Polyvinylidene 
Difluoride (PVDF) membranes. According to the antibody, the blocking solution and 
the incubation time was different as listed in Table 12: Primary antibody below. In order to 
quantify the protein amount, either ß-actin or Rab11 were used as loading controls. 
The precision plus protein marker served as protein size standard. Finally, the 
membranes were hybridized with horseradish peroxidase (HRP)-conjugated 
antibodies according to the host of the primary antibody as listed in Table 13. The blots 
were visualized using the chemiluminescent western blotting detection system 
SuperSignal West Pico PLUS Chemiluminescent Substrate and were analyzed by 
ImageQuant LAS 4000 mini imager. For p53 and cMET antibody detection, 20 µg 
protein were separated in a 12 % Criterion TGX Stain-free gels. The analysis was 
performed using a stain-free total protein method whereby trihalo compounds bind to 
tryptophan residues in proteins when they are exposed to UV light. Hence, the proteins 
in the gel are fluorescent and can be visualized during electrophoresis or blotting. This 
offers the opportunity to normalize the band to total protein in each lane thereby 
circumventing the issue of using a loading control. 
Table 12: Primary antibody 










MDM2 (IF2)  
Mouse - 
54-90 kDa 
5 % MMP in 
PBS/T 
 1:100 PBST+3 % 
non-fat dry milk 




5 % BSA in 
TBS/T 
1:1000 in TBS-T 
+5 % BSA 
Overnight 








5 % BSA in 
TBS/T 
1:1000 in TBS-T 
+5 % BSA 
Overnight 





5 % MMP in 
TBS/T 
1:1000 in TBS-T 
+5 % BSA 
Overnight 






5 % MMP in 
TBS/T 
1:5000 in TBS-T 
+5 % BSA 
Overnight 





5 % MMP in 
TBS/T 
1:1000 in TBS-T 
+5 % BSA 
Overnight 









5 % MMP in 
TBS/T 
1:200 5 % MMP in 
TBS/T 
Overnight 







5 % MMP in 
TBS/T 
1:1000 in TBS/T+ 
5 % BSA 
Overnight 






5 % MMP in 
TBS/T 
1:1000 in TBS/T 
+5 % BSA 
Overnight 
at 4 °C 
Cell 
Signaling 
p53 Mouse  
53 kDa 
5 % MMP in 
TBS/T 
1:500 in TBS/T +5 
% BSA 
Overnight 
at 4 °C 
Santa cruz 
 
Table 13: Secondary Antibody 
Antibody Supplier  Dilution of the 
Antibody 
Incubation time  
Anti-Mouse-HRP Cell signaling 1:2000 in TBS-T 1 h at RT 
Anti-Rabbit-HRP Cell signaling 1:2000 in TBS-T 1 h at RT 
Anti-Goat-HRP Sigma 1:2000 in TBS-T 1 h at RT 
Anti-Sheep-HRP Novus Biologicals 1:500 in TBS-T 1 h at RT 
3.10 Breast cancer cell line treatments and assays 
3.10.1 Experimental Design  
MDM2 was knocked down in the breast cancer cell line ZR-75-1 with siRNA. Untreated 
cells and non-targeting pool cells served as controls. After treatment, the total cell 
number was counted and the cells were analyzed on apoptosis. Additionally, western 
blotting was performed to uncover potential target molecules of MDM2. Moreover, the 
proliferation was assessed by the measurement of the S-phase fraction (Figure 7). 
Additionally, the wound-healing of the cells was determined. In order to determine the 
clinical relevance, ZR-75-1 were treated with AMG232, an MDM2 inhibitor, for 48h and 
72h and equally analyzed as MDM2 knockdown cells. Only Western Blotting was 
skipped in AMG232 treated cells. The detailed protocols for MDM2 knockdown and 






Figure 7: Schematic description of the different assay and analysis after an MDM2 knockdown or an 
AMG232 inhibition 
3.10.2 MDM2 siRNA Knockdown  
ZR-75-1 were seeded at a density of 400.000 cells per T25 tissue flask and cultured in 
RPMI-1640 medium supplemented with 5 % FCS overnight. On the following day, the 
medium was replaced with 2.5, 2.1 and 2.1 ml (untreated, non-targeting pool siRNA, 
and anti-MDM2 siRNA) RPMI-1640 medium supplemented with 1 % FCS, respectively. 
The transfection mix was prepared by incorporation of 10 µl DharmaFECT 1 reagent 
with 190 µl RPMI-1640 in tube A and 17.5 µl MDM2 siRNA with 182.5 µl RPMI-1640 
in tube B. Non-targeting Pool was used as control and prepared in the same matter as 
the anti-MDM2 siRNA. After a 5 min incubation step at RT, tube A and tube B were 
pooled and incubated for additional 20 min. Finally, 400 µl of the transfection mixture 
was added to the appropriate T25 flasks with a final concentration of 70 nM per 
treatment, MDM2 siRNA and non-targeting Pool, respectively. The transfection 
reagent was removed after two days, replaced with RPMI-1640 supplemented with 5 
% FCS, and incubated for additional two days (Figure 8). On day four after transfection, 
the cells were either harvested with trypsin-EDTA for further experiments or lyzed with 
50 µl lysis buffer (100 µl Cell Lysis Buffer, 10 µl PMSF (1 mM), 10 µl HALT Protease 
Inhibitor, and 880 µl aqua dest.) and scraped of the flask with a cell scraper for protein 
biochemical analysis. To determine the protein amount of the lysed cells, the 




in a fresh 1.5 ml cup and stored at – 20 °C until BCA assay. A scheme of siRNA 
knockdown is represented in Figure 8. 
 
Figure 8: Schematic description of siRNA knockdown procedure  
d =day 
3.10.3 AMG232 treatment 
ZR-75-1 were seeded at a density of 400.000 cells per T25 tissue flask and cultured in 
RPMI-1640 medium supplemented with 5 % FCS overnight. The next day the medium 
was changed and the cells treated with DMSO as control or 0.1 M AMG232 inhibitor. 
Untreated cells served as an additional control. 48h and 72h after AMG232 treatment 
the cells were harvested with trypsin-EDTA for further experiments (Figure 9). 
 
Figure 9: Schematic description of the AMG232 treatment procedure 
d =day 
3.10.4 Wound Healing Assay 
Determination of tumor cell wound closure and migratory properties were analyzed by 
a wound-healing assay. In brief, 80.000 cells were seeded in each chamber of a 2-
Well Culture-Insert (35 mm) (Ibidi) fixed in a 6 -well plate and were allowed to adhere 
overnight in their appropriate medium. The next day the insert was removed, the cells 
were washed with PBS to remove cell debris and fresh medium was added to the well. 
The cell scratch was visualized at 20-fold magnification by light microscopy and 
documented at the time 0h, 6h,18h, 24h, 48h, 72h, 96h, and 144h after chamber 
removal. To guarantee the documentation of the same region at each time point the 




For analysis of wound closure, the gap between the two cell layers was marked 
manually using Axio Vision software and the area of interest was calculated 
automatically by Axio Vision software in µm2. For all experiments, untreated cells and 
cells treated with the corresponding resolvent served as controls. 
3.11 Bone Marrow DTC (disseminated cancer cell) single-cell analysis 
(Cooperation with Christoph Klein and Christoph Irlbeck UKR) 
3.11.1 PDX BM staining for DTC detection 
500.000 BM cells per HTM or TM of the P model were stained with PanCK (CK8, CK18, 
CK19) antibody in order to detect DTCs whereas an additional slide with an equal 
amount of cells was stained to control the isotype positivity. In order to compare the 
BM DTCs of HTM and TM P model later on with the primary tumor, 500.000 tumor cells 
from the corresponding primary tumor were stained additionally. In detail, the slides 
were defrosted and dried 20 min prior to the staining. In order to block unspecific 
binding, the slides were incubated with PBS (pH: 7.4) supplemented with 10 % AB 
Serum for 30 min, the buffer was discarded and the primary antibody detecting 
cytokeratin (CK) 8, CK18, CK19 (A 45 B/B3) diluted in PBS (pH: 7.4) / 10 % AB serum 
(1:100) was applied to the slides for 60 min. Accordingly, IgG kappa isotype (1:500) 
diluted in PBS (pH: 7.4) / 10 % AB serum was applied to the isotype control. After 
incubation time the antibody was discarded, the slides were washed three times in 
PBS, and incubated with the secondary antibody (Zytomed ZUC077-100) 
supplemented with 10 % AB serum for 30 min. The solution was discarded, the slides 
were washed three times for 3 min and the development system BCIP/NBT for alkaline 
phosphatase enzymatic substrate was added for 15 min. After a washing step, the cells 
were fixed in 0.5 % formalin (in TBS, pH 7.4) for 5 min and finally washed again. The 
slides were scored for CK positive DTCs cells that appear in dark violet to black. For 
each staining, the tumor cell line ZR-75-1 was used as a positive control. The 
occurrence of CK positive cells in the isotype control excluded the staining from further 
use. 
3.11.2 Single cells isolation and whole genome amplification (WGA) performed 
by Christoph Irlbeck 
The violet stained DTCs (or primary tumor cells) were isolated using a 
micromanipulator and were directly transferred into a PCR tube containing 2 μl of 
proteinase K digestion buffer. The DNA of the DTC was amplified according to the 




product. The WGA was performed by Christoph Irlbeck as published previously (Klein 
et al., 1999). The WGA is a multistep process that provides deterministic, i.e. 
reproducible, amplification of a cell’s genome which is beneficial for copy number 
variation low pass- sequencing or CGH methods. In brief, the DNA solution was 
subjected to protease digestion to destroy residual proteins or DNases that might have 
been accidentally introduced. Next, the DNA was digested using the MseI restriction 
enzyme, which fragments the human genome into pieces that are 150-1500 bp in 
length. Afterwards, the double-stranded adapter oligonucleotide with one of the strands 
lacking a phosphate (to prevent its ligation) was ligated to the DNA. Following the 
ligation, the non-ligated adapter strand was removed by heat denaturation creating an 
overhang of the so-called Lib1 oligonucleotide. In the last step, the final PCR 
amplification was performed using the excess Lib1 molecules as a primer. Hence, the 
polymerase first filled up the previously generated overhangs resulting in a Lib1 
complementary sequence on the reverse strand. This provides the exponential 
amplification of the DNA fragments. Finally, the WGA product is stored at -20° C for 
further downstream applications. 
3.11.3 Control and quality PCR of WGA product  
The successful amplification of the genome from the single-cell DTC was confirmed by 
endpoint PCR (Polzer et al., 2014) (Klein et al., 1999; Stoecklein et al., 2002). For this 
purpose, two different sets of primers (human and mouse) were used in order to 
determine that the origin of the DTC is really human and not a mouse BM cell as well 
as the DNA quality which is reflected by the occurrence of all four human genes. KRAS, 
KRT19, TP53 Exon2/3, and the polymorphic DNA area D5S2117 on chromosome 5 
were used to determine the human origin and DNA quality whereas Polr2a, Taf1b, 
Rps3, and Fank1 were used to identify a mouse-derived BM cell. All primer sequences 
are listed in Table 14 and a master mix for PCR was pipetted according to the scheme 
in Table 15. In the next step, 9 µl of the master mix was applied to the PCR tube 
followed by 1 µl template DNA from the WGA product. Each human PCR was 
performed with a positive control (human: ZR-75-1 cell), a negative control (mouse: 
BM cell), and a water control in order to verify the reagent purity and functionality of 
the reaction. For mouse multiplex PCR the control cells served vice versa. The PCR 
ran according to the program listed in Table 16. The PCR product was loaded onto a 
1.5 % agarose gel and the DTC was considered for further analysis if three or four 




Table 14: Primers for quality PCR of WGA product 
CK19 5' 5' GAAGATCCGCGACTGGTAC 3' 621 bp 
CK19 3' 5' TTCATGCTCAGCTGTGACTG 3' 
Exon2/3 5' 5' GAAGCGTCTCATGCTGGATC 3' 299bp 
Exon2/3 3' 5' CAGCCCAACCCTTGTCCTTA 3' 
D5S2117 5' 5' CCAGGTGAGAACCTAGTCAG 3' 140 bp 
D5S2117 3' 5' ACTGAGTCCTCCAACCATGG 3' 
Kras 5' 5' ATAAGGCCTGCTGAAAAT 3' 91 bp 
Kras 3' 5' CTGAATTAGCTGTATCGTCAAGG 3' 
Polr2a 5’ 5’-ATTGACTTGCGTTTCCATCC-3’  290 bp 
Polr2a 3’ 5’-AACAAAAGGCACCCACTGTC-3’ 
Taf1b 5‘    5’-GAGCCTTAGCCACTTCATGC-3’ 392 
Taf1b 3' 5’-AGAGTCAGGCAAGGGGAAAT-3’   
Rps3 5’  5’-TACTGACTGCTGCCGTGTTC-3’ 687 
Rps3 3'  5’-GGCCCAAGTTTACACAGCAT-3’ 
Fank1 5’ 5’-GGTCCCCTTGTTTGTCTTCA-3’ 148 
Fank1 3' 5’-AGTGGCTGTTCTGGGCTAAA-3’ 
 
Table 15: Mastermix for quality PCR of WGA product 
Reagent Amount per reaction [µl] 
10x FastStart PCR Buffer (with 20mM MgCl2) 1 
Primer mix (8 µM per primer) 1 
dNTPs (from FastStart kit) 0.2 
BSA (20 mg/ml) 0.2 
FastStart Taq Polymerase (5 U/µl) 0.1 
PCR-water 6.5 
 
Table 16: PCR program for quality control of the WGA product 
Cycler program Temperature Time  
Step 1 95 °C 04:00 min  
Step 2 95 °C 00:30 min 
32 cycles (4-5) 
Step 3 58 °C 00:30 min 
Step 4 72 °C 01:30 min 
Step 5 Back to step 2 
Step 6 72 °C 07:00 min  
Step 7 4 °C forever  
3.11.4 Gel electrophoresis 
In order to separate the WGA product according to size 1.5 % gels were cast by 
dissolving 1.5 g agarose in 1 x TBE buffer, boiled in the microwave and added with 4 
µl of ethidium bromide solution. The warm gel was shaken for ethidium bromide 
distribution, immediately transferred into the gel tray and equipped with two combs of 
20 pockets each. After 20 min of polymerization, the gel tray was filled with TBE buffer 




To identify the size of the bands, the first and the last pocket were loaded with 8 µl of 
1 kb DNA ladder. Lastly, the DNA was separated at 160 V for 45 min at 400 mA and 
the bands were visualized using UV light.  
3.11.5 Reamplification  
In order to prevent wasting the basic WGA single cell material and in case of potential 
analysis repetitions, the DNA was reamplified. Therefore, a master mix was pipetted 
according to the scheme of Table 17 and 1 µl of the WGA product was applied to the 
reagents resulting in 50 µl reamplified DNA. 
Table 17: Mastermix for reamplification of DNA 
Reagent Amount  
1x Expand Long Templ.Buffer 5.0 μl 
Lib1 (10µM) (5‘AGT GGG ATT CCT GCT GTC AGT) 5.0 μl 
dNTPs (10mM) 1.75 μl 
BSA (20 mg/ml) 1.25 μl 
Pol Mix 0.5 μl 
H2O 35.5 μl 
The amplification was performed with the cycler program listed in Table 18. 
Table 18: PCR program for Reamplification of DNA 
Cycler program Temperature Time  
Step 1 94.0 °C 1 min  
Step 2 60.0 °C 30 s  
Step 3 65/68 °C 2 min  
Step 4 94.0 °C 30 s 
10 cycles (4-6) Step 5 60.0 °C 30 s 
Step 6 65/68 °C 2 min (+20 s/c) 
Step 7 4.0 °C forever  
Before library preparation, the DNA quality has to be reanalyzed using the PCR 
described at 3.11.3. 
3.11.6 Low pass-sequencing for copy number alteration profiling (performed by 
Christoph Irlbeck) 
Low pass-sequencing which includes library preparation, Qubit DNA concentration 
measurement and bioanalyzer analysis of samples was performed exclusively by my 
cooperation partner (ITEM, Regensburg, Germany) according to the protocol 
described in the doctoral thesis of Christoph Irlbeck submitted in November 2019. For 
Library preparation, the Ampli1™ LowPass kit was used. This kit uses the deterministic 




single-reaction protocol to generate multiplexed, sequencing-ready libraries to detect 
chromosomal aneuploidies and copy number alteration (CNA) by low-pass whole-
genome sequencing. Briefly, starting from purified primary Ampli1™ WGA product, 
barcoded libraries compatible with Illumina® systems were generated. The libraries 
were quantified using the Qubit dsDNA HS reagent kit and the Qubit 3.0 Fluorometer. 
Additionally, the average fragment sizes of the libraries were assessed using the 
Agilent High Sensitivity DNA Kit on the Agilent 2100 Bioanalyzer. The open-source 
software Control-FREEC (Control-Free Copy number caller) was used to obtain copy-
number calls, using the mode without reference sample and without contamination 
parameters. For the evaluation of quality metrics, only samples with more than 200,000 
reads and a derivative log ratio spread (DLRS) < 0.50 were evaluated. 
3.11.7 Preparation of Ref Sequ files and analysis by progenetix software  
Progenetix is an online tool for the generation of genome plots and multi-strip plots to 
summarize user data for further analysis (Baudis and Cleary, 2001). To analyze the 
DTCs and the tumor cells from the primary tumor the Ref Sequ files were transformed 
into the format of Progenetix. The data has to be submitted as a tab-delimited segment 
file with a detailed description of data arrangement at 
https://info.progenetix.org/uploader.html, where they were finally uploaded. The 
genomic CNV profiles obtained in the analysis were visualized as scatter plots in which 
yellow represents genomic gains and blue genomic losses. 
3.12 Panel Sequencing (Performed by Nicole Pfarr and Wilko Weichert TUM) 
3.12.1 DNA Isolation of FFPE tissue  
The panal sequencing was exclusively perfomed by my cooperation partner Nicole 
Pfarr in Munich. Therefore, eight 8‑µm‑thick sections of FFPE primary tumor samples 
or TM tumors were sent for analysis to our cooperation partner in Munich and the panel 
sequencing procedure was exclusively performed by Nicole Parr. The areas containing 
exclusively tumor cells were microdissected, deparaffinized and genomic DNA 
isolation was performed after proteinase K digestion using a fully automated extraction 
system (Maxwell; Promega, Madison, USA) according to the manufacturers' protocol. 
The DNA concentration was measured fluorimetrically using the QuBit 2.0 system and 
the DNA high sensitivity kit (both: Thermo Fisher Scientific, Waltham, USA). Due to the 




that is, the sequencing grade quality was determined by using a qPCR assay (TaqMan 
RNAseP detection assay; Thermo Fisher Scientific) (Pfarr et al., 2017). 
3.12.2 Sequencing Panels 
The Breast Cancer version 3 (BCPv3) panel was designed by the group of Wilko 
Weichert and consists of three primer pools yielding 617 amplicons covering 
mutational hotspot regions located in 353 exons of 59 genes that are known to be 
related to breast cancer. This BCPv3 panel is a modified version from their previously 
designed panels (Pfarr et al., 2017; Kriegsmann et al., 2014). An overview of the panel 
of the interrogated gene regions is provided in Table 19 below.  
Table 19: Genes and exons included in the breast cancer panel.  
 
Exons included are given below each gene and the genes are printed in bold. BCPv3 (59 genes, 617 Amplikons) 
adapted from (Kriegsmann et al., 2014; Pfarr et al., 2017) 
3.12.3 Massive parallel sequencing 
The Library preparation was performed according to the multiplex PCR-based Ion 
Torrent AmpliSeqTM technology (Thermo Fisher Scientific, Waltham, USA) using the 
BCPv3 panel and the Ion AmpliSeq Library Kit v2.0. For the amplification of each 
primer pool, 5 ng of DNA (determined by qPCR) were mixed with 2.5 µl of one of the 
three primer pool (2x concentrated) and 1µl AmpliSeq HiFi Master mix in a 5µl reaction 
and transferred to a thermal cycler (Biometra, Göttingen, Germany). 15 ng Total 
amount of DNA was used. After amplification in a thermal cycler, all three reactions 
were combined yielding 15 µl for further proceeding. Afterward, the amplicons were 
partially digested by adding FuPa reagent. This process was followed by the ligation 




Scientific, Waltham, USA) and the purification was finally conducted using AMPure XP 
magnetic beads (Beckman Coulter, Krefeld, Germany). Subsequently, the library was 
quantified using the Ion Library Quantitation Kit for qPCR on a StepOnePlus qPCR 
machine (Thermo Fisher Scientific, Waltham, USA). Individual libraries were diluted to 
a final concentration of 25 pM and up to 10 of these libraries were pooled and 
processed using the Ion S5 510/520/530 chef Kit on an Ion Chef instrument where the 
libraries were processed for sequencing. Sequencing was conducted on an Ion S5XL 
instrument using the Ion S5 Sequencing chemistry and loaded onto a 530 chip. 
3.12.4 Data analysis and prediction of copy number variations 
Raw sequencing data analysis and the alignment against the human genome (version 
hg19) was performed with the Torrent Suite Software (version 5.10.1) using the TMAP 
algorithm. The build-in plugin „variantCaller“(version 5.8.0.19) was used for mutation 
analysis. Annotation of the variants was obtained by using ANNOVAR-a custom-built 
variant annotation pipeline (Wang et al., 2010). The sequencing reads were visualized 
by the Integrative Genomics Viewer Browser (IGV, http://www.broadinstitute.org/igv/) 
and variants were analyzed for germline or somatic origin using the COSMIC (catalog 
of somatic mutations in cancer) database (Forbes et al., 2015), dbSNP, and Exome 
Variant Server (http://evs.gs.washington.edu/EVS). For each sample and amplicon, a 
coverage data summary was generated by the Torrent Suite software and used for the 
identification of copy number variations (CNVs, amplifications, and deletions) that have 
been ascertained by a four-step algorithm as previously described (Endris et al., 2013; 
Pfarr et al., 2017) 
3.13 Statistical analyses 
The overall survival (OS) of the mice was calculated from the date of tumor 
transplantation to the date of death of any cause. The disease-free survival (DFS) in 
mouse experiments is designated as the period of time between tumor transplantation 
and the occurrence of a palpable tumor. OS and DFS curves were estimated using the 
Kaplan-Meier method and a statistical significance was calculated using the Log-rank 
(Mantel-Cox) test. For all other experiments either Student's t-test, one-way analysis 
of variance (ANOVA) with Tukey’s multiple comparison test, two-way ANOVA with 
Bonferroni post hoc correction, or two-sided Fisher’s exact test was used. The results 
are represented as mean ± SEM and the animal/patient number is assigned in each 




significant outlier with a p-value > 0.05 using GraphPad quickcalcs 
https://www.graphpad.com/quickcalcs/Grubbs1.cfm. All in vitro experiments were 




4 Results  
4.1 Primary tumor patient samples 
33 primary or metastatic tumor specimen were obtained from patients of the Caritas 
Hospital St. Josef Regensburg and were named as primary tumor (PT) in alphabetical 
order (A-GB) (Table 20). All the biopsies donated from the patients derived either from 
solid tumors or liquid metastatic specimens from thoracentesis or laparocentesis. The 
successful PDX, established from primary patient tumor, are highlighted in green. PT 
P (solid tumor) and PT AB (pleural effusion) are Luminal B/ Her2+ tumors. The TNBCs 
PT U (pleural effusion) and PT V (solid tumor), as well as the Her2+ PT X (solid tumor), 
were engrafted to confirm the transplantation method. All of them resulted in a stable 
and retransplantable PDX. The grey lines mark all the patients that died or suffered 
from a relapse during enrollment of patient samples from 2015 until February 2019. 
This overview shows that all of the patients that suffered from metastatic breast cancer 
and received a thoracentesis or a laparocentesis died within a few months. Moreover, 
the Luminal B patient PT R relapsed within just a few months further affirming the 
urgency of markers that subdivide the Luminal B tumors into high and low-risk tumors. 
Several tumors, especially the patients with ascites or pleural effusions, listed in the 
table were pretreated, however, detailed information was not available in all cases. 
The hormone receptor status of each tumor is listed in Table 20 and the detailed 
Remmele Score (0 -12) (Remmele and Stegner, 1987) assessed by a pathologist of 
ER and PR expression was provided if possible. In addition to ER and PR expression, 
the Her2 status (0-3 IHC score), as well as the proliferation index (Ki-67 expression in 
%) of each tumor according to St. Gallen conference 2011 (Goldhirsch et al., 2011; 
Cheang et al., 2009), was used to categorize the samples into Luminal A, Luminal B, 
Luminal B/Her2+, Her2+, or TNBC subtype. The successful propagation of primary 
tumor cells ex vivo is listed here but a detailed description of primary tumor cell 
culturing is provided at 4.2.5 Primary tumor culturing. 
To bypass the long engraftment duration of the primary tumors in NOD-SCID IL2Rγnull 
(NSG) mice, already established Luminal B PDX models CTC#288 (Baccelli et al., 
2014) and BPE2#0 (dissertation of Dr. Massimo Saini 2017) from Prof. Trumpp, HI-
Stem, Heidelberg, Germany were used to generate TM and HTM. CTC#288 derived 
from circulating tumor cells isolated from the peripheral blood by CellSearch® whereas 




Moreover, HBCx3, HBCx22, and HBCx34 (Marangoni et al., 2007; Cottu et al., 2012) 
Luminal B PDX models from Dr. Marangoni (Institute Curie, Paris, France) were used 
to establish TM and HTM in our laboratory. Already established PDX models and the 





Table 20: Overview of all patient samples and the corresponding pathological information, engraftment success, and the survival and relapse status of the patient 
Patient/ PDX 
name 
Biopsies donated Hormone 
receptor  
ER PR Her2 status Proliferation 
index in % 
Disease subtype PDX 
successful 




PT A solid + 6 6 1 18 % Luminal B  No No unpublished Alive No 
PT B Solid + + + 0 30 % Luminal B  No No unpublished Alive No 
PT C Solid + 12 6 3 15 % Luminal B /Her2+ No No unpublished Alive No 
PT D solid + 12 1 0 15 % Luminal B No No unpublished Alive No 
PT E  solid + 12 8 N.A. 5 % Luminal A  No No unpublished Alive No 
PT F  Solid + 12 0 1 5 % Luminal A No No unpublished Alive No 
PT G  Solid + 6 9 1 25 % Luminal B No No unpublished Alive No 
PT H Solid + 12 0 1 6 % Luminal A No No unpublished Alive No 
PT I Solid + 8 6 1 18 % Luminal B  No No unpublished Alive No 
PT J Solid + 12 9 0 45 % Luminal B  No No unpublished Alive No 
PT K Solid + 12 9 1 10 % Luminal A  No No unpublished Alive No 
PT L Solid + 12 6 1 60 % Luminal B  No No unpublished Alive No 
PT M Solid + 12 4 1 8 % Luminal A No No unpublished Alive No 
PT N Solid + 12 2 0 25 % Luminal B No No unpublished Alive No 
PT O Solid + 12 0 1 15 % Luminal B  No No unpublished Alive No 
PT P Solid + 12 0 3 40 % Luminal B/ Her2+ Yes No unpublished Dead - 
PT Q solid + 12 6 1 60 % Luminal B  No No unpublished Alive No 
PT R Solid + 12 9 1 30 % Luminal B  No No unpublished Alive yes 
PT S Solid + 8 8 1 25 % Luminal B  No No unpublished Alive No 
PT T Pleural effusion - 1 0 3 35 % Her2 + Yes No unpublished Dead   
PT U  Pleural effusion  - 0 0 0 25 % TNBC  Yes No unpublished Dead   
PT V Solid  - 1 1 1 80 % TNBC Yes  No unpublished Alive No 
PT W Solid - - - - > 14 % TNBC No No unpublished Alive No 
PT X Solid - 0 0 3 70 % Her2+ Yes No unpublished Dead No 
PT Y Solid + 8 6 1 12 % Luminal A No No unpublished Alive No 
PT Z Solid + 12 9 1 25 % Luminal B  No No unpublished Alive No 
PT AB  Pleural effusion + 12 0 3 >14 % Luminal B/ Her2+ Yes Yes unpublished Dead   
PT BB Solid - 4 0 1 30 % TNBC  No No unpublished Alive No 
PT CB Pleural effusion + + + 3 > 14 % Luminal B/ Her2+ No No unpublished Dead  






Biopsies donated Hormone 
receptor  
ER PR Her2 status Proliferation 
index in % 
Disease subtype PDX 
successful 




PT EB Pleural effusion  + + + N.A.  > 14 % Luminal B  No No unpublished Dead  
PT FB Solid +  8 12 - < 14 % Luminal A No No unpublished Alive No 
PT GB Ascitis + + + N.A.  > 14 % Luminal B  No No unpublished Dead  
CTC#228  Solid (PDX derived- 
former peripheral blood 
CTC derived) 
+ + + - > 14 % Luminal B  Yes Yes (Baccelli et al., 
2014) 
N.A. N.A. 
Bpe 2-0 Solid (PDX derived- 
former pleural effusion 
derived) 
+ + + - > 14 % Luminal B  Yes No unpublished N.A. N.A. 
HBCx3 Solid (PDX derived) + + - - > 14 % Luminal B  Yes No (Cottu et al., 
2012) 
N.A. N.A. 
HBCx22 Solid (PDX derived) + + + - > 14 % Luminal B  Yes No (Cottu et al., 
2012) 
N.A. N.A. 
HBCx34 Solid (PDX derived) + + + - > 14 % Luminal B  Yes No (Cottu et al., 
2012) 
N.A. N.A. 
The table shows an overview of all patient samples (A-GB) and the PDX samples from the cooperation partners with the molecular intrinsic marker expression from the primary tumor. 
HR describes the hormone receptor status in general (ER and PR, ER or PR, PR without ER). ER and PR scores are given as immune reactive score according to Remmele from 0-12. 
Her2 expression is listed as an IHC score from 0-3. The proliferation is depicted in %. The breast cancer subentities according to the given markers are listed in the disease subtype 
column. The PDX success, cell culture propagation of the primary tumor and a relapse of the patient is shown as yes or no answer. The survival status is described as dead or alive. The 
abbreviation N.A. means that the information was not available. Green marked lines show the successful engrafted PDX models from St. Josef, grey marked lines indicate a relapse or 





4.2 Characterization of the primary tumor specimen 
4.2.1 Phenotypical characterization of patient Luminal A and B tumor cells using 
(stem cell FACS) SCF panel 
In order to characterize tumors, metastases, or DTCs the SCF panel including CD45, 
EpCAM, CD44, CD47, cMET, CD24, and Her2 was used as shown in Figure 10. 
Forward versus side scatter identified the main tumor population, thereby excluding 
dead tumor cells. Next, the doublet cells were discriminated by the forward scatter 
width versus forward scatter area. CD45 excluded the immune cells potentially 
harboring in the tumor cell population. Only EpCAM+ cells were then used for further 
analysis of SCF markers (CD44, CD47, cMET, CD24, and Her2). The EpCAM-
population was excluded from the current analysis.  
 
Figure 10: Representative image of the gating strategy for SCF on tumor TM CTC   
The population is depicted as a density plot and the gates are shown in bold black. SCF characterization of 
CD44, CD47, cMET, CD24, and Her2 was performed from gate P4 including the EpCAM + cells. 
First, differences regarding stem cell marker expression were compared between 
Luminal A and Luminal B tumors. Luminal B tumors, as characterized by pathologists 
according to intrinsic molecular marker (ER status, Ki67, and the grading), revealed a 
significantly higher expression of CD24, when compared with Luminal A tumors (two-
way ANOVA with Bonferroni post hoc correction, p < 0.05) (Figure 12 A). All other stem 
cell markers (CD47, Her2, cMET, CD44, and EpCAM) showed no significant difference 
in their expression comparing Luminal A with Luminal B tumors. Secondly, the Luminal 
B cohort was further subdivided to identify specific target molecules for high and low-
risk Luminal B tumors. This is based on retrospective analysis subdividing the patients 
that died, suffered from a relapse, or produced a stable PDX model in the high-risk 




tumor did not produce a PDX model were assigned to the low-risk Luminal B group. 
More specifically, the successful engraftment of a primary tumor in the mouse is per 
se a poor prognostic indicator for the patients' outcome (Whittle et al., 2015). However, 
I could not identify a defined stem cell marker signature that could reliably predict a 
severe progression for Luminal B high-risk tumors (Two-way ANOVA with Bonferroni 
post hoc correction, p > 0.05) (Figure 12 B). 
To detect the metastasis initiating cells (MICs) (Baccelli et al., 2013), which are 
associated with lower overall survival and an increased number of metastatic sites, the 
FACS gating strategy was performed as described in Figure 11. The CD44+ cells were 
analyzed in a further gate on CD47 and cMET positivity. This last gate is important 
because it represents the triple-positive cells (CD44+, CD47+, cMET+) that shows the 
co-expression of CD44+, CD47+, and cMET+ on a single cell. This co-expression 
pattern was described previously as the stem cell population called MIC (Baccelli et 
al., 2013).  
 
Figure 11: Representative image of the FACS gating strategy for SCF MIC subpopulation. 
The gating strategy shows the way to determine the co-expression of EpCAM+, CD44+, CD47+, cMET+ on a 
single tumor cell. The population is depicted as a density plot and the gates are shown in bold, black edging. 
Even though the single stem cell marker expression did not reveal a specific signature 
for high-risk Luminal B breast cancer, the simultaneous triple positivity of a single cell 
showed different results. The co-expression of CD44+, CD47+, cMET+ also defined as 
MICs population were significantly increased in Luminal B high-risk tumors (Student's 
t-test, p = 0.035) (Figure 12 C). In accordance, it has to be emphasized that one patient 
in the low-risk Luminal B cohort exhibits high co-expression of CD44+, CD47+, cMET+ 
potentially predicting the further course of the patient as a high-risk Luminal B tumor. 







































































































































































Figure 12 Stem cell marker expression in 
Luminal breast cancer. 
A) Comparison of Luminal A tumors with Luminal 
B tumors regarding stem cell marker expression 
based on the intrinsic molecular markers 
determined by routine pathology. The number of 
patients is shown in parentheses. The data are 
represented as mean + SEM. B) This figure 
displays the stem cell marker expression of high 
and low-risk Luminal B tumors subdivided 
according to a retrospective survival, relapse, 
and PDX engraftment. The data are represented 
as mean + SEM. C) The % of the triple-positive 
population (CD44+, CD47+, cMET+) of high and 
low-risk Luminal B tumors is shown as mean ± 
SEM. Each dot displays a single patient. The 
circle represents a potential high-risk Luminal B 
individuum. The number of all patients is listed in 
parentheses. Significances were analyzed using 
Two-way ANOVA with Bonferroni post hoc 
correction or Student's t-test (* p < 0.05). 
4.2.2 Immune cell infiltration in primary Luminal patient tumors  
The RECON panel was used to analyze the immune cell infiltration (TIL) into the 
tumors (Figure 13). To determine human immune cells the gate was set by forward 
versus side scatter of all living tumor and immune cells, thereby excluding the dead 
cells seen in the left corner. CD45 as leucocyte common antigen is expressed on all 
human immune cells and, hence, reflects the immune cell infiltration in tumors. In 
addition, plotting CD19 versus CD3 could verify the percentage of B and T-cells, 
respectively. A CD45 drill-down and plotting of CD33 versus side scatter identified on 




granulocytes. However, with the isolation method of the TILs, it is not possible to 
distinguish between stromal and intratumoral cells. 
 
Figure 13: Representative gating strategy of RECON to determine the TILs  
The gating strategy is shown as a scatter plot. To determine the T-, B, and myeloid cells and granulocytes the 
immune cell population were previously gated on CD45. The gates are showed in bold edging. 
Solid Luminal tumors in general exhibit between 4.2-6.9 % TILs whereas no difference 
could be determined between solid Luminal A and solid Luminal B tumors (Figure 14 
A). A significant higher immune cell infiltration of ~ 83 % TILs can be found comparing 
solid Luminal B tumors with Luminal B effusions (One-way ANOVA with Tukey's’ 
multiple comparison test, p < 0.001). Nevertheless, only in highly aggressive breast 
cancer subentities namely Luminal B tumors, but not Luminal A, metastatic effusions 
can be found. Further analysis of the high and low- risk Luminal B cohort (subdivided 
as described before) and its TIL subsets (Figure 14 B) revealed no difference regarding 
T-, B-, myeloid -cells, or granulocytes (Two-way ANOVA with Bonferroni post hoc 
correction, p > 0.05). In detail, there is no distinctive TIL signature that differs between 
high and low-risk Luminal B tumors and no difference regarding the TIL signature 
between Luminal A and Luminal B (data not shown). 
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Figure 14: TIL analysis of primary patient tumors  
A) The figure shows the % CD45+ cells (immune cells) in Luminal A and Luminal B solid tumors and in the 
Luminal B metastatic effusion. Each dot displays a single patient and the data are represented as mean ± SEM. 
B) The different human immune cell subsets (T-cells, B-cells, myeloid cells, granulocytes) in high and low-risk 
Luminal B tumors are shown as mean + SEM. The number of patients is listed in parentheses. Significances 
were analyzed using Two-way ANOVA with Bonferroni post hoc correction or One-way ANOVA using Tukey's’ 
multiple comparison test (*** p < 0.001). 
4.2.3 T cell phenotyping of TILs in the primary tumors of Luminal patients 
Immune cell infiltration in the primary patient tumor was characterized by T-cell marker 
expression of CD3, CD4, CD8a, CD45RA, CD27, and PD-1, see Figure 15. In brief, 
forward versus side scatter identified the main immune cell population. The doublet 
cells were discriminated by forward scatter width versus forward scatter area. All T-
cells feature a CD3 receptor by which the T-cells were identified. CD4 versus CD8a as 
a drill-down of CD3 detected the T-helper cells and the cytotoxic T-cells, respectively. 
Moreover, the activity state (naïve, effector, effector-memory, or effector memory T-
cells re-expressing CD45RA (TEMRA)) of T-helper and cytotoxic T-cells was 
determined by plotting CD45RA against CD27. In addition, the immune-suppressive 
PD-1 expression on T-cells was analyzed by plotting PD-1 against CD4 as a CD3 drill-
down to analyze the occurrence of PD-1 on T-helper and cytotoxic T-cells. The 
isolation method of the T-cells does not allow discrimination between stromal and 
intratumoral T-cells.  
 
Figure 15: Representative image of the gating strategy that was used for T-cell subset identification 
The T-cells were identified by CD3. The drill-down determined the cytotoxic T-cells and the T helper cells. The 
cytotoxic T-cells and the T-helper cells were analyzed on naive, effector, effector memory and TEMRA state. 
PD-1 expression as a drill-down of CD3 was analyzed on cytotoxic T-cells and T-helper cells. The whole PD-1 
population was further analyzed on naive, effector, effector memory or TEMRA state. The gating strategy is 





Comparing the CD4/CD8 ratio, the high-risk patients show an increased CD4/CD8 ratio 
which means the presence of a higher proportion of CD4+ helper cells (Student's t-test, 
p = 0.0170) (Figure 16 A). No differences were detected regarding the subpopulations 
of CD4+ and CD8+T cells (effector, naïve, memory-effector, or TEMRA)between high-
and low-risk Luminal B patients (Two-way ANOVA with Bonferroni post hoc correction, 
p > 0.05) (Figure 16 B and C). In general, PD-1 is expressed on T-cells in Luminal B 
tumors, but neither the whole amount of PD-1 expression nor the PD-1 expression on 
CD4+ or CD8+ cells differs between high and low-risk Luminal B patients (data not 
shown). 
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Figure 16: T-cell subset analysis of TILs in primary 
Luminal B tumors 
A) The difference of CD4/CD8 ratio between high and 
low-risk Luminal B tumors is depicted as mean± SEM 
and each dot represents an individual patient. B) The 
figure shows the % CD4 effector, naïve, mem. eff. 
(memory effector), and TEMRA cells in high and low-
risk Luminal B tumors. The data are represented as 
mean + SEM. C) The data represent the % CD8 
effector, naïve, mem. eff. (memory effector), and 
TEMRA cells in high and low-risk Luminal B tumors. 
The data are represented as mean + SEM. The number 
of patient samples in A), B), and C) is given in 
parentheses. Significances were analyzed using Two-
way ANOVA with Bonferroni post hoc correction or 





4.2.4 Tumor cell phenotyping and immune cell characterization in solid tumors 
compared to effusions (metastases) of Luminal B patients.  
4.2.4.1 SCF and RECON phenotyping of Luminal B solid tumors and Luminal B 
effusions 
Moreover, it was interesting to elucidate the differences between Luminal B primary 
tumors and Luminal B effusions in detail. The EpCAM+ cells of the effusions (pleural 
effusion or ascites) derived from metastasized Luminal B breast carcinoma. EpCAM+ 
cells in effusions were only present to 2.8 % in the mean (data not shown). In line with 
the data shown in Figure 14 A, metastatic breast cancer effusions mainly consist of 
extracellular fluid with immune cells. Despite the other markers (CD47, Her2, CD44, 
CD24), cMET expression was significantly increased in tumor cells isolated from 
Luminal B metastatic effusions compared with solid Luminal B tumors (Two-way 
ANOVA with Bonferroni post hoc correction p < 0.05) (Figure 17 A). Interestingly the 
RECON analysis revealed an increased amount of T-cells in Luminal B breast cancer 
metastases (Two-way ANOVA with Bonferroni post hoc correction p < 0.001), whereas 
the presence of myeloid cells is decreased in Luminal B breast cancer metastases 
(Two way ANOVA with Bonferroni post hoc correction p < 0.001) (Figure 17 B). In 
contrast, the number of B-cells and granulocytes did not differ (Two-way ANOVA with 
Bonferroni post hoc correction p > 0.05). 
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Figure 17: SCF and RECON analysis comparing solid Luminal B tumors with Luminal B effusions 
A) Expression profiles of stem cell markers CD47, Her2, cMET, CD44, and CD24 are presented and were 
previously gated on EpCAM+ cells. B) T-cells, the B-cells, the myeloid (mye.) cells, and the granulocytes are 
shown in solid Luminal B tumors and Luminal B effusion. All data are represented as mean + SEM and the 
number of patient samples is shown in parentheses. Significances were analyzed using Two-way ANOVA with 




4.2.4.2 Characterization of T cell subsets in the primary tumor compared to the 
effusion of Luminal B breast cancer patients 
T-cell subpopulations were characterized in Luminal B solid tumors and Luminal B 
effusion. Interestingly, the CD4/ CD8 ratio is shifted significantly towards CD4+ cells in 
Luminal B effusion (students T-test, p < 0.0001) (Figure 18 A). The CD8 effector cells 
were reduced and naïve CD8+ cells were increased in Luminal B metastatic effusions 
(Two-way ANOVA with Bonferroni post hoc correction, both (effector and naïve) p < 
0.05) (Figure 18 B). This phenomenon is also displayed in the CD4 setting. The CD4 
effector cells were decreased and the CD4 naïve cells were increased in Luminal B 
effusions (Two-way ANOVA with Bonferroni post hoc correction, both (effector and 
naïve) p < 0.01) (Figure 18 C). The total PD-1 expression on T-cells was reduced in 
Luminal B effusions compared to Luminal B solid tumors (Student's t-test, p = 0.0011) 
(Figure 18 D). Detailed analyses revealed that especially the CD8+ T-cells showed 
decreased PD-1 expression in Luminal B effusion compared with the Luminal B solid 
tumors (Student's t-test, p = 0.0003) (Figure 18 E). CD4+T-cells did not differ in PD-1 
expression (data not shown). 
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Figure 18: T-cell subpopulations in Luminal B solid 
tumors compared to Luminal B metastases 
A) The figures show the CD4/CD8 ratio of Luminal B 
solid tumors versus Luminal B effusions. B) The data 
represent the % CD8 effector, naïve, mem. eff. 
(memory effector), and TEMRA cells in Luminal B solid 
tumors and effusions. C) The figure shows the % CD4 
effector, naïve, mem. eff. (memory effector), and 
TEMRA cells in Luminal B solid tumors and Luminal B 
effusions. D) The data represent the total PD-1 
expression on T-cells in solid tumors and effusions in 
Luminal B breast cancer. E) The expression level of 
PD-1 on CD8+T-cells is presented on Luminal B solid 
tumors compared to Luminal B effusions. The data are 
shown as mean + SEM and the group size is indicated 
in parentheses. Significances were analyzed using 
Two-way ANOVA with Bonferroni post hoc correction 
or Student's t-test (*p < 0.05, ** p < 0.01, *** p < 0.001) 
4.2.5 Primary tumor culturing 
To establish a breast cancer tumor cell line, solid primary tumors were dissociated 
mechanically or enzymatically, and cultured in DMEM/F12 supplemented with growth 
factors and nutrients (rhEGF, insulin, hydrocortisone, ß-estradiol). To prevent anoikis 
of primary cells, 10 µM Rock inhibitor was added for 5 days to enhance the survival of 
stem cells, prevent dissociation induced apoptosis, and therefore increase the clonal 
efficiency of the cells (Watanabe et al., 2007). These conditions were not applicable to 
the primary solid tumor cells from our laboratory and did not result in a successful 
culturing of a breast cancer tumor cell line (0/32). The tumor cells were often overgrown 
by fibroblasts. Even though differential trypsinization was performed to remove the 
fibroblasts, the tumor cells could not be propagated. Tumor cell culturing was stopped 
at the latest of seven months later calculated from the first day of seeding. However, 
cells that were isolated from a pleural effusion (PT AB) could be propagated in DMEM 
+ 20 ng/ml EGF + 5 µg/ml Insulin 1 % Amphotericin B + 1 % P/S + 5 % FCS medium, 
and culturing was successful over five passages (Figure 19 A). It took one month for 
visible and countable tumor cell proliferation. Moreover, retransplantations of the 
cultured cells of PT AB resulted in adequate outgrowth of peritoneal tumor cells in 4/4 
TM reflecting the equivalent tumor phenotype from the primary tumor. The tumor cells 
were tested by SCF (EpCAM and Her2 positivity) on the tumor cell origin and by IHC. 
The tumor cells were positive for CK18, and ER, and negative for Vimentin. In addition, 
a medium supplemented with 30 different nutrients and growth factors, provided by our 




2017), opened up the opportunity to culture CTC solid tumors for approximately two 









Figure 19: Representative images of the primary tumor cell culture  
A) The image shows cultured PT AB tumor cells derived from pleural effusion. B) The cultured TM CTC solid 
tumor cells are displayed. The images were taken in 10-fold magnification. 
4.3 Characterization of all Luminal B tumor mice (TM) 
4.3.1 Engraftment success of primary tumors in TM (tumor mice) 
33 primary tumors were transplanted in 99 NSG mice (n=3 each primary tumor). 16 of 
the 33 tumors were Luminal B/ Her2- tumors, 4 Luminal B/Her2+ tumors, 7 Luminal A 
tumors, 4 TNBC tumors, and 2 Her2+ /HR- primary tumors. Luminal/ HER2- tumors did 
not engraft (0/16; 0%) whereas TNBC (2/4; 50%), HER2+ breast cancer (2/4; 50%), 
and Luminal B/HER2+ (1/2; 50%) breast cancer were successfully engrafted. In our 
laboratory settings, only breast cancer single-cells from metastatic effusions engrafted. 
The solid primary breast cancer fragments, which were mechanically or enzymatically 
dissociated into single cells, generally failed in engraftment. However, orthotopic tumor 
fragment transplantations were successful with solid primary breast cancer. The 
missing engraftment success of Luminal B HER2- tumors is indicating the general 
difficulties of the engraftment of HR-positive/Her2- tumors (Table 21). Moreover, only 
primary tumors from Caritas Hospital St. Josef Regensburg with either a low PR 
expression or PR deficiency successfully engrafted in the NSG mice. Additionally, only 
primary tumors with high Ki67 of > 14 % engrafted in our NSG mice.  
Table 21: The Success rate of engrafted PDX models 
Successful / total number Subentity % engraftment success 
1/2 Her2+ 50 % 
0/7 Luminal A 0 % 





2/4 Luminal B Her2+ 50 % 
2/4 TNBC 50 % 
The table represents the number of successful engrafted PDX models versus the received total tumor number 
(n/n) classified according to the subentity. 
4.3.2 Total engraftment numbers of tumors in TM and HTM 
Tumor fragments were transplanted in TM CTC, TM Bpe. The idea of simultaneous 
neonatal tumor cell and hematopoietic stem cell transplantation was realized in the 
HTM CTC and Bpe model. In all other cases, a neonatal humanization prior to tumor 
fragment transplantation was necessary as fragments can only be transplanted in adult 
mice. Single-cell transplantation from the other tumors did not engraft. Hence, tissue 
fragments were transplanted in TM CTC, TM Bpe, TM P, HTM P, TM V, TM X 
orthotropy. PT AB was transplanted as a single-cell suspension. PT P resulted in 15 
TM and 8 HTM, and PT AB in 5 TM as models of the Luminal B /Her2+ entity. The 
TNBC PT V was successful in 2 TM and the TNBC PT U engrafted in 5 TM. 8 TM were 
generated with the Her2+ tumor PT X. As TNBC and Her2+ tumors only served as 
control of transplantation methods the tumors were not transplanted into humanized 
mice. Due to the limited time of the project, HTM were not generated out of TM AB 
mice. The precise passages of the TM and HTM are listed in Table 22. 
Table 22: Number of animals with successful tumor engraftment of different tumors from Caritas 
Hospital St. Josef Regensburg 
Solid primary breast cancer St Josef Regensburg Pleural effusion (metastasis) 
St. Josef Regensburg 
Entity  Luminal B/Her2+  TNBC Her2 +  TNBC Luminal 
B/Her2+ 
PT PT (P) PT (V)  PT (X) PT (U) PT (AB) 
TM/HTM TM  HTM  TM TM TM TM  
Number 
of mice  
15 8 2 8 5 5 
Passage P0- P4 P1- P5 P0- P2 P0- P3 P0-P1 P0-P1 
PT primary tumor, TNBC Triple-negative breast cancer, Her2 human epithelial growth factor receptor 2, TM 
tumor mouse, HTM humanized tumor mouse, P passage 
5 TM and 4 HTM were generated out of TM PT CTC tumors and TM PT Bpe engrafted 
successfully in 5 TM and 6 HTM. The tumors derived from our cooperation partner in 
France resulted in 5 TM and 3 HTM of the HBCx3 tumor, 5 TM and 3 HTM of the 
HBCx34 tumor, and 11 TM and 2 HTM of the HBCx22 tumor. All TM and HTM were 
transplanted with a tumor fragment orthotopically into the mammary fat pad of the 





Table 23: Number of animals with successful tumor engraftment of different Luminal B PDX tumors from 
different cooperation partners 
Luminal B PDX 
Luminal B PDX (solid primary breast cancer) 
cooperation Marangoni 
Luminal B PDX (CTC/Bpe 
derived) cooperation Trumpp 
TM F TM 3 
 
F TM 34 F TM 22 
 
TM CTC TM Bpe 
 
TM/HTM TM  HTM TM  HTM TM HTM TM HTM TM HTM 
Number 
of mice 
















PT primary tumor, TNBC Triple-negative breast cancer, Her2 human epithelial growth factor receptor 2, TM tumor 
mouse, HTM humanized tumor mouse, P passage, CTC circulating tumor cells, Bpe pleural effusion, F cooperation 
model from Dr. Marangoni from the Institute Curie, France 
4.3.3 Characterization of human origin in PDX tumors  
Working with PDX models, it is indispensable to ensure the human origin of the tumors 
grown in NSG mice. Therefore, DNA was isolated from tumors of TM and tested with 
species-specific primers for human tissue content using the HuMo PCR. All PDX 
models generated were shown to be of human and not mouse origin (Table 24). For 
the PDX model TM X, TM AB, TM P the human DNA content was analyzed even after 
the first successful engraftment. The PDX models from our cooperation partner were 
verified on human origin at the end of the experiments as those were analyze by the 
cooperation partners beforehand. Five NSG mice transplanted with other primary 
human tumors (at the age of one year or later) were observed to spontaneously 
develop mouse mammary tumors (data not included in the table). The human origin of 
these tumors was excluded by HuMo PCR, the lack of EpCAM+ cells in SCF flow 
cytometry, and IHC negativity for CK18.  
Table 24: Percentage of human tissue in tumors isolated from all TM at the end of the experiment after 
several retransplantations 
 
4.3.4 The immunohistochemical phenotype of the PDX tumor is congruent with 
the patients’ primary tumor  
Different tumor passages were analyzed immunohistochemically for H&E, ER, PR, 
Her2 and Ki67 expression to verify the maintenance of the intrinsic biological Luminal 
B subtype. The comparison of the different passages of retransplanted tumor 
fragments into TM revealed the stability of the intrinsic biological markers of the 




expression of PR emerges in passage 4 of the TM compared with the primary tumor 
and the TM at passage 0. Moreover, the proliferation (Ki67) seems to be increased in 
passage 4 (Figure 20 A). Noteworthy, the intratumoral heterogeneity of the primary 
tumor can still be maintained in the PDX model. The intrinsic molecular markers (ER, 
PR, Her2, Ki67) coincide in the low passages of the PDX models with the primary 
tumor. This congruency seems to be altered by various passaging of the tumor from 
TM to TM. The clinical report of the patient AB revealed hepatic, pulmonary, pleural, 
adrenal, and osseous metastases detected by computer tomography. A report on the 
occurrence of brain metastases in patient AB was not available. However, the 
metastatic spread of the primary tumor in the patient is in accordance with the 
metastatic spread into the lung, the liver, the spleen, and the brain of the TM AB model 
verified by CK 18 IHC (Figure 20 B). We were not able to determine metastasis in the 










A) H&E, ER, PR, Her2, and Ki67 were analyzed immunohistochemically. The bars represent 100 µm and the 
images are taken at 63-fold magnification. B) IHC CK18 analysis of TM AB is shown in the tumor and the organs 
to detect metastases. The bar represents 100 µm and the images are taken at 20-fold magnification. 
Additionally, all generated PDX models were analyzed on their morphology (H&E), ER, 
PR, Her2, Ki67, EpCAM expression (Table 20). Despite the stable ER, Her2, and Ki67 
expression (if the primary tumor was Her2+) throughout various transplantation, the PR 
expression was lowered in the TM Bpe, F TM 34, and F TM 3 model compared with 
the primary tumor. EpCAM positivity was assessed as this was the basis for the gating 
in flow cytometry in order to detect the tumor cells. In fact, all Luminal tumor PDX 
models revealed EpCAM expressing cells but with varying intensity (Figure 21 A). 
Noteworthy, the expression of ER, PR, Her2, Ki67, and EpCAM remained stable even 
in hematopoietic stem cell cotransplanted HTMs (data not shown). Moreover, all PDX 
models were CK18 positive. However, the tumors differed in cell morphology. F TM 22 
and F TM 3 exhibited huge necrotic areas in the tumor center in contrast to the other 
PDX models (Figure 21 B). 
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Figure 21: Representative images of intrinsic molecular features of all engrafted Luminal B tumors in the 
TM and the metastatic sites of TM AB model  
A) The data show the immunohistochemical staining of H&E, ER, PR, Her2, Ki67, and EpCAM on TM AB, TM P, 
TM CTC, TM Bpe, F TM 34, F TM 22, and F TM 3 tumors. The images are represented in 63- fold magnification. 
The bars show 100 µm. B) The images show a representative IHC staining of CK18 of all Luminal B TM tumors. 
The images were taken at 10-fold magnification. 
4.4 MDM2 /TP53 /MDM4 alterations in Luminal B breast cancer PDX 
4.4.1 Uncovered alterations in Luminal B breast cancer by Panel Sequencing 
To characterize the generated PDX and their corresponding tumor in detail, all 
generated PDX tumors with different subentities were analyzed by panel sequencing 
by our cooperation partner (Nicole Pfarr, TU Munich) to quantify genomic aberrations. 
The panel covers 59 genes on different chromosomes that are related to breast cancer 
(Table 25). Remarkably, all tumors showed alterations in the MDM2/ p53 /MDM4 
pathway. Interestingly, TM P, TM Bpe, TM CTC, and F TM 34 of the Luminal B tumors 
showed an MDM2 amplification. Additionally, TM AB of the Luminal B cohort, as well 
as TM V of the TNBC group, exhibited an MDM4 amplification. F TM 3 and F TM 22 of 
the Luminal B cohort displayed a TP53 Mutation. A TP53 mutation is also frequent in 
the TNBC tumors (TM U and TM V). The analysis revealed that MDM2 amplification 
and TP53 mutations seem to be mutually exclusive. TM P tumor revealed an MDM2 
amplification as well as a TP53 deletion. 
For TM X, TM AB, and TM P the Her2 amplification could be confirmed as it was known 
previously due to the pathological diagnostics and the Her2 FISH performed by the 
institute of pathology Regensburg. The primary tumor PT P, PT X, and PT V were 
analyzed equally and revealed the same amplification, mutations, and deletions as the 
corresponding engrafted TM P, TM X, TM V PDX tumors, indicating that the PDX 
model genetically reflects the primary tumor (data not shown). However, several other 
mutations like PIK3CA (TM AB, TM CTC), PTEN (F TM 3, F TM 22), or deletions like 
CDKN2A (TM AB, TM Bpe, F TM 34, F TM 22) and FOXO3 (TM Bpe, F TM 34), or 
amplifications like GRHL2 (TM Bpe, F TM 34) or MYC (TM Bpe) were detected by 
panel sequencing. The detailed aberrations for each TM PDX model are listed in Table 




Heidelberg that the PDX models stayed stable in its alterations over several passages 
in the animals (data not shown).  
Based on the alterations described above, Luminal B PDX models were subdivided 
into groups of MDM2 amplified Luminal B tumors and MDM2 Wildtype (WT) Luminal B 




























Table 25: Data from the panel sequencing of all TM tumors analyzed by our cooperation partner in Munich 
(Nicole Pfarr) 
 
The chromosomes are indicated at the left side with the corresponding genes analyzed. On top, the TM tumors 
are listed according to their breast cancer entity. The red boxes show an amplification of the gene, the dark green 
box shows a deletion, and the yellow box indicates a genomic mutation. A germline mutation is marked in pink 







4.4.2 Classification of PDX models according to chromosomal aberrations of 
MDM2 and p53 
P53, as a product of the TP53 tumor suppressor gene, normally gets ubiquitinylated 
by MDM2 to be degraded at the proteasome. MDM2 serves therefore as a direct 
negative regulator of p53. As all Luminal B PDX models exhibited alterations in the 
MDM2/ p53 axis, it was interesting to determine the Luminal B tumor properties under 
the aspect of an MDM2 amplification and a TP53 mutation. Based on the results of the 
panel sequencing the Luminal B PDX models were subdivided into two categories. On 
the one hand, four PDX models (TM P, TM CTC, TM Bpe, and F TM 34) exhibited an 
MDM2 amplification and on the other hand F TM 22, FTM 3 and TM AB revealed no 
amplification in the MDM2 gene but alterations in MDM4 and TP53. The IHC of MDM2 
confirmed the expression on protein level in TM P, TM CTC, TM Bpe, and F TM 34 but 
also showed the expression of MDM2 in TM AB tumors. The latter could be due to the 
fact that MDM4 stabilizes MDM2 protein expression which was amplified (Stad et al., 
2001). The FISH analysis revealed a normal ratio of MDM2 signals versus centromeric 
signals in TM Bpe, F TM 22, F TM 3 and TM AB and an increased ratio in the TM P 
and TM CTC model. According to its MDM2 ratio F TM 34 would rather be considered 
as equivocal. However, the gene signals of MDM2 per cell was increased in TM P, TM 
CTC, F TM 34 (Table 26).  
Table 26: Summary of panel sequencing results and IHC, FISH and the corresponding FISH ratios and 
gene doses in the different Luminal B PDX models 
 MDM2 amplified tumors MDM2 WT tumors 
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5,83 4,00 1,68 2,02 1,26 1,28 1,14 
MDM2 
gene dose 
< 10 < 10 3,35 5,05 3,65 3,40 1,65 
The table displays the summarized data of all Luminal B PDX models of the panel sequencing regarding MDM2 
and MDM4 amplification as well as the TP53 mutations. IHC of MDM2 is shown in 63-fold magnification with a 
bar of 100 µm. FISH data are represented in 63-fold magnification and the bar shows 25 µm. The FISH ratio is 
calculated as MDM2 signals per centromeric signal and the single signals per cells of MDM2 are listed as gene 
dose. 
4.4.3 Classification of PDX models according to the MDM2 and p53 protein levels 
In order to determine the protein levels of MDM2 and p53 Western Blot analysis of all 
Luminal B PDX models was performed. Protein levels revealed low expression of p53 
in MDM2 amplified tumors (TM P, TM CTC, TM Bpe, and F TM 34), whereas increased 
p53 expression was observed in F TM 22, and F TM 3 tumors. Interestingly TM AB 
exhibited an increased expression of p53, whereas the tumor features no TP53 
mutation, but an MDM4 amplification. As it was published previously, MDM4 seems to 
stabilize p53 in TM AB (Stad et al., 2001). The MDM2 antibody recognizes four 
Isoforms of MDM2 at 90 kDa, 76 kDa, 74 kDa, and 57 kDa. The expression and 
intensity of the different MDM2 isoforms vary between the different PDX models. In 
accordance with the IHC data, MDM2 is mainly increased in TM P and F TM 34 but 
low expression of MDM2 can also be shown in TM CTC, TM Bpe, F TM 22 and F TM 
3 (Figure 22). 
 
Figure 22: Representative Western Blot of p53 and MDM2 of all Luminal B PDX models 
The Blot represents p53 and MDM2 expression of all Luminal B tumors classified according to the results of 
the panel sequencing in MDM2 amplified and MDM2 wildtype tumors. 
Taken together, the data of Table 25, Table 26 and Figure 22 reason the subdivision 
of the tumors as following: TM P, TM CTC, TM Bpe and F TM 34 are summarized and 
denoted for all further animal experiments as TM MDM2 Amplified (Amp) whereas F 




4.4.4 MDM2 amplification increased tumor weight and tumor volume over time, 
decreased the disease-free survival but did not alter the overall survival  
The TM were analyzed on tumor weight, tumor volume over time, disease-free survival 
(DFS) defined as the date of tumor transplantation until the first occurrence of a 
palpable tumor), and overall survival (OS) (defined as the date of tumor transplantation 
until death) to determine the impact of the MDM2 amplification on tumor growth in vivo. 
The data include 28 TM P tumors, 6 TM CTC tumors, 7 TM Bpe tumors, 12 F TM 34 
tumors which are summarized as TM MDM2 Amp tumors. 10 F TM 3 tumors, 11 F TM 
22 tumors, 5 TM AB tumors were summarized as TM MDM2 WT tumors. The data 
revealed a statistically significant increase in tumor weight of TM MDM2 Amp tumors 
compared with TM MDM2 WT tumors (Student's t-test, p = 0.0005) (Figure 23 A). 
Moreover, the tumor volume was significantly increased in TM MDM2 Amp tumors 
compared with TM MDM2 WT tumors, but only at two months after engraftment (Two-
way ANOVA with Bonferroni post hoc correction, p < 0.05). A tendency towards 
increased tumor volume of TM MDM2 Amp tumors could be observed at 1.5 months 
and 2.5 months engraftment whereas the tumor volume converged to a similar volume 
at 3 and > 4 months after engraftment (Figure 23 B). Noteworthy, the DFS was 
significantly reduced in TM MDM2 Amp tumors compared with TM MDM2 WT tumors 
(Log-rank (Mantel-Cox) test, p < 0.0477) (Figure 23 C). In contrast, the Kaplan Meyer 
curves for analysis of overall survival (OS) did not differ between the two groups (Log-
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Figure 23: Effect of an MDM2 amplification in TM tumors 
A) The figure represents the tumor weight and each dot shows an individual animal. The number of TM is listed 
in parentheses. B) The tumor volume over time is presented in TM MDM2 Amp animals and TM MDM2 WT 
animals. The number of animals is listed below or above each time point and the black-rimmed numbers belong 
to TM MDM2 WT tumors. The data are represented as mean ± SEM. C) The data show the DFS, and D) the OS 
of TM MDM2 WT tumors compared with TM MDM2 Amp tumors. The number of animals is depicted in 
parentheses. Significances were analyzed using Two-way ANOVA with Bonferroni post hoc correction, Student's 
t-test or Log-rank (Mantel-Cox) test (* p < 0.05, ***p <0.001). 
4.4.5 Phenotypic differences and alterations in the MIC population 
(CD44+/cMET+/CD47+) between TM MDM2 amplified tumors and TM MDM2 WT 
tumors 
Amongst TM MDM2 WT and TM MDM2 Amp tumors, the phenotypic alterations 
regarding stem cell marker expression were analyzed by flow cytometry and Western 
Blot to determine the impact of an MDM2 amplification. If two tumors were engrafted 
in one animal the tumor probe was pooled for flow cytometrical analysis. The exact 
distribution is given in 4.4.4. In contrast to the expectancies, the TM MDM2 Amp tumors 
showed a decreased cMET expression compared with TM MDM2 WT tumors, whereas 
CD47, CD44, and CD24 did not differ in their expression levels (Two-way ANOVA with 




confirmed by Western Blot assessment with the highest cMET expression in F TM 22 
and F TM 3 belonging to TM MDM2 WT tumors (Figure 24 B). In addition, flow 
cytometric analysis revealed a significantly decreased expression of the triple-positive 
MIC population ( CD44+, cMET+, CD47+) in TM MDM2 Amp tumors compared with TM 
MDM2 WT tumors (Student's t-test, p < 0.0001) (Figure 24 C). In addition, Western 
Blot analysis of CD44, cMET, and CD47 confirmed that CD44 and CD47 as single 
markers do not serve as a prognosticator in TM MDM2 Amp tumors (Figure 24 D). In 
addition, the EpCAM expression, in general, was shown to be very high (mean 86 - 88 





























































































































































Figure 24: Flow cytometric analysis on stem cell 
markers comparing TM MDM2 WT with TM MDM2 
Amp tumors 
A) The figure shows the SCF analysis comparing TM 
MDM2 WT tumors with TM MDM2 Amp tumors. B) The 
upper panel shows a representative image of the 
cMET Western Blot. The corresponding densitometric 
analysis normalized on total protein for each Luminal 
B PDX model is depicted below. C) The MIC 
population was analyzed by flow cytometry comparing 
TM MDM2 WT with TM MDM2 Amp tumors. D) The 
Western Blot analysis of cMET, CD47, and CD44 of all 
Luminal B PDX models is shown in the graph. E) The 
data represent the EpCAM expression of tumor cells 
comparing TM MDM2 WT with TM MDM2 Amp 
tumors. The animal numbers are represented in 
brackets and the Western Blot analysis was performed 
only once with. The data of A) are shown as mean+ 




mean ± SEM. Each dot represents a single tumor. 
Significances were analyzed using Two-way ANOVA 
with Bonferroni post hoc correction or Student's t-test 
(** p < 0.01, ***p <0.001). 
4.4.6 MDM2 amplified tumors promote lung metastases and differ phenotypically 
from the corresponding tumor  
To determine the lung metastasis of TM MDM2 WT compared to TM MDM2 Amp 
animals, the lungs of the TM were stained for cytokeratin 18 (CK18) and analyzed 
morphometrically. CK18 as a keratin filament is highly expressed in epithelial cells 
of Luminal breast cancer and serves as a marker to identify the Luminal breast 
cancer cells in the periphery. It was shown that the frequency of lung metastases 
occurrence was significantly increased in TM MDM2 Amp animals compared with 
TM MDM2 WT animals (Two-sided Fisher’s exact test, p < 0.0001) (Figure 25). 
TM MDM2 WT TM MDM2 Amp 
  
 TM MDM2 WT TM MDM2 Amp 
P value (TM MDM2 Amp versus TM 
MDM2 WT) 
Lung metastases 2/12 22/24 0.0001 
 
 
Figure 25: Lung metastases in TM MDM2 WT compared with TM MDM2 Amp animals 
Representative images of lung metastases in TM MDM2 WT and TM MDM2 Amp animals. The images are 
shown in 20 -fold magnification and the bars represent 100 µm. The incidence for lung metastases was 
calculated using the two-sided Fisher’s exact test and the p-value is listed in the table. The number of animals 
with detectable CK18 metastases of the total number of animals (n/n) is indicated. 
In addition, only the lung metastases of all TM MDM2 Amp animals were analyzed for 
stem cell marker expression by flow cytometry, because only two animals in the TM 
MDM2 WT (TM AB tumor) tumor group generated lung metastases. The tumor cells in 
the lung were detected using EpCAM. The number of EpCAM+ counts in the lung 
ranges between 200 and 6000 cells per measurement of 0.5 million total lung cells. 
The TM MDM2 Amp lung metastases revealed an increased level of cMET+ and CD44+ 
cells, compared to the corresponding tumor (Two- Way ANOVA with Bonferroni post 
hoc correction, p < 0.001) (Figure 26 A). Moreover, the MIC population (CD44+, CD47+, 
cMET+) was shown to be increased in TM MDM2 Amp lung metastases, compared to 




























































Figure 26: Flow cytometric analysis of lung metastases compared with the corresponding tumor in TM 
MDM2 Amp animals.  
A) The figure shows a comparison of CD47, Her2, cMET, CD44, and CD24 in TM MDM2 Amp tumors vs. TM 
MDM2 Amp lung metastases. B) The MIC population is represented in TM MDM2 Amp tumors and TM MDM2 
Amp lung metastases. The data in A) are shown as mean + SEM and in B) as mean ± SEM whereby each dot 
represents a single animal. The number of animals and the corresponding lung metastases is indicated in 
parentheses. Significances were analyzed using Two-way ANOVA with Bonferroni post hoc correction or 
Student's t-test (*** p < 0.001). 
4.4.7 MDM2 amplification decreases T-cell infiltration in HTM  
In order to determine the influence of the human immune system on Luminal B tumors, 
HTM of the Luminal B TM were generated. Based on the results of TM (Table 25, Table 
26 and Figure 22) HTM tumors were subdivided into two groups for the following 
examinations: HTM P, HTM CTC, HTM Bpe and F HTM 34 were summarised as HTM 
MDM2 Amplified (Amp), whereas F HTM 22, F HTM 3 were combined as HTM MDM2 
wildtype (WT). HTM AB were not generated and are therefore not included in the HTM 
MDM2 WT group.  
As a prerequisite for successful humanization, the CD45+ cells in the spleen of all HTM 
were quantified by flow cytometry. All HTM that harbored Luminal B tumors were 
humanized as shown as % CD45+ cells in the spleen (average: 64 %; range: 18 - 88 
% CD45+ cells) (Figure 27 A). The animals that suffered from graft versus host disease 
(GvHD) were excluded from the analysis, based on the fact that the CD45+ cells in the 
bone marrow consisted mostly of T-cells, in addition to a bad general condition of the 
HTM like anemia or extensive skin itchiness. The TIL analysis revealed a lower 
infiltration rate of CD45+ cells in HTM MDM2 Amp tumors compared with HTM MDM2 
WT tumors (Student's t-test, p = 0.0259) (Figure 27 B). In general, all Luminal B PDX 
HTM tumors exhibited a low infiltration and could, therefore, be considered as non-




and CD8 analysis because the number of total cells is not representative. Interestingly, 
the infiltration of T-cells was also significantly lower in HTM MDM2 Amp tumors 
(students t-test, p = 0.0454) (Figure 27 C). In addition, the HTM MDM2 Amp tumors 
tended to be infiltrated by a lower number of cytotoxic T-cells, however, this was not 
statistically significant (Student's t-test, p = 0.057) (Figure 27 D). About 70 % of the T-
cells (CD4+ and CD8+ cells) were shown to express PD-1 on their surface and it was 
neither influenced by a MDM2 amplification nor dependent on a certain T-cells type 
(cytotoxic or T-helper cells) (data not shown). In addition, the naïve, effector, effector 
















































































































Figure 27: Occurrence of immune cells in the spleen and the tumor of HTM 
A) The spleen of the HTM displays the humanization of all HTM. B) The data show CD45+ immune cell infiltration 
in the tumor comparing HTM MDM2 WT with HTM MDM2 Amp tumors. C) The figure represents the occurrence 
of CD3+ cells within the immune cell gate of HTM MDM2 WT tumors and HTM MDM2 Amp tumors. D) The % of 
cytotoxic T-cells are shown in HTM MDM2 WT tumors and HTM MDM2 Amp tumors. All data are represented 





4.4.8 Effect of MDM2 amplification in Luminal B humanized PDX mice   
The data revealed a statistically significant increased tumor weight of HTM MDM2 Amp 
tumors compared with HTM MDM2 WT tumors (Student's t-test, p < 0.0119) (Figure 
28 A). The tumor volume over time tended to be increased in HTM MDM2 Amp tumors 
compared to TM MDM2 WT tumors (Two-way ANOVA with Bonferroni post hoc 
correction, p > 0.05) (Figure 28 B). The DFS as wells as the OS did not differ between 
HTM MDM2 Amp animals and HTM MDM2 WT animals (Log-rank (Mantel-Cox) test, 
p > 0.05) (Figure 28 C and D). Interestingly, the influence of the human immune system 
becomes visible, when comparing HTM MDM2 Amp tumors with TM MDM2 Amp 
tumors that revealed an increased DFS (Log-rank (Mantel-Cox) test, p = 0.0012) 
(Figure 28 E). Nevertheless, comparing the OS of HTM MDM2 Amp with TM MDM2 
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Figure 28: Effect of an MDM2 amplification in HTM 
A) The in vivo data represent the tumor weight of HTM 
MDM2 WT tumors compared with HTM MDM2 Amp 
tumors. The data are shown as mean ± SEM. Each 
dot signs a single tumor. B) The tumor volume over 
time is shown in MDM2 WT tumors compared with 
HTM MDM2 Amp tumors. C) The DFS, and D) the OS 
are represented in HTM MDM2 Amp and HTM MDM2 
WT animals. The data are shown as mean ± SEM in 
A) and B). E) The data show a comparison of HTM 
MDM2 WT animals compared with HTM MDM2 Amp 
animals regarding DFS. The number of animals is 
indicated in parentheses. Significances were 
analyzed using Two-way ANOVA with Bonferroni post 
hoc correction, Student's t-test, or Log-rank (Mantel-
Cox) test (* p < 0.05, ** p < 0.01) 
4.4.9 HTM MDM2 amplified tumors promote lung metastases that differ 
phenotypically from the corresponding tumor  
. Similar to the findings obtained in TM, IHC CK18 staining in the lung occurred in a 
significant higher frequency in HTM MDM2 amp versus HTM MDM2 WT (Two-sided 
Fisher’s exact test, p = 0.0114). However, the cotransplantation of a human immune 
system did not altered the appearance of EpCAM+ tumor cells in the lung (TM MDM2 
Amp versus HTM MDM2 Amp Student's t-test, p = 0.9549) (Figure 29 B). Hence, the 
immune system does neither promote nor inhibit the metastatic spread to the lung. 
Again, as shown for TM MDM2 Amp lung metastases, HTM MDM2 Amp lung 
metastases revealed an increased level of cMET+ and CD44+ cells, compared to the 
corresponding tumor (Two- Way ANOVA with Bonferroni post hoc correction, p < 
0.001) (data not shown). Moreover, lung metastases differed in increased MIC 
expression pattern from the corresponding primary tumor in the HTM MDM2 Amp 
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Figure 29: Lung metastases occurrence and MIC population in HTM MDM2 Amp and HTM MDM2 Amp 
animals and the influence of the human immune system on lung metastases in TM MDM2 Amp versus 
HTM MDM2 Amp animals 
A) The incidence for lung metastases was calculated using the two-sided Fisher’s exact test and the p-value is 
listed in the table. The number of animals with detectable CK18 metastasis of the total number of animals (n/n) 
is indicated. B) The influence of the immune system was assessed by EpCAM staining with flow cytometric 
analysis in TM MDM2 Amp and HTM MDM2 Amp lungs. C) The data show the MIC population in HTM MDM2 
Amp animals comparing the tumor with the lung metastases. The data are represented as mean ± SEM and the 
number of animals is indicated in parentheses. Each dot represents a single animal. Significances were analyzed 
using two-sided Fisher’s exact test or Student's t-test (* p < 0.05, ** p < 0.01). 
4.4.10 MDM2 amplification does not favor colonization of DTCs in the BM   
In this context, it was interesting to determine the dissemination of tumor cells to the 
BM regarding the impact of the human immune system and the influence of an MDM2 
amplification of the tumor. The DTCs were verified by a PAN CK staining (CK8, CK18, 
CK 19) of the BM. It was possible to detect single DTCs as well as DTC clusters in the 
BM (Figure 30 A). Nevertheless, the DTC existence was neither connected to an 
MDM2 amplification of the Luminal B tumor in TM or HTM (Fishers’ exact test, (TM 
MDM2 Amp vs TM MDM2 WT: p = 0.4223; HTM MDM2 Amp vs HTM MDM2 WT: p = 
0.2929) (Figure 30 B) nor linked to an influence of the human immune system 
comparing HTM with TM (Fishers’ exact test, (TM MDM2 Amp vs HTM MDM2 Amp: p 













 TM MDM2 WT TM MDM2 Amp 
P value (TM MDM2 Amp versus TM 
MDM2 WT) 
BM DTC 4/9 13/20 0.4223 
 
 
 HTM MDM2 WT HTM MDM2 Amp 
P value (HTM MDM2 WT versus 
HTM MDM2 Amp) 
BM DTC 2/5 6/8 0.2929 
 
Figure 30: DTCs in the bone marrow Luminal B breast cancer PDX models  
A) The figure shows a representative image of the purple single cells and a DTC cluster in the BM of a TM. B) 
The Fishers’ exact test analyzed the occurrence of DTCs and is shown comparing TM MDM2 WT with TM MDM2 
Amp and HTM MDM2 WT with HTM MDM2 Amp (not significant). The number of animals with detectable DTCs 
of the total number of animals (n/n) is indicated. 
4.4.11 Copy number variation low pass-sequencing of the Luminal B HTM P and 
TM P PDX model 
In this part, we focused on the analysis of single cells to detect any copy number 
variations between the primary tumor and the DTCs. The isolated single cell DTCs and 
the corresponding single-cell tumor cells of the TM P and HTM P PDX model were 
analyzed by copy number variation low pass- sequencing at the ITEM Regensburg. 
This study focused only on the TM P and HTM P Luminal B model as the dissemination 
of tumor cells was confirmed in all animals and the number of animals (TM and HTM) 
transplanted was the highest including various passages. The Figure 31 shows a 
representative example comparing the profile of a normal healthy immune cell (isolated 
from the BM of an HTM), a BM DTC (DCC), and a cell of the corresponding primary 
tumor cell. The healthy cell represented clearly the normal chromosomal copy number 
of two genes throughout the genome without any gains or losses. In contrast, the BM 
DTC showed losses on chromosome 5 whereas the matching primary tumor cell 
revealed a gain. This demonstrated that the DTC and the matching primary tumor could 
differ genomically. However, there are still regions like on chromosome 8 were the 
DTC exhibited the same gain as the primary tumor revealing that some gains (or 




The whole analysis of all TM P and HTM P DTCs and the corresponding single tumor 
cells of different passages is displayed as a cluster (Figure 31 B). Here, the copy 
number gain is shown in yellow and a copy number loss is depicted in blue. With this 
analysis, the copy number gain or a copy number loss could not be traced back to a 
certain gene but to a certain area on the chromosome. The human origin of each cell 
was always confirmed by endpoint PCR. Only cells that were exclusively positive in 
the human PCR but not in the mouse PCR were included in the sequencing (data 
not shown). By means of the clustering, the cells could be separated into three 
groups due to the mapping of the genetic origin of the cell and their genetic similarity 
(red and blue line). It could be confirmed that the DTCs (in the graph denoted as 
DCCs) cluster mostly in the upper part (separated through a red line), whereas the 
tumor cell and just a few DTC could be found in the middle. In the lower part DTCs 
cluster as a small group that derive mainly from HTM (marked in green boxes) and 
DTC population is separated through a blue line from the tumor cell population 
(Figure 31 B). Comparing population 1 (mainly DTCs) with population 2 (mainly 
tumor cells) the copy numbers vary on chromosome 4 (loss in population 2), 
chromosome 5 (gain in population 1) and chromosome 6 (gain in population 1). 
Comparing population 3 (DTCs) with population 2 (mainly tumor cells) the copy 
number alters on chromosome 4 (loss in population 2), chromosome 6 (gain in the 
population 2 and loss in population 3) and chromosome 5 (gain in population 2 and 
loss in population 3). However, several alterations can be detected between DTCs 
and tumor cells that are not identical. It was also observed that the cell population 
could harbor converse copy number variations. Noteworthy, a gain on chromosome 
17 on the q-arm is present in population 1 and population 2, whereas it is missing in 
the population 3 were most of the cells derived from HTM. This shows that even the 
DTC profiles are not genomically congruent with other DTC profiles. In contrast to 
the HTM DTCs that mainly cluster in the lower part (population 3) DTCs of the TM 














Figure 31: Clustering of DTCs and tumors cells isolated from HTM P and TM P 
A) The figure shows exemplarily CNV profiles of a normal cell, a DTC and the corresponding primary tumor. The 
chromosomes are given at the x-axis and the copy number is depicted on the y-axis. The red boxes mark 
representative alterations for explanation issues. Genomic gains are depicted in red and genomic losses are 
shown in blue. B) The Affymetrix data of the cell profiles were analyzed on progenetix database. The 
chromosomes are listed at the x-axis and the different cells (DTCs or tumor cells) are given at the y-axis. The 
DTCs from HTM are marked with green boxes.DTCs on the y-axis are denoted as DCCs and tumor cells as TZ. 
The DTCs and some tumor cells that cluster in the upper part are denoted as population 1, followed by the tumor 




lines. A loss of genomic material is indicated in blue and a gain of genomic material is marked in yellow color. 
The black boxes mark the regions discussed in the text.  
4.4.12 Metastatic potential of generated PDX and the genetic aberrations of HTM 
and TM tumors 
The following table summarizes the findings of the Luminal B breast cancer PDX 
models in the TM and HTM settings (Table 27). It shows the continuous dissemination 
of all PDX models to the bone marrow, independent of the human immune system. 
Due to the fact of continuous dissemination into the BM all of the generated Luminal B 
PDX models represent a high-risk Luminal B group. Moreover, both, TM and HTM 
models with an MDM2 amplification, generated lung metastases. In contrast, the TM 
and HTM tumors with a TP53 mutation did not cause lung metastases. Even though 
the TM P and HTM P models are MDM2 amplified, the panel sequencing uncovered a 
deletion in the TP53 gene. The TM AB model is outstanding with the amplification of 
MDM4 and in these mice, tumor cells were detected in multiple organs such as the 
bone marrow, lung, liver, and the brain. All other PDX models with either MDM2 
amplification or TP53 mutation did not metastasize to the liver or the brain. 
Table 27: Summary of the metastatic potential of TM and HTM Luminal B breast cancer PDX models 
 BM 
DTCs 
Lung Liver Brain 
 




TM P ✓ ✓ - - (-) ✓ - 
HTM P ✓ ✓ - - (-) ✓ - 
TM CTC ✓ ✓ - - - ✓ - 
HTM CTC ✓ ✓ - - - ✓ - 
TM Bpe ✓ ✓ - - - ✓ - 
HTM Bpe ✓ ✓ - - - ✓ - 
F TM 34 ✓ ✓ - - - ✓ - 
F HTM 34 ✓ ✓ - - - ✓ - 
F TM 22 ✓ - - - ✓ - - 
F HTM 22 ✓ - - - ✓ - - 
F TM 3 ✓ - - - ✓ - - 
F HTM 3 ✓ - - - ✓ - - 
TM AB ✓ ✓ ✓ ✓ - - ✓ 
The models (TM/ HTM) are indicated at the left and the organs are listed above. ✓ = metastases or genetic 
alteration is present, - = no metastases or no alterations exists, (-) = deletion, Amp =amplification, mut =mutation 
4.5 The relevance of immune checkpoints (PD-L1) in Luminal breast cancer  
As immune checkpoint modulations get more and more attention for therapeutic 
intervention, it was one aim of this thesis to evaluate the PD-L1 expression in the HTM 




tumors were rather non-immunogenic with just a minor TIL number (Figure 27). In 
accordance, the PD-L1 expression, as a common defense mechanism of the tumor 
against TILs, was very low in general. No differences in PD-L1 expression were 
determined in the context of an MDM2 amplification (Student's t-test, p = 0.3510) 
(Figure 32 A). Moreover, the data revealed no significant correlation between the PD-
1 CD8+ T-cells with the PD-L1 expression on tumor cells (Spearman’s rank correlation 
coefficient r = 0.1943) (Figure 32 B). In addition, a correlation between PD-1 CD4+ T-
cells and the PD-L1 expression was also not detected (Spearman’s rank correlation 
coefficient: r = 0,09573) (data not shown). The number of total TILs (CD45+ cells) did 
also not correlate with the PD-L1 expression on tumor cells (Figure 32 C). Hence, 
without immune-activating treatments, immune checkpoints play a rather subordinate 































































Figure 32: In vivo PD-L1 expression in tumors of Luminal B HTM 
A) The upper part shows representative images of membrane-bound PD-L1 expression in HTM with 0%, 20 %, 
and 60 % PD-L1 staining and the corresponding score. The images were taken in 100-fold magnification and the 
bars represent 100 µm. The Scores 0-3 of HTM MDM2 WT were compared with HTM MDM2 Amp in the figure 
below. The data are depicted as mean ± SEM and each dot represents an individual animal. B) The PD-L1 CD8+ 
cells determined by flow cytometry were correlated with the IHC PD-L1 Score of all animals. C) The number of 





In this context, it was necessary to determine the PD-L1 status not only in vivo but also 
in vitro. Therefore, the constitutive PD-L1 expression of different breast cancer cell 
lines, cultured under standardized conditions, was analyzed by IHC (Figure 33 A). 
Immunohistochemical staining verified the highest PD-L1 expression on JIMT-1 (Her2+ 
breast cancer) breast cancer cells, with 100 % of the cells being PD-L1+. In contrast, 
MDA-MB-231 (TNBC breast cancer) and SK-BR-3 (Her2+ breast cancer) breast cancer 
cell lines showed heterogeneous PD-L1 expression with PD-L1+ and partially PD-L1- 
cells. BT-474 (Luminal / Her2+ breast cancer) cells appear as PD-L1- (adapted and 
modified from (Rom-Jurek et al., 2018)). The FISH data revealed no significant 
increase of PD-L1 gene copy numbers or alterations of the PD-L1 /centromeric ratio in 
any of the tested cell lines (Figure 33 B). Additionally, PD-L1 expression was analyzed 
in an in vivo model based on NSG mice that were transplanted with human breast 
cancer cell lines (MDA-MB-231, BT-474, SK-BR-3, and JIMT-1) with or without 
simultaneous intrahepatic transplantation of CD34+ hematopoietic stem cells. The 
transplanted mice developed either solid tumors subcutaneously (MDA-MB-231, JIMT-
1), liver-associated tumors (BT-474), or tumor effusions in the peritoneal cavity (SK-
BR-3) and are cell-line derived xenograft models. Moreover, mice transplanted with 
CD34+ cells developed a functional human immune system up to 12 weeks post-
transplant. In line with the in vitro data, the highest PD-L1 expression was found in 
MDA-MB-231 and JIMT-1 breast cancer cell line transplanted animals, both, in the 
presence or absence of a human immune system (Figure 33 C). Interestingly, no PD-
L1+ tumor cells isolated from the peritoneal effusion of SK-BR-3 transplanted mice 
were detectable in vivo in tumor mice (TM) or humanized tumor mice (HTM). However, 
BT-474, MDA-MB-231, SK-BR-3, and JIMT-1 breast cancer cell line tumors apparently 
showed diminished PD-L1 expression in vivo compared to in vitro cultured cells. In 
addition, the expression pattern of PD-L1 in MDA-MB-231 and JIMT-1 TM and HTM 
tumor tissues was very heterogeneous and not expressed ubiquitously. Apparently, 
the co-transplantation of a human immune system in HTMs did not affect the PD-L1 
















Figure 33: Programmed death ligand 1 (PD-L1) expression on different breast cancer cell lines 
A) Immunochemical staining of PD-L1 was performed on FFPE embedded breast cancer cell lines. The bars 
represent 100 µm. B) The data show representative images of FISH analysis in different breast cancer cell lines. 
MDA-MB-231, BT-474, SK-BR-3, and JIMT-1 cell lines were analyzed for PD-L1 (green) and Cen9 (red) gene 
copy numbers. C) The figure shows in vivo PD-L1 expression in tumors of tumor mice (TM) and humanized 
tumor mice (HTM), transplanted with different breast cancer cell lines. Immunohistochemical staining of PD-L1 
is depicted in tumor samples of TM or HTM transplanted with MDA-MB-231, BT-474, SK-BR-3 or JIMT-1 breast 
cancer cell lines cotransplanted with or without human hematopoietic stem cells (HSC). The bars represent 100 
µm. 
 4.6 Targeting MDM2 in ZR-75-1 breast cancer cell line in vitro 
4.6.1 Effect of MDM2 knockdown on apoptosis, S-phase fraction, and cell 
number  
Based on the results of MDM2 amplification in TM Luminal B PDX models, the effect 
of an MDM2 knockdown was analyzed in vitro. The experiments were conducted using 
the Luminal breast cancer cell line ZR-75-1. ZR-75-1 features an increased MDM2 
gene dose and belongs to a TP53 wildtype cell line (data not shown). As a prerequisite 
for all MDM2 knockdown effects, MDM2 knockdown significantly reduced the protein 
expression of MDM2 compared to ctrl and to NT ctrl in all experiments (One-Way 
ANOVA with Tukey’s multiple comparisons test, p < 0.05 (MDM2 KD vs. NT ctrl), p < 




reduced the vital cells and lead to increased early apoptosis when compared with the 
non-target control (Two- way ANOVA with Bonferroni post hoc correction, p < 0.01 vital 
cells and p < 0.05 early apoptosis) (Figure 34 A). There was also a significant reduction 
of vital cells, increased early apoptosis, and increased late apoptosis between the 
control and MDM2 knockdown cells. For reasons of clarity, the significances are not 
indicated in the figure. In accordance with this data, the proliferation, which is 
determined by a high S-phase and low Gap (G1/G2) phase, was decreased by an 
MDM2 knockdown. Reduced MDM2 levels led to a decreased amount of cells in the 
S-phase and an accompanying shift towards the G2-phase when compared with the 
non-target control (Two-way ANOVA with Bonferroni post hoc correction, p < 0.05; 
both, S-phase and G2-phase; Figure 34 B). In addition, the cell number tended to 
decrease after an MDM2 knockdown without reaching statistical significance even 
though the reduced confluence is visible under the light microscope (One-Way ANOVA 
with Bonferroni post hoc correction, p =0.2227) (Figure 34 D). In order to analyze the 
migratory and proliferative effects of an MDM2 knockdown, a wound-healing assay 
was performed. The assay revealed that MDM2 knockdown does not alter the 
migratory properties in vitro (Figure 34 C) - a migratory effect would have occurred 
within the first 12-24 h after chamber removal. Hence, the data of reduced proliferation 
in the wound healing assay after an MDM2 knockdown 48h after chamber removal, 
support the results of decreased proliferation determined by S-phase fraction analysis. 
The proliferation of MDM2 knockdown cells was significantly reduced 48h after 
chamber removal and lasted until 144h a time point when non-treated control cells and 

























































































































Figure 34: Effects of MDM2 knockdown in ZR-75-1 
cells on apoptosis, S-phase fraction, wound 
healing and cell number 
A) The figure displays the effect of MDM2 knockdown 
on vital cells, early apoptosis, and late apoptosis. B) 
Represents the shifts of S-phase, G1- and G2-phase 
after an MDM2 knockdown. The data are shown as 
mean + SEM and the experiments were replicated 
three times. C) The upper panel shows the effect of an 
MDM2 knockdown on wound healing. The data are 
presented as mean ± SEM. The image shows the 
proliferation after 144 h and the red bars mark the gap 
after chamber removal at point 0h and the gap of 
MDM2 knockdown cells after 144 h. D) The upper 
panel represents an image of the decreased 
confluence after an MDM2 knockdown. The lower 
panel shows the cell number after an MDM2 
knockdown, compared with non-treated controls, and 
non-target siRNA treated controls. The data are shown 
as mean + SEM and the experiments were replicated 




correction or One-way ANOVA with Tukey’s multiple 
comparisons test (* p < 0.05, ** p < 0.01, ***p <0.001). 
4.6.2 Effect of AMG232 inhibition on apoptosis, S-phase fraction, and cell 
number 
In order to elucidate the therapeutic aspect of MDM2 inhibition, ZR-75-1 breast cancer 
cell line was treated with AMG232 in vitro. The cells were treated with 0.1 µM AMG232 
for 48h or 72h. The optimal concentration of AMG232 was determined in a separate 
experiment based on the publication of (Werner et al., 2015) (data not shown). The 
results of an MDM2 inhibition with AMG232 were identical to those of the MDM2 
knockdown in ZR-75-1 breast cancer cell line showing a S-phase reduction and a shift 
towards the G2 phase as well as the prohibited wound closure after AMG232 
treatment. In detail, it was demonstrated that an AMG232 inhibition reduced the vital 
cells 48 h after treatment when compared with the DMSO control (Two- way ANOVA 
with Bonferroni post hoc correction, p < 0.05 vital cells) (Figure 35 A). In contrast, the 
treatment of AMG232 did not alter the apoptosis 72 h after treatment (Two- way 
ANOVA with Bonferroni post hoc correction, p > 0.05). In accordance with these data, 
the proliferation, which is determined by a high S-phase and low Gap (G1/G2) phase, 
was decreased 48 h and 72 h after an AMG232 treatment (Two- way ANOVA with 
Bonferroni post hoc correction, S-phase 48 h, and 72 h: p < 0.01) (Figure 35 B). The 
AMG232 inhibition led to a decreased number of cells in the S-phase and an 
accompanied shift towards the G2-phase compared with the DMSO control 72 h after 
treatment (Two-way ANOVA with Bonferroni post hoc correction, p < 0.05; G2-phase). 
In order to analyze the migratory and proliferative effects of an AMG232 treatment, a 
wound-healing assay was performed. The assay revealed that AMG232 inhibition did 
not alter the migratory properties in vitro because this would have occurred within the 
first 12-24h after chamber removal (Figure 35 C). However, the data showed a reduced 
proliferation 144 h after chamber removal in the wound healing assay after AMG232 
treatment. This supports the results of decreased proliferation determined by S-phase 
fraction analysis. The proliferation of AMG232 treated cells was still reduced 216 h 
after chamber removal when non-treated control cells and DMSO treated cells had 
already closed the wound (Two-way ANOVA with Bonferroni post hoc correction, p < 
0.001) (Figure 35 C). In addition, the cell number was significantly decreased 48 h and 
72 h after AMG232 treatment. (Two-way ANOVA with Bonferroni post hoc correction, 

































































































































































Figure 35 AMG232 treatment effects of ZR-75-1 on 
apoptosis, SPF, wound healing and cell number 
A) Displays the effect of AMG232 treatment on vital cells, 
early apoptosis, and late apoptosis. B) Represents the 
shifts of S-phase, G1- and G2-phase after an AMG232 
treatment. The data are shown as mean + SEM and the 
experiments were replicated three times. C) The upper 
panel shows the effect of an AMG232 treatment on wound 
healing. The data are presented as mean ± SEM. The 
image shows the proliferation after 144h and the red bars 
mark the gap after chamber removal at point 0h and the 
gap of AMG232 treated cells after 144h. D) It depicts the 
cell number after an AMG232 treatment, compared with 
the DMSO treated control. The data are shown as mean + 
SEM and the experiments were replicated three times. * p 








4.6.3 MDM2 knockdown increases apoptosis via the p53 pathway 
As demonstrated above, MDM2 knockdown increased apoptosis and reduced 
proliferation of ZR-75-1 breast cancer cells. These findings were further elucidated by 
assessing the molecular mechanism that is implicated in MDM2 regulation. For 
densitometric analysis of the MDM2 Western Blot, only the bands with the protein size 
of 90 kDa, 76 kDa, and 57 kDa were examined as the 74 kDa band is not affected by 
an MDM2 knockdown (Figure 36 A). Therefore, it can be concluded that the effect of 
MDM2 knockdown on apoptosis, SPF, and wound-healing was due to the isoforms 90 
kDa, 76 kDa, and 57 kDa of MDM2 protein. In contrast, p53 protein which is normally 
tagged by MDM2 for protein degradation increased significantly in MDM2 knockdown 
cells (One -Way ANOVA with Tukey’s multiple comparisons test, p < 0.05 (MDM2 KD 
vs. NT ctrl), p < 0.05 (MDM2 KD vs. ctrl)) (Figure 36 B). MDM2 knockdown resulted in 
a decrease of phosphorylated focal adhesion kinase (pFAK) without reaching statistical 









































































































































Figure 36: Effects of MDM2 knockdown on 
protein levels 
A) The protein level of MDM2 in ZR-75-1 cells 
after an MDM2 siRNA-mediated knockdown is 
shown compared with the ctrl and the NT ctrl. B) 
The data depict the effect of an MDM2 
knockdown on p53 protein levels. C) The figure 
shows the effect of an MDM2 knockdown on FAK 
phosphorylation. D) Representative Western 
blots are depicted for each protein including FAK 
total protein. The Western blots were replicated 
three times except for FAK which only was 





The current differentiation between high and low-risk Luminal tumors using the 
proliferation marker Ki67, the grading, and molecular assays for risk assessment 
(Goldhirsch et al., 2011; Cheang et al., 2009; Narain and Adcock, 2017) remains 
unsatisfying. Still, there is a lack of appropriate markers that clearly distinguish 
between high and low-risk Luminal B tumors. As high-risk Luminal B patients do not 
necessarily respond to endocrinological therapy compared to low-risk Luminal A 
patients, the chemotherapy is administered if patients suffer from a Luminal B tumor 
(Rouzier et al., 2005; Hayes et al., 2007; Goldhirsch et al., 2011). However, it is still 
disputed if all Luminal B patients profit from chemotherapeutic intervention. Another 
problem in Luminal B breast cancer is represented by the occurrence of distant 
metastases. Those metastases do not necessarily coincide with the pheno- or 
genotype of the primary tumor (Al-Hajj et al., 2003; Baccelli et al., 2013; Schmidt-Kittler 
et al., 2003). Hence, it is important to elucidate the pheno- and genotype of the 
corresponding metastases in order to determine potential therapeutic targets for the 
treatment of metastasized Luminal B breast cancer patients. Therefore, this study 
focused on the detection of new Luminal B high-risk pheno- and genotypic markers in 
Luminal B tumors and metastases using the TM and HTM model. With these markers 
it should be possible to identify the patients that have a high susceptibility to 
metastasize. In the following chapters the determined geno- and phenotypic markers, 
as well as the influence of human immune cells in Luminal B breast cancer, will be 
discussed in detail.  
5.1. Luminal B breast cancer PDX models and Luminal B primary tumor cell 
culturing  
Patient-derived xenograft (PDX) models are immunodeficient mice transplanted with 
malignant tissue or single cells from a patient's primary or metastatic tumor. These 
PDX mice enable the opportunity to study human cancer biology in a model system 
which has turned out to be a reliable tool for cancer research. Previously it was 
demonstrated that those PDX models could predict treatment responses like the PARP 
inhibitors and mTOR inhibitors that reveled a benefit for TNBC patients (Kawaguchi et 
al., 2017). Moreover, the PDX models enabled the detection of new targets to fight 
breast cancer such as the CD44+ tumor cells that are able to initiate tumor growth and 
the coexpression of CD44+, cMET+, and CD47+ that promote metastases in breast 




tumors belong to the Luminal subentity, the tissue availability for research is limited 
due to the fact that recent techniques are able to detect breast cancer in a very early 
stage and low tumor size. Hence, the tissue is only used for diagnostic properties. 
Moreover, the phenomenon of poor engraftment of Luminal breast cancer tumors in 
mice has been reported previously (DeRose et al., 2011; Fleming et al., 2010; Vaillant 
et al., 2013; Oakes et al., 2012; Kabos et al., 2012; Zhang et al., 2013). Vaillant 
demonstrated 12 % Luminal breast cancer engraftment rate (Vaillant et al., 2013; 
Oakes et al., 2012), Marangoni: 4 % (Marangoni et al., 2007), Cottu: 2.5 % (Cottu et 
al., 2012; Marangoni et al., 2007), Zhang: 2 % (Zhang et al., 2013), and 0 % was 
evaluated by Petrillo (Petrillo et al., 2012). In contrast, other subentities like the highly 
aggressive TNBC (60.7%: (Vaillant et al., 2013), 100 %: (Petrillo et al., 2012)) and 
Her2+ breast cancer (35.7 %: (Vaillant et al., 2013)) showed an enhanced take rate in 
mice. 25 % take rate was reported additionally by Cottu et al. for all non-luminal PDX 
models (TNBC and Her2+ breast cancer) (Cottu et al., 2012).  
In this work, we provided evidence that the molecular intrinsic Luminal subtype of the 
primary tumor (ER, PR, Her2, Ki67) was maintained in each Luminal PDX model. This 
is a clear advantage of the PDX models as those were shown previously to recapitulate 
the individual tumor morphology, gene expression, and drug susceptibility of each 
patient (Kawaguchi et al., 2017; Marangoni et al., 2007; Zhang et al., 2013). Hence, 
the models reflect the human situation better than cell line-derived xenograft models 
making the PDX a powerful tool for translational relevant breast cancer research. In 
contrast to the PDX models the cell-line derived xenografts are more standardizable 
due to the unlimited availability to cell line material that can be transplanted 
simultaneously under equal conditions in several animals (Wege, 2018). With the 
limited access to primary material and the varying cell number in tumor fragments the 
PDX model generation remains still challenging. 
In this thesis, we were able to successfully establish five PDX models with different 
breast cancer entities. As published before, in our laboratory settings the aggressive 
breast cancer tumors, like TNBC (50 %), Luminal B Her2+ (50 %), and hormone 
receptor-negative Her2+ tumors (50 %) engrafted better in NSG mice compared to 
Luminal A (0 %) and Luminal B Her2- tumors (0 %). The low engraftment seems to be 
dependent on the ER positivity of the tumors, which might be due to the characteristics 




the engraftment is unknown. It is more likely that the reduced take rate (especially of 
the low proliferating Luminal A tumors) is evoked by the secondary characteristics of 
ER+ tumors. First, ER+ breast cancer tumors (especially Luminal A tumors) are slowly 
proliferating and characterized by low grading (Goldhirsch et al., 2011), which could 
limit the engraftment in NSG mice. Second, Her2 was shown previously to enhance 
the engraftment in mice as cell survival pathways such as the PI3K/AKT signaling and 
RAS/ERK pathways were more activated (Kanaya et al., 2017). Moreover, Her2 might 
serve as a driver for growth due to the constitutive kinase activity that promotes the 
high proliferative capacity of Her2 amplified tumors (Olayioye, 2001). Hence, the intake 
rate of Luminal B tumors without Her2 amplification is decreased.  
Another reason for the low take rate of ER+ tumors could be the differences between 
the hormonal status between mice and women. Although supplementation of estrogen 
was provided by estrogen pellet transplantation, the supply could be insufficient to 
mimic the situation in women.  
All of the generated PDX models in this study were shown to be either PR negative or 
expressed PR only to a minor extent. Hence, PR negativity seems to be an additional 
factor for engraftment success. This could be explained by the regulation of PR that 
hinders upon high PR expression, the growth-promoting functions of ER and therefore 
decreases the tumor aggressiveness (Finlay-Schultz et al., 2017). Additionally, PR 
negativity was shown to be associated with a worse prognosis for the patient (Onitilo 
et al., 2009; Dunnwald et al., 2007) and the lack of PR expression led to a more 
aggressive phenotype of the tumor in the PDX model (Bergamaschi et al., 2009). In 
addition, high PR expression was linked previously to a less aggressive breast cancer 
entity, namely the Luminal A breast cancer (Lim et al., 2016) 
In this study, the transplantation of single cells derived from a solid tumor that was 
dissociated enzymatically or mechanically was not successful in general. Only single 
cells that originally derived from circulating tumor cells (TM CTC) or effusions (TM Bpe, 
and PT AB) were able to successfully engraft. Solid primary tumor samples (PT P, PT 
X, F TM 3, F TM 22, F TM 34) needed to be transplanted as small tissue fragments. 
This divergence between the single-cell or tissue fragment transplantation methods 
might originate from accelerated anoikis during the dissociation process that is 
employed to create single-cell suspensions. Anoikis, as anchorage-dependent 




the extracellular matrix (Frisch and Ruoslahti, 1997). Hence, anoikis hinders the 
engraftment of tumor cells in the mouse mammary fat pad. The intact extracellular 
matrix, where the primary tumor cells are embedded in, therefore supports the 
engraftment success (DeRose et al., 2013; DeRose et al., 2011). Another reason is 
displayed by the fact that the metastases from pleural effusions or ascites already exist 
as single cells and do not have to be treated harmful by enzymatical or mechanical 
dissociation. Another possible scenario is that metastases undergo anoikis resistance 
if they settle from the primary tumor site into the periphery (Simpson et al., 2008), and 
therefore feature the ability to reattach to other matrices. Our study revealed that breast 
cancer metastases, such as pleural effusions or ascites derived tumor cells (PT AB 
and PT U), or primary solid tumors in an advanced state (as a secondary tumor or 
relapse) (PT P or PT X), showed an engraftment advantage over untreated primary 
solid tumors. Moreover, higher engraftment rates of metastases, compared to solid 
tumors, have also been previously reported by Marangoni and colleagues (Marangoni 
et al., 2007). 
Noteworthy, four out of five patients, where the PDX generation was successful, died 
within two years after tissue, pleural effusion or ascites removal. This correlation of 
successful engraftment and patient survival has also been reported previously to be 
an independent prognostic factor for disease outcome (DeRose et al., 2011; Whittle et 
al., 2015).  
Another aim of the thesis was the culturing of primary breast cancer tumor cells, which 
resulted in one propagatable cell culture derived from a pleural effusion (PT AB) and a 
short-term culturing of the TM CTC tumor. All other primary breast cancer tumor cells 
failed in culturing. A reason for the limited culture success of primary tissue fragments 
could be the dissociation-induced production of self-inhibiting or suicidal signals of the 
tumor cells (Simpson et al., 2008; Frisch and Ruoslahti, 1997). This goes along with 
our observation of limited tumor engraftment in mice after transplantation of 
dissociated single cells. Another explanation for the failure in primary tumor culturing 
is that one or more of the key growth factors are missing in cell culture. It was previously 
shown that mimicking the right physiological conditions (e.g. growth factors or 
cytokines) of the tumor microenvironment is challenging (Ethier et al., 1993). Moreover, 
a low tumor cell density and fast proliferating fibroblasts that overgrow the tumor cells 




why PT AB cells were successful in culturing might be that the metastatic cells already 
existed as single cells. Those single cells did not require enzymatical dissociation or 
mechanical shearing, which granted a more successful propagation. Moreover, the 
high number of tumor cells seeded, and the putative low amount of mesothelial cells 
(in PT AB effusion) that could overgrow the tumor cells (Ip and Asch, 2000) contributed 
to the successful growth. However, TM CTC, as a tissue fragment, was indeed a 
special case. The TM CTC tumor was mechanically dissociated and a short-term 
culturing in a special medium, which contained 30 supplements (dissertation Massimo 
Saini, 2017), was possible. This medium was kindly provided by our colleges from 
Heidelberg (HiSTEM, Heidelberg, Germany). The high content of different nutrients 
and growth factors could have contributed to the culturing success (dissertation 
Massimo Saini, 2017). Moreover, the TM CTC cells that were cultured and 
retransplanted several times are used to the medium and might, therefore, be more 
resistant towards mechanical dissociation as primary tumor cells that are dissociated 
out of an intact microenvironment for the first time.  
Nevertheless, there are several possibilities to improve the primary breast cancer cell 
culturing. 2D conditions, where the cell surface is coated with collagen I or Geltrex, 
might be an option, as published previously (Janik et al., 2016). Moreover, feeder cells 
or conditioned media have already been used to establish primary breast cancer cell 
cultures (Wang et al., 2001). In addition, different medium supplements like cholera 
toxin and ethanolamine have been previously shown to contribute to successful 
culturing (Ethier et al., 1993). Another possibility is to sort the tumor cells for stem cell 
markers, like CD44high/CD24low, as those cells were shown to harbor the capacity for 
tumor-initiation and self-renewal (Sheridan et al., 2006). Three-dimensional bioprinting 
would also be an option, because it mimics the perfect microenvironment by 
incorporating multiple cell types into scaffold-free tumor tissues with defined 
architecture (Langer et al., 2019). The development of the so-called mini-breast in 
adherent or non-adherent floating gels could contribute to establish breast cancer 
cultures. The mini breast is generated from reduction mammoplasty and exhibits the 
regenerative potential of terminal ductal lobular units (Linnemann et al., 2015). 
Therefore, the mini-breast could serve as a kind of carrier architecture for culturing 




5.2. Genomic and phenotypic markers that could identify a high-risk Luminal B 
tumor 
In the clinical practice, Luminal tumors are differentiated according to their molecular 
intrinsic markers like hormone receptor positivity and Her2 status, and, by means of 
proliferation and grading, differentiated into Luminal A and B. Further stratification 
through gene expression profiler assays, such as PAM 50, is time-consuming, cost-
intensive. Most importantly, this assay only provides a likelihood for relapse or 
metastatic spread, which is used as a basis for the decision of chemotherapeutic 
intervention. Hence, further markers are needed to classify the high-risk luminal 
tumors. In this study, all the patients that suffered from Luminal B tumors and died, or 
had a relapse were retrospectively assigned to high-risk Luminal B tumors. 
Additionally, the primary luminal B tumors that resulted in successful PDX engraftment, 
which is a separate prognosticator of poor outcome, were dedicated to the high-risk 
group. The low-risk Luminal B group comprises all other Luminal B patients that are 
still alive without distant metastases or a relapse. A summary is listed in the table 
below. 
High risk Low risk 
dead alive 
relapse recurrence-free 
tumor engrafted in the mouse tumor did not engraft in the mouse 
5.2.1 Genomic markers 
A central finding of the panel sequencing of the primary patient tumors and the TM 
tumors that engrafted was the significant overlap between the successful engraftment 
and genomic MDM2 amplification. This amplification leads to increased MDM2 protein 
expression in the TM, as confirmed by IHC. According to the MDM2 amplification of 
the tumor, the TM CTC, TM Bpe, TM P, F TM 34 were assigned to the TM MDM2 
amplified group. F TM 22, F TM 3, and TM AB were dedicated to the TM MDM2 WT 
group, as those tumors exhibited no MDM2 amplification. The following results 
discussed are based on this subdivision. 
In healthy cells, the E3 ligase MDM2 is responsible for the degradation of p53 at the 
proteasome, which inhibits repair mechanisms after cell damage, or p53 mediated cell 
death. The overexpression of MDM2 protein, caused by an MDM2 gene amplification, 




uncontrolled cell proliferation (Danovi et al., 2004). Those processes would thereby 
enhance the engraftment in mice. Moreover, MDM2 amplification has been associated 
with ER+ breast cancer and was reported to appear in a varying range of 1.7 % - 32 % 
in Luminal B breast cancer patients (Network, 2012; Yu et al., 2014; Haupt et al., 2017; 
Choschzick et al., 2010). MDM2 is able to stimulate the transcription of the ERα gene, 
which leads to increased levels of ERα, in a p53-independent manner (Kim et al., 2011; 
Brekman et al., 2011; Swetzig et al., 2016).  
Moreover, our data revealed that MDM2 amplification positively correlates with tumor 
size and tumor volume over time in TM and HTM. As the in vitro results in this study 
demonstrated decreased proliferation, increased apoptosis, and decreased wound 
healing in a p53 dependent manner after an MDM2 knockdown, the increased tumor 
size in MDM2 amplified tumors could be explained by uncontrolled proliferation. In 
support of our in vivo findings, another study reported that a decreased tumor size was 
caused by an MDM2 knockdown in HR-positive breast cancer cell line xenografts (Gao 
et al., 2019). 
The detected upregulation of p53 protein expression after an MDM2 knockdown could 
act via two pathways. The first possibility is the p53-mediated activation of BAX or 
PUMA, which causes apoptosis. The second possible pathway could be the p53-
mediated activation of p21, where the cells will undergo cell cycle arrest (Ozaki and 
Nakagawara, 2011). P21 activation by the overabundant p53, in turn, inhibits CDK1/ 
Cyclin B complex formation, leading to a stagnation of the cells in the G2 phase, and 
consequently, the cells could not enter mitosis and stop proliferation (Khan et al., 2016; 
Lu et al., 2016). This G2 shift was also determined in this study after an MDM2 
knockdown in ZR-75-1 breast cancer cell line.  
Noteworthy, the western blot results of ZR-75-1 MDM2 knockdown cells demonstrated 
an MDM2 isoform-dependent regulation of p53. The knockdown only targeted the 
MDM2 90 kDa, 76 kDa, and 57kDa, but not the 74 kDa isoform. Hence, all effects of 
an MDM2 knockdown are attributed to the 90 kDa, 76 kDa or 57kDa isoforms. In line 
with those data, Alkhalaf 2005 described the MDM2 90kDa isoform to be responsible 
for the regulation of the p53 protein stability (Alkhalaf et al., 2005). 
In order to reverse translate this knowledge of MDM2 downregulation into a clinical 
therapeutic relevance, a pharmacological MDM2 inhibitor experiment with AMG232 




decreased proliferation, and a shift towards the G2 phase, similar to the MDM2 
knockdown. Consequently, the Luminal B breast cancer patients with amplified MDM2 
status might benefit from a p53-MDM2 inhibitor treatment, which would reduce tumor 
cell proliferation. Therefore, the AMG232 treatment could be useful in the future to treat 
MDM2 amplified tumors and serve optional as an alternative in case of endocrine 
resistance or additively to chemotherapeutic interventions. 
Besides an increased tumor weight and volume, MDM2 amplified PDX showed a 
decreased DFS in TM MDM2 amplified (Amp) mice compared with TM MDM2 wild type 
(WT) mice. This might be attributed to the increased proliferative capacity of TM MDM2 
amplified tumors. Interestingly, the OS of TM MDM2 Amp animals did not differ from 
TM MDM2 WT mice. In line with those data is the significant positive correlation 
between MDM2 amplification and reduced DFS that has been reported previously for 
breast cancer patients. (Cuny et al., 2000).  
Taken together, all the in vitro and in vivo results demonstrated that an MDM2 
amplification in Luminal B tumors is associated with enhanced engraftment in PDX, 
and therefore with aggressivity of the patients’ tumor. Of note, the PAM 50 assay for 
Luminal risk stratification includes MDM2 gene assessment, however, the information 
might get lost since multiple genes are included in the risk calculation (Alvarado et al., 
2015). 
Despite the discussed MDM2 amplification that accounts for high-risk Luminal B 
tumors, the TP53 mutation (FTM 22 and F TM 3 model) and an MDM4 amplification 
(TM AB PDX) were also determined in the panel sequencing in the generated PDX 
models. Interestingly, MDM2, p53, and MDM4 belong to the same pathway and can 
regulate each other. TP53 mutation, as a tumor suppressor gene, leads to a loss of 
function in the p53 protein and therefore hinders apoptosis and promotes uncontrolled 
proliferation (Lacroix et al., 2006). Hence, similar to how MDM2 hinders the p53 
function, the TP53 mutation also leads to a loss of function in the p53 protein and 
therefore prevents apoptosis of the tumor cells. In turn, this could enhance the 
engraftment success in mice. TP53 mutations in Luminal B breast cancer were found 
in 32 % of the patients, but the incidence in non-luminal breast cancer is much higher 
(TNBC: 84%; Her2+ breast cancer: 75% (Network, 2012). TP53 mutations were shown 
to predict a poor progression-free survival after systemic treatment and additionally, 




(Berns et al., 2000; Langerød et al., 2007). The MDM4 protein is structurally 
homologous to MDM2, but acts differently than MDM2. MDM4 can stabilize p53 and 
MDM2 protein levels, leading to nuclear accumulation of the p53-MDM2 complex, 
thereby disabling the p53 function (Stad et al., 2001). In the MDM4 amplified tumor 
(TM AB) MDM4 stabilizes MDM2, as the IHC of TM AB tumor in this study revealed a 
high expression of MDM2. However, the MDM2 protein overexpression in MDM4 
amplified tumors could block p53 mediated cell death and therefore, result in better 
engraftment. 
Noteworthy, the results of the panel sequencing might give a hint that MDM2 and TP53 
seems to be mutually exclusive, even if the number of the analyzed PDX tumors is 
very low (four MDM2 amplified and two TP53 mutated). However, a TP53 deletion was 
detected in the TM P PDX model simultaneously with an MDM2 amplification. The 
phenomenon of the unlikely occasion of simultaneous alteration in TP53 and MDM2 
has been published decades ago in osteosarcoma (Lonardo et al., 1997) but was also 
published recently in breast cancer (Haupt et al., 2017). 
5.2.2 Phenotypic markers  
In this study, the phenotypic markers EpCAM, CD44, CD47, Her2, cMET, and CD24 
were evaluated as they are associated with certain functionalities like stemness, EMT 
or immune escape. The data of the SCF phenotyping revealed a high expression of 
CD24 in Luminal B patient tumors, compared with Luminal A patient tumors. 
Additionally, all of the engrafted Luminal B PDX models (TM and HTM), which belong 
to the high-risk Luminal B tumors, exhibited a high CD24 expression. High CD24 
expression in Luminal breast cancer and TNBC was previously shown to be associated 
with a poor prognosis (Kwon et al., 2015). In addition, it was reported previously that 
high CD24 expression was detected in highly aggressive breast cancer cell lines from 
the basal subtype (Chekhun et al., 2013). Recently, CD24 expression in breast cancer 
tumor cells was shown to serve as a potential immune checkpoint through its 
interaction with the inhibitory receptor sialic-acid-binding Ig-like lectin 10 (Siglec-10) 
that is expressed by M2-like tumor-associated macrophages (Barkal et al., 2019). 
Hence, a high CD24 expression forces Siglec-10 binding, thereby inhibiting 
phagocytosis of the tumor cells by macrophages. Prospectively, CD24-Siglec-10 




In addition, our investigations showed an increased expression of cMET in the 
metastatic effusions of the Luminal B patient samples compared with Luminal B 
primary tumors. This phenomenon of increased cMET expression was also displayed 
in the TM MDM2 Amp lung metastases, compared with the corresponding primary 
tumor. Additionally, the TM MDM2 Amp lung metastases exhibited and increased 
CD44 expression, compared with TM MDM2 solid tumors. A possible scenario is that 
only a few cells of the primary tumor cells express cMET and CD44 and those cells 
exclusively are able to migrate to other organs and to initiate metastases (Baccelli et 
al., 2014; Baccelli et al., 2013). Previous studies demonstrated a link between cMET 
expression in the primary tumor with poor survival, the occurrence of distant 
metastases, and breast cancer progression (Baccelli et al., 2014; Baccelli et al., 2013; 
Jia et al., 2018). In detail, cMET serves as an inducer of EMT where the cancer cell 
reversibly acquires an invasive and motile phenotype (Wallwiener et al., 2013; Polyak 
and Weinberg, 2009). cMET and CD44, as tumor metastases proteins, were shown to 
interact by a complex formation of cMET, the CD44v6 isoform, and HGF and as a result 
enhanced cMET signaling (Orian-Rousseau, 2010; Orian-Rousseau et al., 2002). 
Hence, in the future other therapeutic targets like cMET inhibitors could be taken into 
account to treat metastatic breast cancer. There are clinical studies ongoing that 
evaluate cMET inhibitors and monoclonal antibodies directed against cMET in TNBC 
patients (Ho-Yen et al., 2015). Additionally, the co-expression of cMET+ and CD47+ 
CTCs promoted the outgrowth of bone marrow metastases, served as an independent 
prognostic marker for poor overall survival, and was strongly associated with lymph 
node metastases in Luminal breast cancer patients (Baccelli et al., 2014). This further 
emphasizes a responsibility of cMET+/ CD47+ co-expression that enables the tumor 
cells to colonize other organs. 
Additionally, high co-expression of CD44/cMET/CD47 was determined phenotypically 
by SCF in high-risk Luminal B primary tumors. Despite the high co-expression of 
CD44/cMET/CD47 in primary Luminal B patient samples, the TP53 mutated and 
MDM4 amplified tumors (summarized as TM MDM2 WT in the results part) also 
exhibited high levels of CD44/cMET/CD47. This triple-positive population has been 
described as the population that induces metastases in breast cancer so-called MICs 
(Baccelli et al., 2013). CD47 as “don’t eat me signal” prevents phagocytosis of the 
tumor cells and thereby evades immune cell recognition (Baccelli et al., 2014). cMET 




induces angiogenesis and invasion in breast cancer (Orian-Rousseau, 2010). When 
all those functions merge, the tumor cell is protected against multiple eradication 
attempts and the tumor cell is empowered to survive even in the periphery and could 
generate metastases. Hence, the co-expression of CD44/cMET/CD47 serves as a 
high-risk marker for Luminal B breast cancer. In this context, it is important to note that 
one patient of the low-risk Luminal B patient samples exhibited a high CD44+, CD47+, 
and cMET+ expression, potentially predicting relapse or the occurrence of distant 
metastases in the follow-up care. In support of this data, TM and HTM MDM2 Amp 
lung metastases exhibited an increased expression level of the triple-positive MICs 
(CD44/cMET/CD47) compared with the corresponding primary tumor that is also 
indicative for a high-risk Luminal B tumor. 
5.3 Immune cell interactions and immune cell checkpoint relevance in Luminal 
B breast cancer  
In breast cancer research the immunological influence gets more and more in the 
focus, intending to determine predictive and prognostic factors that account for tumor 
progression and survival, as well as to target them with therapeutic interventions. 
Despite the retrospective clinical assessments of patient samples to study the 
influence of the human immune system, there is a lack of adequate models. To 
overcome this problem, the humanized PDX turned out to be a good solution to 
remodel human immune cell and tumor cell interactions.  
Supporting the data about low TILs in Luminal B breast cancer determined in patient 
samples (Pruneri et al., 2017), this study revealed a low infiltration of immune cells in 
the Luminal B breast cancer patients as well as in the humanized PDX models. Hence 
the humanized PDX model matches with the observation in Luminal B breast cancer 
patients and again demonstrate the non-immunogenicity of Luminal B tumors. Even if 
the tumors are infiltrated to a low amount it was demonstrated previously that high TILs 
in Luminal/Her2- breast cancer are an adverse prognostic indicator for survival 
(Denkert et al., 2018). This was explained by the differential immune cell composition 
in luminal Her2- breast cancer compared with TNBC and Her2+ breast cancer. The 
determined T-cells in TNBC were shown to correlate with increased overall survival 
whereas this was not the case for Luminal breast cancer (Denkert et al., 2018). In 
contrast, high TILs in TNBC or HER2+ breast cancer rather predicted a survival benefit. 
Hence, the TIL composition might play a pivotal role. As described in the literature, 




implicated in tumor suppression, whereas Tregs, M2 macrophages or Th 2-helper cells 
promote tumor progression (Salgado et al., 2015).  
An interesting finding in the patient's primary tumors, analyzed by the TCF, is the 
increased CD4/CD8 ratio that was determined in high-risk Luminal B tumors. This 
means that in our analyzed high-risk Luminal B tumors the predominant immune cell 
type was CD4+ cells and could, therefore, account as a marker for high-risk Luminal B 
tumors. In addition, the Luminal B patient effusions also showed an increased 
CD4/CD8 ratio in this study. In general, CD4+ cells (especially Tregs) are associated 
with a poor prognosis for Luminal breast cancer patients (Bates et al., 2006). Tregs 
characterized as CD4+ CD25+ FOXP3+ are known to act immunosuppressive and 
promote tumor progression by the downregulation of effector T-cells. Previously, Su et 
al suggested that tumor-infiltrating Tregs arise from chemotaxis of circulating naive 
CD4+ T-cells being recruited into the tumor that differentiate into Tregs in situ (Su et 
al., 2017). Hence, it could be speculated the determined CD4+ cells in our Luminal B 
tumors are Tregs and prohibit therefore an immunologic defense of effector T-cells. 
This hypothesis could partially be supported by the fact that the CD4+ and CD8+ TILs 
in the Luminal B patients metastatic effusion were naïve, in contrast to the Luminal B 
solid patients’ tumor. 
Interestingly, this study revealed an advantage in DFS of HTM MDM2 Amp animals 
compared with TM MDM2 Amp animals. Conversely, the HTM MDM2 Amp animals did 
not differ regarding DFS compared with HTM MDM2 WT mice. First, these data 
implicate that the human immune cells control tumor cell proliferation. Second, the 
MDM2 amplification but no other alterations seem to be responsible for the DFS effect, 
as HTM MDM2 Amp animal and HTM MDM2 WT animals did not differ in DFS. It could 
be speculated that the TILs in MDM2 amplified tumors control the proliferation for a 
certain period of time but with increased tumor size the eradication by the limited 
number of TILs fails. This again would explain the unchanged OS between the groups. 
The next level of therapeutic intervention in breast cancer might be represented by 
immune checkpoint inhibition. This treatment option turned out to be auspicious for the 
various malignancies. A prerequisite for efficient immune checkpoint inhibition is the 





The results of the humanized Luminal B PDX models and the already published results 
of humanized CDX models (Rom-Jurek et al., 2018) coincide with the finding of low or 
absent PD-L1 expression in Luminal HTM PDX. As the PDX models in this dissertation 
were shown to be non-immunogenic, the low impact of immune checkpoints in Luminal 
B breast cancer was not surprising. This finding in the HTM CDX model is probably 
due to the co-transplantation of tumor- and immune cells that ensure the development 
of tolerance of the human immune system towards mouse tissue and allogeneic tumor 
cells. As a consequence, the immune cells seem not to be activated by the tumor cells 
and thus, no tumor infiltration and e.g. IFNγ release, as a PD-L1 stimulus, occurred 
(Rom-Jurek et al., 2018). 
Contrary to the Luminal breast cancer, a high PD-L1 expression was determined in 
aggressive TNBC and one Her2+ breast cancer cell line of the HTM CDX model (Rom-
Jurek et al., 2018). Enhanced PD-L1 expression in TNBC and HER2 positive tumors 
in vivo seems to be associated with an enhanced load of neoantigens in those cells. 
Such a phenotype attracts immune cells and triggers a tumor-immune cell interaction 
that can finally be inhibited by PD-L1/PD-1 interaction. Hence, the PD-L1 negativity 
might permit T-cell invasion into tumor tissue. However, IFNγ released by activated T-
cells can induce PD-L1 expression (Garcia-Diaz et al., 2017) and, vice versa, the PD-
L1 expression by tumor cells can impede T-cell activation and IFNγ release that could 
subsequently entail decreased PD-L1 expression (Garcia-Diaz et al., 2017). Even 
though, the role of immune cell infiltration and tumor attack in Luminal breast cancer 
patients is still doubtful, a clinical trial in metastatic hormone receptor-positive women 
with negative Her2 status has started to treat patients with a combination of Anti-PD-
L1 and Anti-CTLA-4 antibody combined with hormone therapy (NCT03430466 
https://clinicaltrials.gov/). Moreover, a pilot study that determines the PD-L1 expression 
during preoperative treatment with Nab-Paclitaxel and Pembrolizumab (PD-1 inhibitor) 
in hormone receptor-positive breast cancer (NCT02999477 https://clinicaltrials.gov/) is 
recruiting currently. 
As mentioned above, the PD-1 expression on immune cells, as the counterpart of PD-
L1, determines the immunological answer. In the Luminal B HTM PDX model the PD-
L1 expression on tumors cells did not correlate with the PD-1 expression or the TIL 
rate. In this study, increased PD-1 expression was only determined on the cytotoxic T-




metastatic effusion. However, even though a high PD-1 expression was determined 
on all TILs no difference in PD-1 expression on T-helper cells was observed comparing 
Luminal B patient's primary tumor with Luminal B metastatic effusion. Recently it was 
shown that increased CD8+ PD-1+ TILs were associated with prolonged DFS (Yeong 
et al., 2019). The PD-1 expression on immune cells has also been determined to 
predict a favorable outcome for the patient (Brockhoff et al., 2018; Noske et al., 2019). 
It could be speculated that the antigen-induced anti-tumor immune pressure provokes 
the recruitment of immune cells to the tumor and results in successful antitumor 
defense. Hence, a lack of PD-1 expression on cytotoxic T-cells in Luminal B 
metastases might explain the unfavorable prognosis for patients.  
Another important observation of this study was that the human immune system did 
not alter the metastatic frequency or the metastatic sites in all Luminal B PDX models. 
Those remain completely identical to those of the TM PDX. It is tempting to speculate 
that the geno- and phenotypic configuration of the tumor cell is responsible for the 
metastatic behavior. Another possibility is the influence of microenvironmental factors 
of the certain tissue that could contribute to tumor cell colonization like MMPs for lung 
colonization and IL-6 for bone marrow colonization (Chen et al., 2018).  
5.4 Genotypic differences between the primary tumor and bone marrow DTCs  
The prevalent metastatic site in Luminal B breast cancer, independent of the Her2 
status, is the bone marrow (Wu et al., 2017). In general, the persistence of DTCs 
predicts a poor outcome with the possibility of a potential relapse for the patient (Janni 
et al., 2011). However, the biology behind the dissemination of tumor cells is not fully 
understood. The theory of late dissemination of tumor cells was a long time well 
accepted in the scientific community (Koscielny et al., 1985) whereas the hypothesis 
of early dissemination and parallel progression of tumor growth came more and more 
in the focus (Klein, 2009). Moreover, the primary tumor and the corresponding DTCs 
could differ genetically (Schmidt-Kittler et al., 2003). Nevertheless, the differences 
were not yet assigned to a certain breast cancer subentity even with or without the 
influence of a human immune system.  
Low pass-sequencing of primary HTM P and TM P tumors and the matching HTM P 
and TM P bone marrow DTC genomic profiles were shown to cluster in three 
populations (1. mainly DTC, 2. mainly tumor cells, 3. DTCs). More precisely, we 




differences in gains and losses on certain genomic regions. The genomic 
heterogeneity between tumor cells and DTCs might be explained by the early 
dissemination hypothesis (Klein, 2009). According to that theory, the tumor cells 
acquire different genomic mutations during differentiation and proliferation, whereas 
the DTCs that left the primary tumor at a very early time point, only exhibit the genomic 
aberrations from the initial tumor cells and stay in dormancy (Magbanua et al., 2018). 
However, this study is only able to evaluate the endpoint of tumor development, while 
the alterations a tumor harbors at the beginning cannot be determined. Hence, the 
differences and concordances of the tumor and DTC profiles cannot distinguish 
between acquired and initial genetic alterations. The concordance between tumor cell 
and DTC profiles could rather be due to a late metastatic event. It was reported 
previously that 30 to 70 % of the patients that harbored DTCs in the bone marrow do 
not necessarily generate metastases later on (Klein, 2003).  
Interestingly, the 3. population mainly consisted of DTCs from HTM PDX tumors and 
revealed gains and losses in the cell profile that differed from the tumor cell population 
and the DTCs from the TM. Two scenarios are possible to explain this incongruency. 
First, it can be speculated that the human immune system promotes a selection 
pressure on certain genomic aberrations of the tumor cells that migrate through the 
periphery into the bone marrow and manifest as DTCs other than those of the TM 
DTCs. Second, the micromilieu in the bone marrow niche of the HTM PDX, which is 
repopulated with human immune cells and progenitors, releases factors that contribute 
to the hosting of DTCs with a special genetic constellation. However, treating bone 
marrow metastases in breast cancer patients still lacks of alternative treatment options 
other than the chemotherapeutic intervention. However, the chemotherapeutic 
intervention would not target the dormant cells because only cells that are actively 
proliferating would be eradicated.  
In our TM and HTM Luminal B PDX models not only single DTCs were detected in the 
bone marrow, but also DTC clusters. Linde 2018 demonstrated that the presence of 
more than five DTCs in a cluster tended to positively influence proliferation markers, 
and consequently, were considered as growing micrometastases (Linde et al., 2018). 
It was reported in CTC clusters that this formation might take advantage of their 
oligoclonal origin, which enhances their survival in the bloodstream and helps to settle 




clusters might profit from their inhibition of immunological detection and survive better 
than single DTCs. However, the functional relevance of DTC clusters in Luminal B 
breast cancer remains to be elucidated.  
5.5 Organotropism in Luminal B breast cancer due to genetic alterations 
Breast cancer metastases are frequently found in the distant lymph nodes, the liver, 
the lung, and the bone marrow, and the brain (Wu et al., 2017). However, different 
breast cancer subentities were also shown to determine metastases in certain organs, 
such as the liver, the lung, and the distant lymph nodes, which are the predominant 
sites in Luminal B breast cancer. This so-called organotropism was shown to be driven 
by the different breast cancer subentities, different gene signatures, and different 
signaling pathways of metastatic tumor cells (Chen et al., 2018) 
In this study, the tumors that harbored an MDM2 amplification (four different PDX 
models) promoted metastatic lesions in the lung and bone marrow DTCs, whereas a 
TP53 mutation (two different PDX models) prevented metastatic lesions in the lung, 
but caused bone marrow DTCs. This indicates an organotropism that is promoted by 
the genetic aberration of the different Luminal B tumors. However, different genetic 
aberrations could account for different phenotypes that drive the metastatic spread. 
Minn et al. identified a set of genes that mark and mediate breast cancer metastasis to 
the lung, like MMP1 or VCAM1 (Minn et al., 2005). Moreover, the genetic signature 
was shown to be tissue-specific (Chen et al., 2018). Interestingly, all Luminal B PDX 
tumors showed a DTC colonization of the bone marrow. As all of the tumors share a 
high EpCAM expression in the primary tumor, it could be speculated that EpCAM 
positivity correlates with bone marrow dissemination. EpCAM positivity and high 
EpCAM expression was reported to be associated with a CSC phenotype of the tumor 
cells. Hence, mainly EpCAM positive cells harbor the capacity for self-renewal and 
differentiation, showing increased sphere formation in vitro and tumorigenicity in vivo 
(Hiraga et al., 2016). The occurrence of bone marrow metastasis was previously shown 
to be associated with a high EpCAM positivity of the primary tumor (Hiraga et al., 2016). 
In this context, the high EpCAM expression of all Luminal B PDX tumors might be a 
detrimental factor that promotes the dissemination of the tumor cells to the bone 
marrow.  
This study also revealed that the MDM4 amplification of the tumor in TM AB led to 




metastases correlated with those of the primary patient tumor. However, even though 
the MDM4 amplification of the tumor is supposed to be correlated with the metastatic 
sites, this organotropism cannot be over-interpreted due to the limited availability of 
just that one model. 
In summary, the MDM2 amplification (four different PDX models), TP53 mutation (two 
different PDX models) and the MDM4 amplification (one PDX model) of the primary 
tumor could potentially predict the metastatic sites the tumor cells will colonize. 
However, the mechanisms have to be further elucidated with an increased number of 
MDM2 amplified/ TP53 mutated/ MDM4 amplified PDX tumors. 
5.6 Conclusion  
In this study, we provided evidence for the benefit of using (humanized) PDX models 
to identify high-risk markers for Luminal B breast cancer. CD24, cMET, CD44 and the 
co-expression of CD44/cMET/CD47 were determined as phenotypic markers that are 
able to identify high-risk Luminal B tumors. Moreover, TP53 mutation and especially 
MDM2 gene amplification seemed to be strongly associated with aggressiveness of 
Luminal B tumors, which is indicated by increased tumor engraftment, increased tumor 
size, and metastases in HTM and TM. Potentially, luminal tumors can routinely be 
scored for a genomic MDM2 gain, via in-situ hybridization (ISH), or MDM2 expression 
via IHC, in order to identify high-risk luminal B tumors with increased aggressiveness 
and an enhanced capacity to metastasize. The analyzed Luminal B PDX models and 
the primary Luminal B patient tumors were shown to be rather nonimmunogenic. 
However, even the few determined TILs showed an increased CD4/CD8 expression 
ratio that additionally accounts as a marker for high-risk Luminal B tumors. Bone 
marrow DTCs in the TM and HTM P models were shown to differ genetically from the 
primary tumor, and moreover, the human immune system seems to influence the 
colonization of bone marrow DTCs with certain genetic aberrations. This further 
confirms the importance to determine the genetic constitution of the DTCs to ensure a 
personalized therapy decision in case of recurrence. In summary, our study pointed 
out different high-risk geno- and phenotypic markers, in addition to a high-risk TIL 
signature in Luminal breast cancer. This might help to identify patients who might 
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